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1.1 The G protein-coupled receptor (GPCR) family  
GPCRs are the largest group of membrane-integrated receptors (Lagerström and 
Schioth, 2008). The main structural characteristics of GPCRs are seven hydrophobic 
transmembrane domains forming α helices connected with three extracellular and three 
intracellular loops and terminated with an extracellular N-terminus and an intracellular C-
terminus (Kobilka, 2007). The name of GPCRs originates from their ability to interact with 
guanine nucleotide-binding proteins (G proteins). However, especially in the newer literature 
these receptors are frequently referred to as seven transmembrane receptors (7TMRs) 
because of their structure and their ability to activate not only G protein-dependent but also G 
protein-independent signaling pathways (cf. section 1.3.1) (Kenakin and Miller, 2010). More 
than 800 full length members of the GPCR family have been identified in the human genome 
(Fredriksson et al., 2003). GPCRs play important roles in numerous physiological and 
pathophysiological processes. About 30 % of all drugs currently available on the market 
target GPCRs (Overington et al., 2006), which are continued to be explored as a very 
attractive and promising drug targets. 
On the basis of phylogenetic criteria, the GPCR superfamiliy is divided into five main 
groups termed rhodopsin, glutamate, adhesion, frizzled/taste 2 and secretin receptor families 
(Lagerström and Schioth, 2008). The rhodopsin family, comprising about 700 members, is 
the largest family of GPCRs and is subdivided into four groups (α, β,  and ) (Lagerström 
and Schioth, 2008). The α group of rhodopsin-like GPCRs includes, among others, receptors 
that can be activated by biogenic amines. Receptors of interest in this thesis, i.e. the 
histamine H2 receptor (H2R), the histamine H4 receptor (H4R) and the β2-adrenergic receptor 
(β2AR), are members of this aminergic receptor cluster (Fredriksson et al., 2003).  
 
1.2 G protein-dependent signaling of GPCRs 
In case of G protein-mediated signaling, the first event after binding of endogenous 
or synthetic agonists to GPCR is an interaction of the agonist-receptor complex with 
regulatory heterotrimeric G proteins consisting of an α subunit (Gα) and a β complex (Gβ). 
Binding of an agonist to the GPCR stabilizes an active receptor conformation, which enables 
the dissociation of guanosine 5’-diphosphate (GDP) from the catalytically inactive Gα protein 
(Fig. 1.1, step 1). This allows the formation of a ternary complex consisting of an agonist, the 
receptor and the nucleotide-free heterotrimeric G protein (Fig. 1.1, step 2). For a given 
receptor agonist affinity is the highest, when the ternary complex is formed. Upon binding of 
guanosine 5`-triphosphate (GTP) to Gα, the ternary complex is disrupted resulting in reduced 
agonist affinity and dissociation of heterotrimeric G protein into the Gα and the Gβ subunits 
(Fig. 1.1, step 3). Both the Gα-GTP and the Gβ complex can activate downstream signaling 
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pathways (step 4). The intrinsic GTPase activity of the Gα subunit terminates G protein 
activation by the hydrolysis of GTP into GDP and inorganic phosphate (Pi) (Fig. 1.1, step 5). 
Then, Gα and Gβ re-associate, and the initial state is restored (Fig. 1.1, step 6) (Hermans, 
2003; Schneider and Seifert, 2010). Particularly noteworthy is the fact that some GPCRs are 
present in an active conformation and couple to G proteins in the absence of a bound 
agonist. This phenomenon is referred to as constitutive activity (Seifert and Wenzel-Seifert, 
2002). The most common approaches applied in the investigation of GPCR activity at the 
level of the G protein cycle are (I) determination of high-affinity agonist binding to a given 
GPCR (e.g., using fluorescent or radio-labeled ligands), (II) monitoring of the dissociation of 
the ternary complex with e.g. radio-labeled non-hydrolysable GTP analogs like guanosine 5`-
[γ-thio]triphosphate ([35S]GTPγS binding assay) and (III) determination of the intrinsic 
GTPase activity of the Gα subunit by, e.g., measuring the hydrolysis of radio-labeled GTP to 
GDP and Pi in steady-state GTPase activity assays (Schneider and Seifert, 2010). 
 
 
Fig. 1.1 G protein-activation by GPCRs upon agonist binding. Adapted from Schneider and Seifert 
(2010). 
 
In order to describe pharmacological properties of a given GPCR upon interaction 
with an appropriate ligand, the extended ternary complex model is often used. According to 
this model, GPCRs exist in an inactive (R) and active (R*) conformation, which are 
equilibrated (Kenakin, 2004). Only GPCRs in the R* state are able to couple to G proteins 
and trigger signaling events. Agonists are ligands with higher affinity to the R* state, resulting 
in an activation or enhancement of GPCR-mediated downstream signaling events. On 
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contrary, inverse agonists are compounds that effectively stabilize the R state. Neutral 
antagonists bind to both states with comparable affinity and thereby compete with agonists 
and inverse agonists for binding to the receptor without affecting the equilibrium. Partial 
agonists have reduced ability to activate GPCRs, whereas partial inverse agonists have 
reduced ability to inhibit GPCRs relative to full agonists and inverse agonists, respectively 
(Seifert and Wenzel-Seifert, 2002).  
GPCRs can couple to a diversity of heterotrimeric G proteins resulting in different 
intracellular signaling processes as shown in Table 1.1. Moreover, GPCRs can 
promiscuously interact with unrelated G proteins resulting in simultaneous activation of 
multiple signaling pathways (cf. section 1.3.2) (Hermans, 2003). Experimental approaches to 
the investigation of the G protein-coupling include the use of pertussis toxin (PTX) for 
selective inactivation of Gαi/o proteins (Vallar et al., 1990; Gailly et al., 2000), specific 
antibodies raised against G proteins (Kühn et al., 1996; Alberts et al., 2000; Cussac et al., 
2002), genetic repression (Tang et al., 1995) and fusion protein approaches, where the C-
terminus of the receptor is directly fused to the G protein of interest (Milligan, 2000; Wenzel-
Seifert et al., 2001).  
 
Table 1.1 G-protein subunits and their effectors. 
Subunit Family Subtypes Effector(s) 
α αs Gαs, Gαolf AC ↑ 
 αi/o Gαi1, Gαi2, Gαi3 AC ↓ 
  GαoA, GαoB K+ channels ↑ 
  Gαt1, Gαt2 PDE ↑ 
  Gαz PDE ↑, AC ↓ 
 αq/11 Gαq, Gα11, Gα14-16 PLC ↑ 
 α12/13 Gα12, Gα13 Rho guanine-nucleotide-exchange factors ↑ 
β and γ β1-5 and γ1-12 various βγ complexes  AC ↑/↓, PLC ↑, PI3K ↑, PKC and PKD ↑, 
GPCR kinases ↑, Ca2+ and K+ channels 
Adapted from Hermans (Hermans, 2003), Worzfeld et al. (Worzfeld et al., 2008) and Smrcka (Smrcka, 
2008). AC, adenylyl cyclase; PDE, phosphodiesterase; PLC, phospholipase C; PI3K, 
phosphatidylinositol-3-kinase; PKC, protein kinase C; PKD, protein kinase D. 
 
In addition to the investigation of the G protein cycle, compounds targeting GPCRs 
can be characterized by monitoring numerous downstream signaling events. A frequently 
used read-out is the measurement of cyclic adenosine 3',5'-monophosphate (cAMP) turnover 
as a result of an activation or inhibition of adenylyl cyclases (ACs) by Gs and Gi proteins, 
respectively. Moreover, determination of PLC-mediated inositol-1,4,5-trisphosphate (IP3) 
formation or intracellular Ca2+ concentration are common methods for the assessment of Gq-
coupled GPCRs (Schneider and Seifert, 2010). The gene reporter assay is another common 
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technique applied in the characterization of compounds in recombinant test systems (Lim et 
al., 2008). 
Termination of GPCR activation is achieved by an auto-regulatory process of 
desensitization. Desensitization processes can differ between different GPCRs (Evans et al., 
2010). Therefore, the desensitization of the β2AR, one of the best characterized GPCRs, is 
described briefly in the following. Deactivation of the β2AR after stimulation with an agonist 
occurs within minutes by phosphorylation of the receptor by PKA or G protein-coupled 
receptor kinases (GRKs) (Johnson, 1998). Sites of phosphorylation are serine and threonine 
residues in the third intracellular loop and the C-terminus of the receptor (Johnson, 2006). 
Phosphorylation of the β2AR leads to uncoupling of the receptor from G proteins and to 
association with the scaffolding proteins β-arrestin-1 and/or β-arrestin-2. β2AR/arrestin 
complexes are subsequently internalized into clathrin-coated pits, forming coated vesicles 
which then fuse with endosomes (Evans et al., 2010). The internalized β2ARs are either 
recycled back to the cell membrane or degraded (Hanyaloglu and von Zastrow, 2008). 
GPCRs are differently susceptible to desensitization (Bristow et al., 1986; Michel et al., 1990; 
Summers et al., 1997; Broadley, 1999). In addition, desensitization can markedly depend on 
the localization of a given receptor. β2ARs on human bronchial smooth muscles are more 
resistant to desensitization than β2ARs on human lymphocytes (Johnson, 2006).  
 
1.3 Future directions in the investigation of GPCRs 
Early descriptions of GPCRs as “on-off” switches resulting in the modulation of a 
single uniform signaling event are obsolete (Kenakin, 2001). At present, GPCRs are rather 
considered as “microprocessors”, navigating diverse intracellular signaling events (Kenakin, 
2009). The behavior of a single GPCR is influenced by a complex interplay of numerous 
factors, which render the interpretation of pharmacological data more and more complex. 
Some of these factors, which are gaining interest in the GPCR research field, are discussed 
in the following. 
 
1.3.1 G protein-independent signaling via β-arrestin 
Besides the aforementioned classical G protein-dependent signal transduction, 
there is rapidly growing evidence of G protein-independent signaling of GPCRs (Luttrell, 
2008). One example of the latter is signaling via β-arrestins 1 and 2, which have originally 
been regarded as regulators of GPCR desensitization (Lefkowitz and Shenoy, 2005). β-
arrestins 1 and 2 are expressed in virtually all tissues, indicating their high relevance for 
regulation of GPCR signaling in general (Lefkowitz and Whalen, 2004). β-Arrestins as a 
multifunctional scaffold or as adapter proteins possess the ability to signal through numerous 
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pathways mediated e.g. by mitogen-activated protein kinases (MAPKs), phosphatidylinositol-
3-kinase (PI3K), non-receptor tyrosine kinase SRC and nuclear factor-κB. Consequently, β-
arrestins 1 and 2 are co-navigators of crucial cellular processes such as gene transcription, 
cell growth and differentiation (Rajagopal et al., 2010). In contrast to rapid and transient G 
protein-mediated responses, β-arrestin-mediated effects are considered low-level and long-
lasting (Kenakin and Miller, 2010). β-arrestin-signaling, triggered by numerous receptors, 
appears to be pro-survival, cytoprotective and anti-apoptotic (Violin and Lefkowitz, 2007). For 
example, β-arrestin-mediated signaling after activation of the β1AR was reported to have 
cardioprotective effects in mice (Noma et al., 2007). Therefore, it is not surprising, that this 
novel research area is gaining interest not only because some previously unexplained GPCR 
effects can be re-evaluated, but also because of its high clinical relevance.  
Several methods have already been applied in the investigation of GPCR-β-arrestin 
interactions. Redistribution of fluorescently-labeled β-arrestin to activated GPCR can be 
visualized by fluorescence microscopy (Hudson et al., 2006). Proximity assays monitor the 
distance between β-arrestin and GPCR after ligand binding by means of enzyme fragment 
complementation, bioluminescence (BRET) or Förster resonance energy transfer (FRET) 
(Rajagopal et al., 2010). Whereas the aforementioned approaches monitor only receptor-β-
arrestin interaction, measurement of phosphorylation of extracellular regulated kinases 1/2 
(ERK1/2) enables the assessment of β-arrestin-mediated functional consequence of GPCR 
activation as ERK1/2 are regulated by β-arrestins (Violin and Lefkowitz, 2007). A drawback 
of the latter method is the fact that ERK1/2 can also be phosphorylated via G protein-
dependent signals (Galandrin et al., 2008; Evans et al., 2010). In addition, genetically 
modified systems such as transgenic animals (knockout of β-arrestin or GRKs) or knockdown 
of β-arrestin with small interfering RNA technology enable the investigation of β-arrestin-
signaling pathways in vivo (Noma et al., 2007).  
 
1.3.2 Functional selectivity 
The complexity of GPCR signaling is further increased by the ability of ligands to 
differentially activate distinct signaling pathways by stabilizing ligand-specific conformation of 
a given receptor. In literature this observation is frequently termed functional selectivity 
(Galandrin et al., 2007). As a given GPCR can promiscuously couple to different G proteins 
(Gαs, Gαi/o, Gαq/11 and Gα12/13) and additionally trigger downstream responses via β-arrestin, 
structurally different ligands are able to individually activate and/or inactivate multiple 
signaling pathways simultaneously. For example, the β-adrenoceptor antagonist carvedilol, 
successfully used in the therapy of heart failure, has β2AR-mediated inverse agonistic 
properties regarding the Gs-dependent activation of ACs, and is an agonist for β-arrestin-
dependent ERK1/2 phosphorylation in HEK 293 cells (Wisler et al., 2007). Whereas (R,R)-
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fenoterol was reported only to couple to Gs proteins in rat cardiomyocytes, (S,R)-fenoterol 
couples dually to Gs and Gi proteins after activation of the β2AR in the same test system 
(Seifert and Dove, 2009; Woo et al., 2009). Moreover, ligand-directed signaling was reported 
for the H2R and the H4R in recombinant test systems (Appl et al., 2011; Rosethorne and 
Charlton, 2011). Very recently, Khasai and coworkers provided additional evidence for 
predominantly ligand-specific, and not agonist/inverse agonist-specific, conformations of the 
β2AR using quantitative mass spectrometry, supporting the concept of functional selectivity 
(Kahsai et al., 2011). 
There is no doubt that functionally selective ligands have therapeutic relevance in 
some cases (Kenakin and Miller, 2010). Selective activation of Gs signaling via β2AR is 
discussed to be beneficial in the treatment of congestive heart failure, whereas Gi-signaling 
could have detrimental effects (Woo et al., 2009). However, the vast majority of data on 
functional selectivity were obtained from transiently transfected cells (Rajagopal et al., 2010). 
As functional selectivity also depends on the cell type used, there is a growing interest to 
expand investigations on animal models and functionally intact human primary cells as 
physiologically more relevant test systems. New technologies have been developed, where 
dynamic mass redistribution in label-free cells after GPCR-activation is monitored by 
measuring changes of electrical impedance or by using optical biosensors. In both cases, 
real-time data provide unique kinetic patterns that can be used to recognize specific signaling 
pathways like Gs-, Gi- or Gq-mediated responses (Kenakin, 2009).  
 
1.3.3 Formation of homo- and heteromers 
Providing even more versatile and fine-tuned effects, GPCRs can modulate G 
protein-dependent and -independent responses not only as monomeric units, but also as 
homomers (two or more identical GPCRs in complex) and heteromers (two or more distinct 
GPCRs in complex) (Smith and Milligan, 2010). Binding of a particular ligand to homo- and 
heteromers can trigger responses distinct from those caused by monomeric GPCRs, 
because in higher-order GPCR-complexes the conformation of monomeric units is altered. 
For instance, co-stimulation of classically Gs-coupled dopamine D1 receptor and Gi-coupled 
dopamine D2 receptors, which were reported to form D1-D2 heterodimers, led to the 
stimulation of a solely Gq-mediated Ca2+ increase in vitro (Lee et al., 2004). Moreover, 
probably the most prominent evidence for the formation of functional GPCR homodimers in 
vivo is a recent report of Rivero-Müller and colleagues (2010). Crossbreeding of mice with a 
binding-deficient version of luteinizing hormone (LH) receptor and mice with a signaling-
deficient LH receptor rescued the wild-type phenotype with normal LH signaling. 
Methods for the investigation of homo- and heterodimers comprise classical 
approaches like radioligand binding studies and co-immunoprecipitation as well as optical 
8  Chapter 1 
methods like BRET, FRET and functional reconstitution of impaired monomers through 
dimerisation (Smith and Milligan, 2010). In addition, tracking of receptor dimerization by 
application of bivalent ligands is becoming increasingly popular (Shonberg et al., 2011). 
Bivalent ligands are compounds with two pharmacophoric moieties, joined by a linker, 
becoming able to simultaneously target two distinct binding sites on a monomer or dimer 
(Smith and Milligan, 2010). However, despite occasionally extremely high potencies in 
recombinant test systems and animal models, unfavorable physicochemical properties of 
bivalent ligands are probably the main hurdle on their way to become clinically relevant 
candidates (Birnkammer, 2011; Shonberg et al., 2011). Characterization of highly potent H2R 
bivalent agonists in human primary cells was one of the subjects of this work (cf. chapters 2 
and 4).  
Keeping in mind G protein-dependent and -independent signaling, functional 
selectivity of particular ligands, formation of receptor homo- and heteromers as well as 
additional factors not discussed above (receptor reserve and compartmentation, 
susceptibility to desensitization), GPCRs can indeed be considered as “microprocessors” of 
information. A plethora of such signaling events can be mediated via a given GPCR as 
shown with a theoretical example in Fig. 1.2. Nevertheless, the development of compounds 
that preferentially stabilize a certain GPCR conformation that triggers event(s) of clinical 
benefit on the one hand while blocking adverse effect(s) on the other hand, will be a future 
challenge. Thus, for the characterization of such compounds diverse complementary 
predictive test systems are required (Kenakin, 2009). This issue has especially been 
considered in this work (cf. chapters 2, 3 and 4). 
 
 
Fig. 1.2 Theoretical example for the complexity of GPCR-mediated signaling. After binding of the 
ligand X, the receptor A can signal differently as monomer, as homodimer and as heterodimer with 
receptor B. Ligands X and Y are able to modulate distinct downstream signaling events after binding 
to the same receptor, receptor A. Black lines stand for stimulating effect and red lines for inhibitory 
ones.  
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1.3.4 Extracellular regions of GPCRs 
Extracellular regions of GPCRs, the N-terminus and the three extracellular loops, 
have been regarded as inert peptide linkers, enabling the correct positioning of functionally 
important transmembrane regions (Peeters et al., 2011). In 2000, the first crystal structure of 
a class A GPCR, bovine rhodopsin, was resolved (Palczewski et al., 2000). This structure 
enabled first insights into the three-dimensional architecture of a representative GPCR, 
where the second extracellular loop is positioned deeply in the binding cavity and is in direct 
contact with the bound ligand. Based on this observation, studies addressing the importance 
of extracellular regions of aminergic GPCRs are intensified and provided evidence for their 
involvement in ligand recognition, receptor activation, subtype and species selectivity as well 
as allosteric modulation (Shi and Javitch, 2002; Peeters et al., 2011). Extracellular domains 
are the most variable part of GPCRs besides the C-terminus (Peeters et al., 2011). 
Therefore, compounds targeting these regions could function as allosteric modulators with 
e.g. beneficial subtype selectivity (Bokoch et al., 2010). 
Valuable information on the location of amino acids in the extracellular area have 
been provided from resolved crystal structures of the human β2-adrenergic receptor 
(Cherezov et al., 2007; Rasmussen et al., 2007; Rosenbaum et al., 2007; Rasmussen et al., 
2011a; Rasmussen et al., 2011b; Rosenbaum et al., 2011), the turkey β1-adrenergic receptor 
(Warne et al., 2008), the human histamine H1 receptor (Shimamura et al., 2011) and others. 
Nevertheless, extracellular regions as highly flexible parts of receptors are often incompletely 
resolved in crystal structures, e.g. in the crystal structure of the human adenosine A2A 
receptor (Jaakola et al., 2008). Moreover, a limitation of crystal structures is that they only 
provide a snapshot-conformation of a given GPCR, therefore there is a lack of information 
about dynamics. By contrast, recent advances in nuclear magnetic resonance spectroscopy 
provide also information about the dynamic behavior of extracellular regions (Ahuja et al., 
2009; Tikhonova and Costanzi, 2009; Bokoch et al., 2010). Most frequently classical 
mutagenesis studies, sometimes in combination with molecular dynamic simulation, are 
applied in the investigation of extracellular domains, an item also addressed in the present 
work (cf. chapters 2, 4 and 5).  
 
1.4 Species-specificity of GPCRs  
Mostly, GPCRs are considered as targets for compounds that could bring 
therapeutic benefit in humans. An investigation of drug candidates in translational animal 
models is indispensable before such compounds enter clinical trials. However, affinities of 
compounds at a given GPCR and the resulting biological effects can substantially differ from 
species to species. Species-dependent pharmacological properties of certain compounds 
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have been reported for the angiotensin AT2 receptor (Feng et al., 2005), the cannabinoid CB2 
receptor (Mukherjee et al., 2004), the melanocortin 5 receptor (Huang et al., 2000), the 
histamine H3 receptor (Hancock, 2006; Schnell et al., 2010) and the gondotropin-releasing 
hormone receptor (Reinhart et al., 2004), to name only few. High amino acid homology 
between species in no guarantee for an identical pharmacological profile of a compound as 
in some cases the mutation of a single amino acid has a dramatic impact as shown for 
example for the 5-HT1B receptor (Oksenberg et al., 1992). 
Therefore, tissue and species-specificity of GPCRs should be addressed early in 
the drug discovery process in order to avoid ineffectiveness of drugs in clinical trials and to 
reduce side effects. Species-specific behavior can already be investigated in a very early 
stage of drug development e.g. according to a high-throughput screening approach 
(Swanson and Beasley, 2010). Mutagenesis studies are frequently applied in order to identify 
single amino acids or regions, responsible for a divergence in affinity and functionality of test 
compounds in different species (cf. chapters 4 and 5) (Oksenberg et al., 1992; Lim et al., 
2008; Strasser et al., 2008). Moreover, computer-aided homology models and molecular 
dynamic simulations can provide useful information on species-specific interactions of 
compounds with GPCRs (cf. chapter 5) (Schnell et al., 2010). The generation of transgenic 
animals, in which the rodent GPCR is replaced by the human GPCR (knockin animals, e.g. 
humanized mouse) is another strategy to overcome species-specific problems (Gladue et al., 
2006).  
 
1.5 The histaminergic system 
1.5.1 Histamine as endogenous ligand  
HA (2-(1H-imidazol-4-yl)ethanamine) is a local mediator, immunomodulator and 
neurotransmitter targeting the histaminergic system. First biological effects of HA like 
vasodilatation and smooth muscle contraction were reported more than one hundred years 
ago (Dale and Laidlaw, 1910). Throughout the last century our understanding of histamine 
and its (patho)physiological role has increased enormously and resulted in the discovery of 
blockbuster drugs in the therapy of, e.g., allergic reactions and peptic ulcer. Still, because of 
their involvement in disorders of the central nervous system (CNS) and immune system, HA-
mediated effects are very active areas of research. 
The main sources of histamine are mast cells and basophil granulocytes (Bäumer 
and Rossbach, 2010). Moreover, histamine is also stored in enterochromaffin-like cells of the 
stomach (Prinz et al., 1999), blood platelets (Saxena et al., 1989), in neurons (Haas et al., 
2008), and it is present in many other tissues (Zimmermann et al., 2011). HA is synthesized 
in the body from the amino acid L-histidine through decarboxylation (Fig. 1.3). This reaction 
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is catalyzed by histidine decarboxylase (Haas et al., 2008). Normally, HA is then translocated 
from the cytosol into secretory vesicles by the vesicular monoamine transporter VMAT2 
(Dimaline and Struthers, 1996). In addition, in various cells like macrophages, dendritic cells, 
neutrophils and T cells HA is synthesized de novo (Thurmond et al., 2008; Smuda and 
Bryce, 2011). After release in response to immunological and non-immunological stimuli, HA 
is degraded by two catabolic pathways. The first pathway involves methylation of HA by 
histamine N-methyltransferase and the second pathway involves oxidative deamination by 
diamine oxidase (Ogasawara et al., 2006).  
 
 
Fig. 1.3 Biosynthesis of histamine. 
 
Histamine mediates its pleiotropic effects by targeting four histamine receptor 
subtypes, referred to as histamine H1 (H1R), H2 (H2R), H3 (H3R) and H4 receptor (H4R). The 
activated H1R couples to Gq/11 proteins and promotes typical effects of allergic reactions like 
increased vascular permeability (Hill et al., 1997). The H3R signals via Gi/o proteins and is 
primarily involved in CNS functions like cognition, learning, memory and emotion (Haas et 
al., 2008). Because of being in focus of the present work, the H2R and H4R are more 
extensively discussed in the next two sections. 
    
1.5.2 The histamine H2 receptor 
The existence of the H2R subtype was confirmed in 1972 by Black and coworkers 
(Black et al., 1972). Their observation that, in contrast to the H1R antagonist mepyramine, 
burimamide inhibited the HA-induced gastric acid secretion in anaesthetized rats and the HA-
stimulated increase in heart rate at the isolated guinea pig right atrium led to the 
classification of burimamide as the first H2R antagonist. Almost twenty years later, molecular 
cloning of the H2R from canine and human gastric parietal cells by Gantz and coworkers 
triggered extensive characterization of the H2R also in recombinant test systems (Gantz et 
al., 1991a; Gantz et al., 1991b). 
The gene encoding for the human H2R (hH2R) is located on the chromosome gene 
locus 5q35.2 (Traiffort et al., 1995). The overall amino acid sequence homology between the 
hH2R and the H2R from other species like canine (dog), guinea pig, mouse and rat is 
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relatively high (> 80 %) (Gantz et al., 1991a; Gantz et al., 1991b; Ruat et al., 1991; Traiffort 
et al., 1995; Kobayashi et al., 1996). Two isoforms of the hH2R are listed in the database of 
the National Center for Biotechnology Information, isoform 1 with 397 amino acids and 
isoform 2 with 359 amino acids (cf. chapter 3) (Strausberg et al., 2002). Several single 
nucleotide polymorphisms (SNP) in the promoter and encoding region of the hH2R gene 
have been identified in different populations, but reports on the pathological relevance in 
schizophrenia are controversial (Orange et al., 1996; Ito et al., 2000; Mancama et al., 2002). 
Moreover, formation of H2R dimers and higher-degree complexes was reported in 
recombinant test systems (Fukushima et al., 1997).  
The H2R predominantly couples to Gs proteins, resulting in an activation of ACs and 
the subsequent formation of cAMP (Hill et al., 1997) (Fig. 1.4). The second messenger cAMP 
activates PKA, which, in turn, leads to modulation of numerous downstream signaling 
pathways like activation of transcription factor termed cAMP response-element binding 
(CREB) protein resulting in altered gene transcription (Bakker and Leurs, 2005). In addition 
to Gs coupling, the coupling to Gq/11 proteins was observed for the H2R in some but not all cell 
systems (Seifert et al., 1992; Kühn et al., 1996; Wellner-Kienitz et al., 2003). The 
consequence of Gq/11-coupling is an increase in intracellular Ca2+ concentration mediated by 
the PLC. Constitutive activity of the H2R was observed in some recombinant test systems 
(Smit et al., 1996; Seifert and Wenzel-Seifert, 2002; Preuss et al., 2007). 
 
 
Fig. 1.4 Signal transduction pathways activated by the H2R stimulation. 
 
The H2R is expressed in numerous tissues. In gastric parietal cells, the H2R is 
responsible for the HA-mediated stimulation of gastric acid secretion (Black et al., 1972). 
Activation of H2Rs in atrial and ventricular tissues results in positive chronotropic and 
inotropic effects (Levi et al., 1982). Moreover, H2R-mediated smooth muscle relaxation in 
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airways, blood vessels and the uterus was reported (Black et al., 1972; Eyre and Chand, 
1982; Levi et al., 1982). Activated H2Rs on neuronal membranes in the CNS normally 
potentiate excitation, e.g. by inhibiting long-lasting hyperpolarisation (Haas and Panula, 
2003). The H2R is also expressed on numerous cells of the immune system like monocytes, 
dendritic cells, Th1/2 cells, mast cells, eosinophils and neutrophils (Bäumer and Rossbach, 
2010). H2Rs are negative regulators of the Th1- and Th2-mediated immune response (Jutel 
et al., 2001; Kunzmann et al., 2003) and are involved in the modulation of cytokine 
production (Akdis and Simons, 2006). Cimetidine was reported to have anti-tumor activity by 
inhibiting the H2R-induced suppression of the immune system (Lefranc et al., 2006). Finally, 
stimulation of H2Rs on promyeloid leukemic cells induces their differentiation into mature 
granulocytes (Seifert et al., 1992; Klinker et al., 1996), therefore, H2R agonists could be 
beneficial in the therapy of acute myeloid leukemia. 
The selective H2R antagonists cimetidine, ranitidine, famotidine, nizatidine and 
roxatidine have been successfully used in the treatment of gastric and duodenal symptoms 
(ulcers), but are nowadays mostly replaced by more effective proton pump inhibitors 
(Parsons and Ganellin, 2006).  
 
1.5.3 The histamine H4 receptor 
Although the existence of an additional histamine receptor subtype besides the H1R, 
H2R and H3R was predicted long ago (Raible et al., 1994), the H4R was discovered not until 
the year 2000 (Nakamura et al., 2000; Oda et al., 2000; Liu et al., 2001a; Morse et al., 2001; 
Nguyen et al., 2001; Zhu et al., 2001). Extensive characterization of the H4R in the past 
decade contributed to a better understanding of some symptoms of allergic reactions and 
asthma that could not be explained by the action of HA at the other three histamine receptors 
subtypes. Nevertheless, numerous questions about the (patho)physiology of the H4R remain 
to be answered. 
The gene for the human H4R (hH4R) is located on the chromosome gene locus 
18q11.2 of the human genome (Haas et al., 2008). Full-length hH4R consists of 390 amino 
acids. In contrast to other histamine receptor subtypes, the amino acid sequence homology 
between different species is quite low for the H4R. For example, hH4R shares only between 
65 and 71 % sequence homology with guinea pig, mouse, rat and canine H4Rs (Liu et al., 
2001b; Jiang et al., 2008). Two splice variants of the full-length hH4R were detected in 
eosinophils and mast cells, H4R67 and H4R302. Both splice variants are non-functional as 
monomers but can negatively regulate the full-length hH4R presumably by forming hetero-
oligomers (van Rijn et al., 2008). Various SNPs were detected in the encoding and intron 
regions of the hH4R gene and some of them are associated with atopic dermatitis (Leurs et 
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al., 2009; Yu et al., 2010). The formation of homodimers of the recombinant and 
endogenously expressed hH4R was observed by van Rijn and coworkers (2006).  
The H4R couples to members of the PTX-sensitive Gi/o proteins (Fig. 1.5). Thus, 
activation of the H4R reduces cAMP formation and further downstream events like CREB-
mediated gene transcription (Leurs et al., 2009). In addition, the H4R can activate the MAPK 
pathway via PTX-sensitive mechanisms (Morse et al., 2001). Furthermore, activation of H4R 
in mast cells and eosinophils leads to a mobilization of intracellular [Ca2+]i (Buckland et al., 
2003; Hofstra et al., 2003). An increase in [Ca2+]i is sensitive to PTX and PLC inhibitors, 
indicating that PLC is activated by the dissociated Gβγ subunit after H4R activation (de Esch 
et al., 2005). Recently, signaling of the H4R, presumably via a G protein-independent β-
arrestin pathway, resulting in a phosphorylation of ERK 1/2 in U2OS cells has been reported 
(Rosethorne and Charlton, 2011; Seifert et al., 2011). The H4R exerts high levels of 
constitutive activity (Morse et al., 2001; Schneider et al., 2009).  
 
 
Fig. 1.5 Signal transduction pathways activated by the H4R stimulation. In general, among ten 
AC isoforms, only isoforms 1, 5 and 6 can be inhibited by Gαi/o proteins (Tang and Hurley, 1998; 
Sadana and Dessauer, 2009). 
 
The H4R is preferentially expressed in cells of the immune system, in particular in 
mast cells, eosinophils, T cells, dendritic cells, basophils and monocytes, and many reports 
implicate its role in the modulation of immune and inflammatory responses (Thurmond et al., 
2008; Bäumer and Rossbach, 2010). The H4R induces chemotaxis of mast cells, eosinophils, 
dendritic cells and T cells in vitro (Hofstra et al., 2003; Ling et al., 2004; Gutzmer et al., 2005; 
Morgan et al., 2007). Furthermore, HA acting through the H4R stimulates upregulation of 
adhesion molecules, actin polymerization and shape changes of eosinophils (Buckland et al., 
2003; Ling et al., 2004). Moreover, a role of the H4R is considered in the modulation of 
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various cytokine responses, leading e.g. to the Th2 T cell polarization relevant in the 
pathophysiology of asthma (Thurmond et al., 2008). A beneficial effect of H4R antagonism 
was confirmed in vivo, where H4R-deficiet mice and mice treated with H4R antagonist 
JNJ7777120 (1-[(5-chloro-1H-indol-2-yl)carbonyl]-4-methylpiperazine) showed reduction of 
allergic lung inflammation accompanied by decreased Th2 response (Dunford et al., 2006). 
In addition, H4R antagonism proved to be effective by inhibiting longer-term Th2 cytokine-
driven pathologies like lung remodeling in a sub-chronic asthma model in mice (Cowden et 
al., 2010). Furthermore, beneficial anti-inflammatory effects of H4R antagonism have been 
observed in acute pruritus models in mice (Dunford et al., 2007; Rossbach et al., 2011) and 
an acute colitis model in rat (Varga et al., 2005). Moreover, H4R antagonists of 2-
aminopyrimidine class, structurally different from JNJ7777120, had pain-reducing effect in rat 
(Cowart et al., 2008; Liu et al., 2008) and reduced inflammation in zymosan-induced 
peritonitis in mice (Strakhova et al., 2009). Expression of the H4R was also reported in 
synovial cells of patients with rheumatoid arthritis, suggesting an involvement of the receptor 
in the pathophysiology of this disease (Ohki et al., 2007). The use of H1R antagonists in 
combination with H4R antagonist JNJ7777120 showed a synergistic inhibitory effect on the 
HA-induced scratching in mice (Dunford et al., 2007) and eosinophil infiltration into 
bronchoalveolar lavage fluid in an acute murine asthma model (Deml et al., 2009), indicating 
that combined H1R/H4R antagonism may also entail benefits compared to monotherapy with 
classical H1R antagonists.  
Although the majority of reports suggests pro-inflammatory effects as a 
consequence of the H4R activation, some recent reports are not in accordance with this 
dogma. JNJ7777120, used as a selective H4R antagonist in numerous animal studies, has 
shown inverse agonistic activity at the hH4R and partial agonistic activity at rat, mouse and 
dog H4Rs in steady-state GTPase assay using Sf9 insect cell membranes (Schneider et al., 
2010; Schnell et al., 2011). Moreover, the same ligand behaved as an agonist in a β-arrestin 
recruitment assay (Rosethorne and Charlton, 2011). In addition, a possible anti-inflammatory 
role of the H4R in a murine asthma model has been discussed recently (Neumann et al., 
2010). And last but not least, very recently, no beneficial effect of H4R antagonists was 
observed in canine model of acute atopic dermatitis (Bäumer et al., 2011). Therefore, new 
selective H4R ligands and additional in vitro and in vivo studies are needed to provide 
conclusive evidence about beneficial effects of the H4R-modulation in inflammatory and 
immunological disorders like bronchial asthma, chronic pruritus and rheumatoid arthritis 
(Zampeli and Tiligada, 2009).  
Eleven years after its discovery, ligands targeting the H4R subtype are not yet on 
the market. The H4R antagonist UR-63325 (undisclosed structure, Palau Pharma, Spain) is 
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currently in the phase II clinical trial, where its effectiveness in the therapy of asthma and 
allergic rhinitis is investigated (Leurs et al., 2011). 
 
1.6 The adrenergic system 
1.6.1 The endogenous ligands adrenaline and noradrenaline 
The adrenergic system is responsible for a variety of physiological responses in the 
central and peripheral nervous system also named “fight-or-flight” responses. The 
endogenous ligands of this system are catecholamines adrenaline (ADR, 4-[(1R)-1-hydroxy-
2-(methylamino)ethyl]benzene-1,2-diol), commonly referred to as epinephrine, and 
noradrenaline (NA, 4-[(1R)-2-amino-1-hydroxyethyl]benzene-1,2-diol), also referred to as 
norepinephrine. The biosynthesis of NA and ADR is shown in Fig. 1.6. The synthesis of NA 
takes place in noradrenergic neurons, whereas ADR is finally synthesized mainly in the 
medulla of the adrenal gland (Hein, 2004). After release from postganglionic sympathetic 
nerves and adrenal medulla, the action of ADR and NA is terminated by reuptake into nerve 
terminals. By analogy with other catecholamines, ADR and NA are metabolized by two 
enzymes, monoamine oxidase and catechol-O-methyl transferase (Kopin, 1994; Oeltmann et 
al., 2004). 
 
 
Fig. 1.6 Biosynthesis of noradrenaline and adrenaline. 
 
The hormone ADR and the neurotransmitter NA trigger diverse effects in the human 
body by targeting the α1-adrenergic receptors (α1AR), the α2-adrenergic receptors (α2AR) and 
the β-adrenergic receptors. The latter are subdivided into the β1AR, β2AR and β3AR subtypes 
(http://www.iuphar-db.org/index.jsp). α1ARs couple to Gq/11 proteins and play an important 
role in the control of smooth muscle tonus whereas α2ARs, Gi/o-coupled receptors, mainly act 
as negative regulators of neurotransmitter release (Minneman and Esbenshade, 1994; 
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Philipp and Hein, 2004). β1ARs and β3ARs classically couple to Gs proteins and their 
activation results in increased cardiac contractile force and heart rate as well as increased 
lipolysis, respectively (Hein, 2004).  
  
1.6.2 The β2-adrenergic receptor 
The existence of the β2AR subtype was suggested by Lands and colleagues on the 
basis of the observation that certain agonists and antagonists could be used to 
pharmacologically discriminate between βAR-mediated effects among tissues like cardiac 
muscle and bronchial smooth muscle (Lands et al., 1967). The first recombinant β2AR, 
cloned from hamster genomic library, was available to the research community nearly twenty 
years later (Dixon et al., 1986). At present, the β2AR is probably the best characterized 
GPCR.  
The encoding region of the human β2AR (hβ2AR) gene is located on chromosome 
5q31 (Liggett, 1997). The hβ2AR consists of 413 amino acids and shares high sequence 
homology with β2ARs of other species like hamster (87 %), guinea pig (88 %), dog (90 %) 
and cattle (88 %) (Kobilka et al., 1987; Huang et al., 1997; Einspanier et al., 1999; 
Oostendorp et al., 2002). More than 80 SNPs of the hβ2AR were identified so far (Gnadt, 
2011). Among them, three SNPs that alter the amino acid sequence of the hβ2AR were 
suggested to have significant clinical relevance in the therapy of asthma (Liggett, 1997; 
Johnson, 2006). The SNP corresponding to amino acid position 16 (arginine or glycine) has 
influence on receptor down-regulation after exposure to an agonist. Moreover, glutamate at 
position 27 (instead of glutamine) seems to protect receptor against down-regulation. 
Another SNP is located in the TM IV at amino acid position 164 (threonine or isoleucine) and 
alters agonist-binding properties of the β2AR, also resulting in altered coupling to further 
downstream signaling pathways. The β2AR forms homodimers as well as heterodimers with 
the β1AR, β3AR, angiotensin type 1 receptor and others (Smith and Milligan, 2010). Like the 
H2R and H4R, the β2AR is constitutively active (Seifert and Wenzel-Seifert, 2002). 
The β2AR classically couples to Gs proteins, leading to AC activation and cAMP 
production and consequently to PKA activation (Johnson, 2006). Further downstream 
signaling events are e.g activation of p38 MAPK (Zheng et al., 2000) and relaxation of 
smooth muscle, where PKA is responsible for the phosphorylation of regulatory proteins 
controlling the availability of Ca2+ and myosin light-chain kinase activity (Anderson, 2006). In 
addition to Gs coupling, the β2AR interacts with Gi proteins, resulting in an activation of 
ERK1/2 and p38 MAPK via Gβγ protein (Evans et al., 2010). Phosphorylation of the β2AR by 
PKA was reported to switch the coupling of the receptor from Gs to Gi proteins (Daaka et al., 
1997). However, PKA-dependent Gi-coupling of the β2AR remains controversial (Friedman et 
al., 2002; Seifert and Dove, 2009). Moreover, the recruitment of β-arrestin, which is primarily 
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responsible for receptor desensitization, to the β2AR leads to the ERK1/2 and p38 MAPK 
activation in a G protein-independent manner (Azzi et al., 2003; Gong et al., 2008). A 
simplified depiction of complex promiscuous signaling of the β2AR, described extensively by 
Evans et al. (2010), is given in Fig. 1.7. 
 
 
Fig. 1.7 Simplified depiction of cross-talk of signaling pathways upon β2AR activation. Adapted 
from Evans et al. (2010). 
 
The β2AR is widely distributed in the lung. The highest density of the β2AR was 
found in smooth muscle cells of the respiratory tract (30,000 - 40,000 receptors per cell) and 
it is also expressed in pulmonary epithelial and endothelial cells and mast cells (Johnson, 
2006). Activated β2ARs in airways elicit bronchodilatation and inhibit liberation of 
inflammatory mediators like HA and cytokine production after an allergen challenge 
(O'Connor et al., 1992; Anderson, 2006). In addition, β2ARs, localized in myocardium and 
atrial-ventricular conducting system, regulate heart force and rate (Anderson, 2006). 
Relaxation of uterine, vascular and gastrointestinal smooth muscles can be achieved via 
β2ARs (Tanaka et al., 2005). Presynaptic localisation of β2ARs on the noradrenergic axons is 
responsible for stimulation of neurotransmitter release (Ariens and Simonis, 1983). And last 
but not least, the β2AR is also expressed on inflammatory cells like mast cells, monocytes, T 
cells, eosinophils and neutrophils. β2AR agonists, mainly used as bronchodilatators, 
additionally inhibit activation of inflammatory cells, their recruitment to bronchoalveolar 
lavage and release of inflammatory mediators (Johnson, 2002). 
β2AR agonists are used in therapy of asthma and to a lesser extent in chronic 
obstructive pulmonary disease. Short-acting β2AR agonists (SABA) like salbutamol and 
fenoterol with rapid onset are used in acute asthma attacks whereas long-acting β2AR 
agonists (LABA) like salmeterol, formoterol and indicaterol are used in long-term control of 
asthma symptoms (Sears and Lötvall, 2005; Gnadt, 2011). β2AR agonists such as 
salbutamol are also used as myometrial relaxants to prevent premature labor (Gill et al., 
2006). 
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1.7 Short introduction to the test systems used in the thesis  
1.7.1 Neutrophil granulocytes as a test system for characterizing H2Rs and β2ARs 
Neutrophil granulocytes or polymorphonuclear neutrophils are white blood cells 
from the myeloid lineage (Galli et al., 2011). As one of the key players of the innate immune 
response, neutrophils are able to phagocytose, kill and digest invading microorganisms 
(Segal, 2005). Neutrophil function is, among others, regulated by numerous GPCRs on the 
plasma membrane, e.g. the formyl peptide receptor, the platelet-activating factor receptor, 
the complement factor 5a receptor, prostaglandin receptors, the H2R and the β2AR (Omann 
et al., 1987; Seifert and Schultz, 1991).  
Generally, pro-inflammatory responses of neutrophil granulocytes are inhibited by 
cAMP-increasing agents (Moore and Willoughby, 1995; Flamand et al., 2004). Therefore, 
H2R- and β2AR-mediated effects on neutrophil granulocytes are mainly of the anti-
inflammatory type, because both receptors classically couple to Gs proteins (Gespach and 
Abita, 1982; Lad et al., 1985; Bäumer and Rossbach, 2010). In the following, few examples 
of H2R- and β2AR-dependent effects are mentioned. HA inhibits N-formyl-L-methionyl-L-
leucyl-L-phenylalanine (fMLP)- and platelet-activating factor-induced leukotriene (LT) 
synthesis in human neutrophils via the H2R (Flamand et al., 2004). The H2R negatively 
regulates neutrophil infiltration to the site of inflammation (Hirasawa et al., 2002). The β2AR 
agonist formoterol attenuates fMLP-induced synthesis of LTB4 (Gravett et al., 2010). In 
addition, β2AR agonists suppress peroxidase release from neutrophil granules (Yasui et al., 
2006). Activation of both receptors leads also to the inhibition of NADPH oxidase that is 
crucial enzyme for initiation of the respiratory burst (Burde et al., 1989; Betten et al., 2003; 
Yasui et al., 2006).  
Collectively, the influence of the H2R and the β2AR on intracellular events in 
neutrophil granulocytes can be monitored by different downstream read-outs. Moreover, 
neutrophils are the most abundant white blood cells in humans and can be easy isolated 
from venous blood in sufficient quantities (Selvatici et al., 2006). Hence, isolated human 
neutrophils have been used as a physiologically relevant test system for the characterization 
of ligands targeting the H2R and the β2AR in the present work (cf. chapters 3 and 4). 
 
1.7.2 The Sf9 insect cell system 
Sf9 insect cells are derived from Spodoptera frugiperda pupal ovarian tissue and 
are suitable for high-level expression of functional GPCRs and other proteins (Schneider and 
Seifert, 2010). For instance, the hβ2AR was purified from Sf9 insect cells in sufficient 
quantities to allow its crystallization (Cherezov et al., 2007). The GPCR of interest can be 
recombinantly expressed by infection of the Sf9 cells with genetically modified baculoviruses 
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(Autographa californica) that carry the inserted gene encoding the GPCR of interest. An 
additional advantage of Sf9 cells is their ability to perform most post-translational 
modifications of GPCR present in mammalian cells (Aloia et al., 2009). Sf9 insect cells 
endogenously express Gq- and Gs-like proteins as well as one Gi isoform (Kühn et al., 1996; 
Knight and Grigliatti, 2004). Mammalian GPCRs couple only poorly to insect Gq and Gs 
proteins (Houston et al., 2002; Dolby et al., 2004). Gi proteins from Sf9 cells normally do not 
couple to mammalian GPCRs as was also shown for the hH4R (Schneider et al., 2009; 
Schneider and Seifert, 2010). Therefore, limited coupling of expressed mammalian GPCRs 
with endogenous G proteins ensures favorably high signal-to-noise ratios.  
In an early stage of the drug development process, recombinant test systems are 
useful tool for providing some valuable mechanistic data by keeping the maintenance 
requirements low (Aloia et al., 2009; Kenakin, 2009). As such, the Sf9 cell system enables 
the reconstitution of the GPCR of interest in a defined environment that precludes cross-talk 
with other receptors. Moreover, controlled co-expression of the selected GPCR and G 
protein(s) as well as the use of GPCR-G protein fusion proteins enables the precise 
assessment of the G protein coupling profile (Lachance et al., 1999; Gazi et al., 2003). 
Expression of GPCRs in Sf9 cells enables both, binding studies (e.g. high-affinity agonist 
binding) and functional studies like cAMP accumulation, [35S]GTPS binding to the Gα 
protein, GTPase activity of the Gα protein, Ca2+ mobilization and IP3 formation (Schneider 
and Seifert, 2010). Experiments can be carried out either with whole cells (Zhang et al., 
1999) or with broken-cell preparations (membranes) as in the present study (cf. chapters 4 
and 5). 
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As outlined in the General Introduction, in drug research recombinant test systems 
are frequently applied in the characterization of G protein-coupled receptors (GPCRs). 
However, the question arises, if such artificial systems in deed represent the 
(patho)physiological situation and if pharmacological profiles of compounds determined at 
recombinant receptors are predictive for their behavior on native GPCRs. Therefore, there is 
a tendency toward the use of native test systems, where GPCRs are characterized in a more 
or less intact environment. Human neutrophil granulocytes represent such a native test 
system, where endogenously expressed histamine H2 receptors (H2Rs) and β2-adrenergic 
receptors (β2ARs) mediate anti-inflammatory responses of potential therapeutic relevance 
(Johnson, 2002; Bäumer and Rossbach, 2010). The first aim of this thesis was the 
characterization of both receptors on these immune cells. Precisely, the role of these GPCRs 
in the accumulation of cyclic adenosine 3',5'-monophosphate and in the production of 
superoxide anions should be evaluated. Results should be compared with published data, 
obtained for the H2R and the β2AR in recombinant test systems, in order to elucidate test 
system peculiarites. Moreover, under the same experimental conditions the analysis of the 
H2R and the β2AR should reveal a potential divergence in their anti-inflammatory action on 
neutrophils. 
 
New selective H2R agonists are not only needed as valuable pharmacological tools, 
but could also become potential drug candidates, e.g. in the therapy of severe acute myeloid 
leukemia. Monovalent and bivalent NG-acylated hetarylpropylguanidines, developed in our 
laboratory, turned out to be highly potent H2R agonists (Kraus et al., 2009; Birnkammer, 
2011). However, these ligands are generally more potent at the guinea pig than at the human 
H2R, whereas standard H2R agonists such as amthamine and dimaprit are equipotent at both 
species orthologs. Although already addressed in a previous study (Birnkammer, 2011), 
molecular determinants for the species selective profile of acylguanidines are not completely 
understood. A second object of this work was to explore by mutagenesis studies, if there is a 
potential involvement of the extracellular N-terminus of the H2R in species-divergence. 
The aforementioned acylguanidines are amphiphilic cationic compounds and 
therefore prone to interactions with biological membranes and off-targets. Moreover, they 
have cytotoxic and hemolytic activity at higher concentrations and bind strongly to serum 
albumin (Birnkammer, 2011). Acylguanidines have been characterized at the human H2R 
only on Sf9 cell membranes so far. Under these conditions unfavorable physicochemical 
properties do obviously not hamper the effectiveness of the agonists. However, their 
physicochemical nature could be problematic with respect to hH2R-mediated responses in 
live cells. To evaluate the drug-likeness of representative monovalent and bivalent 
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acylguanidines, their agonistic activity was intended to be evaluated at endogenously 
expressed H2R on human neutrophil granulocytes.  
 
Frequently occurring species-specific characteristics of GPCRs are a major problem 
because an examination of drug candidates in translational animal models is inevitable. In 
particular, the behavior of the histamine H4 receptor (H4R) orthologs depends largely on the 
species used (Jiang et al., 2008; Lim et al., 2010; Schnell et al., 2011). However, which 
regions or amino acids of the H4R are responsible for this divergence between species is 
poorly investigated. Amino acid homology of the extracellular N-teminus and three 
extracellular loops between e.g. human and canine H4R is very low, and it is conceivable, 
that these regions contribute to species differences. Therefore, an additional aim of this work 
was to elucidate the importance of extracellular regions for the large species differences 
between the human and the canine H4R. In order to achieve this aim, human/canine H4R 
chimeras with modified extracellular regions should be constructed and the influence on 
expression in Sf9 cells as well as on ligand binding and receptor activation should be 
examined.   
  
38  Chapter 2 
2.1 References 
Bäumer W and Rossbach K (2010) Histamine as an immunomodulator. J Dtsch Dermatol 
Ges 8:495-504. 
Birnkammer T (2011) Highly potent and selective acylguanidine-type histamine H2 receptor 
agonists: synthesis and structure-activity relationships of mono- and bivalent ligands. 
Doctoral thesis, University of Regensburg, Germany. http://epub.uni-
regensburg.de/22237/ 
Jiang W, Lim HD, Zhang M, Desai P, Dai H, Colling PM, Leurs R and Thurmond RL (2008) 
Cloning and pharmacological characterization of the dog histamine H4 receptor. Eur J 
Pharmacol 592:26-32. 
Johnson M (2002) Effects of 2-agonists on resident and infiltrating inflammatory cells. J 
Allergy Clin Immunol 110:S282-290. 
Kraus A, Ghorai P, Birnkammer T, Schnell D, Elz S, Seifert R, Dove S, Bernhardt G and 
Buschauer A (2009) NG-acylated aminothiazolylpropylguanidines as potent and 
selective histamine H2 receptor agonists. ChemMedChem 4:232-240. 
Lim HD, de Graaf C, Jiang W, Sadek P, McGovern PM, Istyastono EP, Bakker RA, de Esch 
IJ, Thurmond RL and Leurs R (2010) Molecular determinants of ligand binding to H4R 
species variants. Mol Pharmacol 77:734-743. 
Schnell D, Brunskole I, Ladova K, Schneider EH, Igel P, Dove S, Buschauer A and Seifert R 
(2011) Expression and functional properties of canine, rat, and murine histamine H4 
receptors in Sf9 insect cells. Naunyn Schmiedeberg's Arch Pharmacol 383:457-470. 
 
 
39 
Chapter 3 
Distinct pharmacological profile of the histamine H2 
receptor and the β2-adrenergic receptor on human 
neutrophil granulocytes  
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3.1 Introduction 
In humans neutrophil granulocytes represent 50 to 60 % of the total white blood 
cells and are involved in defense of the host organism against invading infectious agents 
such as bacteria, fungi, protozoa, viruses and tumor cells (Selvatici et al., 2006). After 
phagocytosis of invading agents neutrophils are able to destruct them by releasing proteases 
and antimicrobial proteins and by respiratory burst (Bertram and Ley, 2011). One important 
player in the process of the so-called respiratory burst is an enzymatic complex, namely the 
NADPH oxidase, localized on the plasma and phagosome membrane of neutrophils and 
some other cells of the immune system (Seifert and Schultz, 1991). This enzyme catalyzes 
the univalent reduction of molecular oxygen (O2) to the superoxide anion (O2•-) with NADPH 
as the specific electron donor according to the following reaction: 2O2 + NADPH  2O2•- + 
NADP+ + H+ (Morel et al., 1991; Seifert and Schultz, 1991). H2O2 is generated by superoxide 
dismutase from O2•- and further metabolized to other reactive oxygen species and 
hypochloric acid (Bertram and Ley, 2011).  
Activation of neutrophil granulocytes is triggered by numerous intercellular 
molecules like platelet activating factor, adenosine 5’-triphosphate (ATP) and bacterial formyl 
peptides (Burde et al., 1989). Upon binding of N-formyl-L-methionyl-L-leucyl-L-phenylalanine 
(fMLP) to the formyl peptide receptor (FPR), which is Gi-coupled (Gierschik et al., 1989; 
Wenzel-Seifert et al., 1999), O2•- production in neutrophils increases (Selvatici et al., 2006) 
(Fig. 3.1). This happens via activation of phospholipase C (PLC) resulting in the cleavage of 
phosphatidylinositol-4,5-bisphosphate (PIP2) yielding 1,2-diacylglycerol (DAG) and inositol-
1,4,5-trisphosphate (IP3). DAG activates protein kinase C (PKC) and IP3 induces Ca2+-
mobilization from intracellular stores (Morel et al., 1991). The activation of PKC is required for 
the phosphorylation of NADPH oxidase resulting in its activation (Bertram and Ley, 2011).  
fMLP-stimulated O2•- production in neutrophil granulocytes and HL-60 cells is 
counteracted by some agents that increase the intracellular cyclic adenosine 3',5'-
monophosphate (cAMP) concentration (Seifert and Schultz, 1991). These agents are, among 
others, prostaglandins, the unspecific inhibitor of phosphodiesterases, 3-isobutyl-1-
methylxanthine (IBMX), the cell-permeable cAMP analog dibutyryl cAMP as well as agonists 
of the histamine H2 receptor (H2R) and the β2-adrenergic receptor (β2AR) (Wong and Freund, 
1981; Burde et al., 1989; Seifert and Schultz, 1991; Mitsuyama et al., 1995; Mirza et al., 
2002).  Furthermore, fMLP-stimulated O2•- formation is enhanced by the incubation of 
neutrophils with N-(2-{[(E)-3-(4-bromophenyl)prop-2-enyl]amino}ethyl)isoquinoline-5-
sulfonamide (H-89), an inhibitor of cAMP-dependent protein kinase (PKA) (Mitsuyama et al., 
1995). It is not exactly clear, how cAMP increasing agents counteract the fMLP-stimulated 
O2•- production, but mechanisms involving the phosphorylation of FPRs, Gi proteins, PLC and 
p47 subunit of NADPH oxidase by PKA are discussed (Seifert and Schultz, 1991). A newer 
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study suggests the H2R-induced inhibition of fMLP-stimulated O2•- production to be upstream 
of PKC (Betten et al., 2003). 
 
 
Fig. 3.1 Simplified depiction of the fMLP-induced O2•- production signaling pathway and the 
interference of the latter with the signaling pathways of the H2R and 2AR in human (h) 
neutrophil granulocytes. O2•- and cAMP accumulation (marked with red circles) were chosen as read 
outs for the characterization of the hH2R and the h2AR.  
 
The H2R and β2AR, also expressed on neutrophil granulocytes, are some of the 
best characterized aminergic GPCRs. Classically, both, the H2R and the β2AR couple to Gs 
proteins in order to activate adenylyl cyclases (AC) resulting in increased intracellular cAMP 
turnover (Fig. 3.1). Nevertheless, the β2AR can also “signal” via Gi proteins, Gq proteins and 
-arrestin, triggering responses distinct from those activated through Gs proteins (Wenzel-
Seifert and Seifert, 2000; Seifert and Dove, 2009; Evans et al., 2010). Signaling of the H2R 
can also be Gq-mediated (Kühn et al., 1996; Wang et al., 2000). Therefore, because of the 
above-mentioned promiscuous coupling to G proteins, a multiplicity of signaling pathways 
can be activated via H2Rs and β2ARs. To make the situation even more complicated, this 
promiscuous signaling varies with different cell types, and various ligands are able to 
selectively direct the signaling in the same test system (Evans et al., 2010).  
As H2R and β2AR agonists inhibit fMLP-stimulated O2•- production on neutrophil 
granulocytes, they harbor a potential as anti-inflammatory agents (Burde et al., 1990; Mirza 
et al., 2002). The aim of the present study was the characterization of the H2R and the β2AR 
on human neutrophil granulocytes with a series of standard H2R and β2AR ligands, 
respectively (Fig. 3.2). Neutrophil granulocytes can be considered as a cell test system of 
high physiological relevance. cAMP accumulation assays and O2•- production assays were 
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chosen as read-outs. Measurement of the cAMP content in neutrophils is an event rather 
proximal to ligand-receptor interaction, whereas monitoring of H2R- and β2AR-mediated 
effects on fMLP-stimulated O2•- production (O2•- assay) is a rather indirect way of 
characterizing the above-mentioned receptors (Fig. 3.1). Hence, the O2•- assay is more 
susceptible to potential modulation by intracellular signaling events. Nevertheless, such 
downstream modulations of ligand-induced in vivo effects are in general of high clinical 
relevance, e.g. responsible for side effects of drugs, and should always be taken into 
consideration, when new ligands are developed. Therefore, the O2•- assay, in combination 
with the cAMP assay, enabled deeper insight into the behavior of selected receptors on 
neutrophil granulocytes and rendered the direct comparison of the H2R and the β2AR 
possible. In this work, we report on functional selectivities of examined H2R and β2AR 
agonists. Moreover, as repeatedly reported in the literature for other test systems (Seifert et 
al., 1998; Wenzel-Seifert et al., 2001; Baker et al., 2003; Baker, 2008), on neutrophil 
granulocytes hH2Rs and hβ2ARs have distinct pharmacological profiles. And last but not 
least, possible reasons for the unexpected divergence in determined pKB values for H2R 
antagonists are discussed.     
 
3.2 Materials and Methods 
3.2.1 Materials 
Histamine (HA), amthamine (AMT), 5-methylhistamine (5-MHA), tiotidine (TIO) and 
thioperamide (THIO) were obtained from Tocris Bioscience (Avonmouth, Bristol, UK). 
Mepyramine (MEP), dimaprit (DIM), famotidine (FAM), zolantidine (ZOL), (-)-isoproterenol 
(ISO), (-)-adrenaline (ADR), (±) salbutamol (SAL) and (±) dobutamine (DOB) were from 
Sigma-Aldrich Chemie (Steinheim, Germany). (-)-ephedrine (EPH) was from Mallinckrodt (St. 
Louis, MO, USA) and (±) dichlorisoproterenol (DCI) from Aldrich (Milwaukee, WI, USA). 
Impromidine (IMP) (Durant et al., 1978) was synthesized in our laboratory. Chemical 
structures of ligands are depicted in Fig. 3.2. Stock solutions of HA, DIM, AMT, 5-MHA, IMP, 
MEP, THIO, ZOL (10 mM each) and TIO (5 mM) were prepared in Millipore water. Stock 
solution of FAM (2 mM) was prepared in 2 mM HCl. Stock solutions of ISO, ADR, SAL, DOB, 
EPH and DCI (10 mM each) were prepared in 1 mM HCL. Dilution series of all ligands were 
prepared in Millipore water.  
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Fig. 3.2 Structures of the examined H2R and β2AR ligands. 
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10 x Dulbecco’s PBS (DPBS) without Ca2+ and Mg2+ (pH 6.5 – 7.0) was purchased 
from PAN Biotech (Aidenbach, Germany) and Biocoll separating solution from Biochrom 
(Berlin, Germany). Trypan blue solution, ferricytochrome c, cytochalasin B, fMLP and IBMX 
were from Sigma-Aldrich Chemie (Steinheim, Germany). Solvents for extraction and HPLC 
analysis were purchased as follows: HPLC-gradient grade water and methanol from J. T. 
Baker (Deventer, The Netherlands), ammonium acetate from Sigma-Aldrich Chemie 
(Steinheim, Germany) and acetic acid from Riedel-de Haen (Hannover-Seelze, Germany). 
Tenofovir was obtained from the National Institutes of Health (Bethesda, MD, USA) and 
cAMP (> 99 %) from Biolog Life Science Institute (Bremen, Germany). 
All reagents, used for the reverse transcription of RNA, were obtained from 
Fermentas (St. Leon‐Rot, Germany). For PCR the DNA primers were purchased from MWG 
Biotech (Ebersberg, Germany). Phusion High-Fidelity DNA Polymerase and Phusion HF 
buffer were obtained from Finnzymes (Espoo, Finland). Sequencing was performed by 
GATC Biotech (Konstanz, Germany). 
 
3.2.2 Isolation of human neutrophils  
Human neutrophils were isolated from venous blood of healthy volunteers of either 
sex (1.6 mg EDTA/ml blood as anticoagulant) or from buffy coat preparations, obtained from 
the Institute for Transfusion Medicine (Medical School of Hannover, Germany). All isolation 
steps were carried out at room temperature. Firstly, 7 ml of venous blood or 5 ml of buffy 
coat was diluted to 35 ml with 1 x DPBS and carefully layered onto 15 ml of Biocoll 
separating solution (density 1.077 g/ml) in a 50 ml-Falcon tube. Following centrifugation (30 
min, 400 x g), the upper three layers were removed. The residual pellet (2 ml), which 
contained erythrocytes and granulocytes, was re-suspended in 18 ml of Millipore water and 
incubated for 1 min under gentle agitation in order to achieve selective lysis of the 
erythrocytes. Afterwards, isotonicity was restored by adding 2.2 ml of 10 x DPBS and 
centrifugation at 300 x g for 5 min followed. The lysis step was repeated once to remove 
residual erythrocytes. The cell pellet was re-suspended in 5 ml of 1 x DPBS and sedimented 
by centrifugation at 300 x g for 5 min. Normally, the resulting cell preparation consisted of 
viable neutrophils (> 98 %), as assessed by the trypan blue exclusion test. Finally, 
neutrophils were suspended in 1 x PBS (1 x 106 cells/ml for the superoxide anion assay or 1 
x 107 cells/ml for the determination of cAMP) and stored on ice until use. Experiments were 
performed within 4 h after completion of isolation. 
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3.2.3 Superoxide anion generation (O2•- assay) 
Reactions were carried out in 96-well plates in triplicate. Standard reaction mixtures 
(total volume 200 µl) contained 1 mM CaCl2, 100 µM ferricytochrome c, 0.3 µg/ml 
cytochalasin B, examined ligand at different concentrations and 1 x 105 neutrophils in 1 x 
DPBS. After pre-incubation of the reaction mixtures for 3 min at 37 °C, reactions were 
initiated by addition of stimulatory fMLP (1 µM). Reference samples contained all 
components listed above except for fMLP. O2•- formation was continuously measured by 
monitoring the reduction of ferricytochrome c at 550 nm for 30 min at 37 °C, using a Synergy 
4 microplate reader (BioTek Instruments, Winooski, VT, USA). The difference in absorbance 
at 550 nm between 0 min (addition of fMLP) and 30 min was used for subsequent data 
analysis, in order to assess agonistic activity of examined ligands. With the exception of 
DOB, all examined ligands did neither reduce ferricytochrome c nor stimulate O2•- production 
per se (data not shown). As at DOB concentrations higher than 500 nM, ferricytochrome c 
reduction took place, the maximum concentration of DOB used in the O2•- assays was 500 
nM. 
 
3.2.4 cAMP accumulation and extraction from neutrophils (cAMP assay) 
Reactions were conducted in triplicate in 1.5 ml Eppendorf reaction vessels in a 
total volume of 100 µl. First of all, 50 µl of the reaction mixture containing CaCl2 (1 mM final 
concentration after addition of neutrophils), IBMX (non-selective phosphodiesterase inhibitor; 
100 µM) and the respective ligand at different concentrations in 1 x DPBS were pre-
incubated for 5 min at 37 °C. Isolated neutrophils suspended in 1 x DPBS were pre-
incubated separately for 10 min at 37 °C. Following the addition of 50 µl of neutrophils (5 x 
105 cells/reaction vessel) to reaction mixture, samples were incubated for 10 min at 37 °C. 
Afterwards, samples were incubated for 10 min at 95 °C in order to stop the enzymatic 
reaction and then cooled to 4 °C. One hundred µl of ice-cold internal standard (tenofovir; 100 
ng/ml) in eluent A (3/97 MeOH/H2O, 50 mM NH4OAc, 0.1 % HOAc) were added. The 
suspension was centrifuged at 20.800 x g at 4 °C for 5 min in order to remove denatured 
proteins. The cAMP concentration of the supernatant was determined by reversed phase-
coupled HPLC-MS/MS. 
 
3.2.5 Quantitation of cAMP by HPLC-MS/MS  
The chromatographic separation was performed on an Agilent 1100 Series HPLC 
System (Agilent Technologies) equipped with a binary pump system and with a 100 µl 
sample loop. A combination of Supelco Column Saver (2.0 µm filter, Supelco Analytical, 
Bellafonte, CA, USA), Security Guard Cartridge (C18, 4 x 2 mm) in an Analytical Guard 
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Holder KJO-4282 (Phenomenex, Aschaffenburg, Germany) and an analytical Zorbax Eclipse 
XDB-C16 column (50 x 4.6 mm, 1.8 µm particle size, Agilent Technologies, Santa Clara, CA, 
USA), temperature controlled by a HPLC column oven at 25 °C, were used. The binary pump 
system supplied eluent A (50 mM ammonium acetate and 0.1 % (v/v) acetic acid in a 
methanol/water mixture (3/97 (v/v)) and eluent B (50 mM ammonium acetate and 0.1 % (v/v) 
acetic acid in a methanol/water mixture (97/3 (v/v)). The injection volume was 50 µl and the 
flow rate of 0.4 ml/min remained constant throughout the chromatographic run. From 0 to 5 
min, the gradient of eluent B was linearly increased from 0 to 50 % of eluent B, and re-
equilibrium of the column to 100 % of eluent A was achieved from 5 to 8 min. Retention times 
of the analyte cAMP and the internal standard tenofovir were 6.2 and 5.4 min, respectively 
(Fig. 3.3). The internal standard was used to mathematically correct the loss of cAMP during 
preparation as well as possible variabilities in HPLC-MS/MS measurement. 
 
 
Fig. 3.3 Representative chromatogram of tenofovir (340 pmol/ml) and cAMP (320 pmol/ml) after 
HPLC-MS/MS detection. Blue peak, tenofovir transition +288/176 (quantifier); red peak, tenofovir 
transition +288/159 (qualifier); green peak, cAMP transition +330/136 (quantifier); grey peak, cAMP 
transition +330/312 (qualifier). 
 
Analyte detection was conducted on an AB Sciex QTRAP 5500 triple quadropole 
mass spectrometer (AB Sciex, Foster City, CA, USA) using selected reaction monitoring 
(SRM) analysis in positive ionization mode. For this purpose nitrogen was used as collision 
gas. Using a 50 ms dwell time, SRM transitions were monitored as follows: cAMP +330/136 
and +330/312, tenofovir +288/176 and +288/159 (Fig. 3.3). The transition +330/136 was the 
most intense transition of cAMP and therefore used for quantification. Additionally the 
+330/312 transition of cAMP was used as qualifier. The transition +288/176 of tenofovir was 
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used as quantifier and the transition +288/159 as qualifier. The mass spectrometer 
parameters were as follows: ion source voltage: 4500 V, ion source temperature: 600 °C, 
curtain gas: 30 psi and collision gas: 9 psi. 
cAMP in samples was quantified by applying the standard curve, obtained by 
analysis of known amounts of pure cAMP at: 0.0262, 0.066, 0.164, 0.41, 1.024, 2.56, 6.4, 16, 
40, 100, 250 pmol/tube. 
 
3.2.6 mRNA isolation from neutrophil granulocytes, reverse transcription PCR, 
cDNA amplification and sequencing 
Neutrophil granulocytes were isolated as described in section 3.2.2, though under 
sterile conditions. Total RNA was isolated from neutrophil granulocytes (7.8 x 108 cells) using 
NucleoSpin RNA II kit (Macherey-Nagel, Düren, Germany) according to the manufacturer’s 
instructions. The RNA content was determined with a Nanodrop 1000 Spectrometer (Thermo 
Scientific, Wilmington, DE, USA). Purified RNA was then used immediately for the synthesis 
of single-stranded cDNA (cDNA) or stored at -80 °C until use. For the synthesis of cDNA, 
each reaction mixture (final volume 20 µl) contained 3 µg of RNA, 0.5 µg of Oligo (dT)18, 2 
mM of dNTP Mix, 20 units of RevertAid M-MULV Reverse Transkriptase and 1 x supplied 
PCR buffer. RNA and Oligo(dT)18 were denatured at 65 °C for 5 min prior to transcription (60 
min, 37 °C). Finally, to inactivate enzymes, the reaction mixtures were incubated at 95 °C for 
2 min.  
For the amplification of cDNA by PCR two pairs of primers were used in order to 
discriminate between isoform 1 and isoform 2 of the hH2R. mRNA sequences of the isoform 
1 (mRNA accession number NM_001131055.1, http://www.ncbi.nlm.nih.gov/nuccore/ 
NM_001131055.1) and the isoform 2 (mRNA accession number NM_022304.2, 
http://www.ncbi.nlm.nih.gov/nuccore/NM_022304.2) from NCBI database were used for the 
design of the primers. The forward primer hH2R_F (5’-GATGGCACCCAATGGCACA-3’) was 
devised to align non-selectively in the region of the START codon of both H2R isoforms (Fig. 
3.4). The reverse primer hH2R_R_Iso1 (5’-CATCATAATTCCTGGCATGTGGTGG-3’) was 
constructed to selectively anneal to the isoform 1 sequence in the area of STOP codon (Fig. 
3.4). In the same manner, the reverse primer hH2R_R_Iso2 (5’-CTATTACCTGTCTGTGG 
CTCCCTG-3’) was designed for selective annealing to the isoform 2 in the area of STOP 
codon (Fig. 3.4). Reaction mixtures (total volume 50 µl) consisted of 5 µl of reverse 
transcripted cDNA, 200 µM of dNTP Mix, 200 nM of selected primers, 1 unit of Phusion High-
Fidelity DNA polymerase and 1 x Phusion HF buffer. In order to exclude contamination by 
external DNA, a control PCR reaction mixture, containing all components mentioned above 
except cDNA, was prepared in parallel. PCR reactions were conducted under the following 
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conditions: 1 min at 98 °C, 30 cycles of [10 s at 98 °C, 20 s at 70 °C, 35 s at 72 °C], at 72 °C 
for 8 min.  
 
 
Fig. 3.4 Schematic depiction of annealing areas of selected primers on hH2R isoform 1 and 
isoform 2 cDNA sequences. Expected lengths of PCR products using different primer pairs were as 
follows: 1197 bp with primer pair hH2R_F/hH2R_R_Iso1, 1085 bp with primer pair hH2R_F/ 
hH2R_R_Iso2 and 1249 bp with primer pair hH2R_F_Iso2_seq/hH2R_R_Iso2_seq. 
 
In order to enable sequencing of the complete hH2R isoform 2 between the START 
and the STOP codon, new primers for the isoform 2 were designed. The forward primer 
hH2R_F_Iso2_seq (5’-GGCATAGTTGTCACATTGGGAGC-3’) annealed to 23 base pairs 
(bp) upstream of the START codon of the isoform 2 and the reverse primer 
hH2R_R_Iso2_seq (5’- CCAGCACCACCTAAACAGCAG-3’) annealed to 21 bp of the isoform 
2 downstream of the STOP codon (Fig. 3.4). Reaction mixtures (total volume 50 µl) consisted 
of 5 µl reverse transcripted cDNA, 200 µM of dNTP Mix, 200 nM of primers 
hH2R_F_Iso2_seq and hH2R_R_Iso2_seq each, 1 unit of Phusion High-Fidelity DNA 
polymerase and 1 x Phusion HF buffer. The control PCR reaction mixture contained all 
aforementioned components except cDNA. PCR was performed under the following 
conditions: 1 min at 98 °C, 38 cycles of [10 s at 98 °C, 20 s at 69 °C, 40 s at 72 °C], 8 min at 
72 °C. The complete nucleotide sequence of the isoform 2 was determined by sequencing 
using primers hH2R_F_Iso2_seq, hH2R_R_Iso2_seq, hH2R_F_middle (5’-GAAGTGTACGGG 
CTGGTGGATG-3’) and hH2R_R_middle (5’-CATCCACCAGCCCGTACACTTC-3’) (Fig. 3.4). 
 
3.2.7 Miscellaneous 
Chromatograms, obtained by the HPLC-MS/MS analysis, were analyzed with the 
Analyst Software 1.5.1 (AB Sciex, Foster City, CA, USA). Data from the O2•- assay and the 
cAMP assay were analyzed with the Prism 5.01 software (GraphPad, San Diego, CA, USA). 
The means ± S.E.M. were always determined by the analysis of at least three independent 
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experiments, performed in triplicates, if not indicated otherwise. Statistical significance was 
always defined as p  0.05 (95 % confidence interval). 
 
3.3 Results 
3.3.1 Characterisation of the H2R on human neutrophil granulocytes with standard 
H2R agonists and antagonists 
In order to extensively characterize the H2R on human neutrophil granulocytes the 
O2•- assay and the cAMP assay were used as read-outs. As already explained in the 
introduction, the effect of H2R agonists can be measured as an inhibition of fMLP-stimulated 
O2•- production in the O2•- assay (Fig. 3.5), whereas in the cAMP assay the H2R agonistic 
activity is directly proportional to an increase in cAMP accumulation (Fig. 3.6). In both cases, 
the inter-experimental variability was very high (Fig. 3.5C and Fig. 3.6B). Inter-individual 
variability of human neutrophil function had been observed previously (Seifert et al., 1991). 
In the O2•- assay, an IC50 value of 22.5 µM (pIC50 4.65) was determined for the 
endogenous and standard H2R agonist HA (Table 3.1). This value is 2.8-fold higher than 
IC50 value (8 µM) in a similar assay format reported more than two decades ago (Burde et 
al., 1989). We can exclude the possibility that different concentrations of cytochalasin B are 
responsible for this divergence (0.3 µg/ml in our O2•- assay and 1 µg/ml in assay from Burde 
et al. (1989)). The same group characterised HA in neutrophil granulocytes also in the 
absence of the cytochalasin B, and the resulting IC50 value was 6.7 µM (Burde et al., 1990). 
Cytochalasin B in the O2•- assay has a primig role by enhancing O2•- formation upon exposure 
to fMLP (Jesaitis et al., 1986; Seifert and Schultz, 1991). Nevertheless, the concentration of 
Ca2+ and Mg2+ in the test tubes and also handling of neutrophils during isolation and O2•- 
assay (shear forces) can influence the activation of neutrophils (Seifert and Schultz, 1991; 
Oh et al., 2008). In our O2•- assay the concentration of CaCl2 was identical with the CaCl2 
concentration in the O2•- assay from Burde et al. (1989), whereas MgCl2 concentration 
differed between assays (0 mM and 1 mM, respectively). Additionally, instead of Biocoll 
separating solution, Dextran T 500 was used previously (Burde et al., 1989) as a polymer for 
isolation of neutrophils. Therefore, besides unequal handling of neutrophils also the 
presence/absence of MgCl2 and usage of different separation polymer could influence the 
extent of activation of neutrophil granulocytes and could be the reason for different potencies 
of HA in different test systems. Nevertheless, with respect to the potency of HA our data are 
comparable with the data of Ozaki and co-workers, who reported an IC50 value of about 30 
µM for the HA-induced inhibition of the luminol-dependent chemiluminescence of 
granulocytes (Ozaki et al., 1984). 
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Fig. 3.5 Superoxide anion generation assay (O2•- assay). The O2•- production in human neutrophil 
granulocytes (1 x 105 cells per well) was monitored by measuring the superoxide dismutase- 
inhibitable reduction of ferricytochrome c at 550 nm as described in section 3.2.3. (A) Continuous 
measurement of O2•- production for 30 min under control conditions (control), after stimulation with 1 
µM fMLP (fMLP) and in the presence of 1 µM fMLP in combination with 100 µM HA (fMLP + HA) or 1 
µM ISO (fMLP + ISO). Data shown are from one representative experiment performed in triplicate. (B) 
Concentration-response curves for HA and ISO in the O2•- assay. Data shown are from eight (HA) or 
nine (ISO) independent experiments, performed in triplicate (data points are means ± S.E.M.). Data 
were analyzed by non-linear regression and were best fitted to sigmoidal concentration/response 
curve. (C) Inter-experimental variability of inhibitory effect of 100 µM HA and 1 µM ISO on fMLP-
stimulated O2•- production. Each data point represents one independent experiment. Dashed lines 
connect data points obtained in one experiment. Increase in absorbance at 550 nm during 30 min after 
addition of fMLP was set to 1.00 and increase in absorbance in the presence of 100 µM HA (+ fMLP) 
or 1 µM ISO (+ fMLP) in each assay was compared to this value. 
 
 Results  51 
-12 -10 -8 -6 -4 -2
0.0
0.2
0.4
0.6
0.8
1.0
1.2
HIS
ISO
A
ligand (log M)
cA
M
P 
(r
el
at
iv
e 
to
m
ax
im
al
 H
A 
or
 IS
O
 e
ffe
ct
)
 
0
5
10
15
20
25 B
basal HA
100 µM
ISO
1 µM
cA
M
P 
(p
m
ol
/1
x1
06
 c
el
ls
)
Fig. 3.6 Measurement of cAMP content in neutrophil granulocytes (cAMP assay). The cAMP 
level in human neutrophil granulocytes (5 x 105 cells per sample) was monitored by HPLC-MS/MS 
system as described in sections 3.2.4 and 3.2.5. (A) Concentration-response curves for HA and ISO in 
the cAMP assay. Data shown are from four (ISO) to five (HA) independent experiments, performed in 
duplicate or triplicate (data points are mean ± S.E.M.). The maximal HA- and ISO-induced cAMP 
production was set to 1.00. Data were analyzed by non-linear regression and were best fitted to 
sigmoidal concentration/response curve. (B) Inter-experimental variability of basal cAMP concentration 
in neutrophil granulocytes (basal) and cAMP level after stimulation with 100 µM HA (HA 100 µM) and 
1 µM ISO (ISO 1 µM). Each data point represents one independent experiment. Dashed lines connect 
data points, obtained in one experiment. 
 
Burde and coworkers reported IMP being a more potent H2R agonist than HA in the 
O2•- assay with an IC50 value of 2 µM and with efficacy comparable to HA (Burde et al., 
1989). Surprisingly, in our O2•- test system IMP shows very weak partial agonistic activity with 
an IC50 value above 100 µM (Table 3.1). We do not have a plausible explanation for this 
difference. However, IMP was more potent than HA in the cAMP assay on neutrophil 
granulocytes, but still possessing only weak partial agonistic activity. 
The potencies and efficacies of the H2R agonists HA, DIM, AMT, 5-MHA and IMP in 
the O2•- and the cAMP assay are given in Table 3.1. Additionally, the EC50 and Emax values of 
ligands determined in steady-state GTPase activity assays using membrane preparations of 
Sf9 insect cells expressing the hH2R-GsαS fusion protein (Preuss et al., 2007; Igel, 2009; 
Kraus et al., 2009) are listed in Table 3.1. Comparing these data, an increase in potency is 
observed in the order O2•- assay < cAMP assay < GTPase assay for all ligands without 
exception. Unfortunately, the efficacy of H2R agonists in all three test systems cannot be 
reliably compared because of the weak effect of DIM, 5-MHA and IMP in the O2•- assay. 
Slightly superior efficacies of DIM, AMT and 5-MHA were determined in the cAMP assay in 
comparison to the GTPase assay whereas the efficacy of IMP was higher in the GTPase 
assay.  
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Table 3.1 Comparison of potencies and efficacies of standard H2R agonists, determined in 
three different test systems. 
Cpd. 
O2•- assay 
(hH2R on neutrophil 
granulocytes) 
cAMP assay 
(hH2R on neutrophil 
granulocytes) 
GTPase assay 
(recombinant protein 
hH2R-GsαS) 
pIC50 Emax pEC50 Emax pEC50 Emax 
HA 4.65 ± 0.06 1.00 5.47 ± 0.03 1.00 6.00b 1.00 
DIM < 4 0.60 ± 0.03a 4.79 ± 0.07 1.04 ± 0.04 6.04b 0.85 ± 0.02b 
AMT 5.52 ± 0.07 1.06 ± 0.04 6.05 ± 0.03 0.94 ± 0.01 6.72b 0.91 ± 0.02b 
5-MHA 4.21 ± 0.15 0.62 ± 0.03a 4.92 ± 0.07 1.09 ± 0.04 5.54c 1.01 ± 0.03c 
IMP < 4 0.10 ± 0.03a 6.37 ± 0.19 0.38 ± 0.04 6.80b 0.82 ± 0.02b 
 
On human neutrophil granulocytes, the O2•- assay (1 x 105 cells per well) was performed as described 
in section 3.2.3 and the cAMP assay (5 x 105 cells per cup) was performed as described in sections 
3.2.4 and 3.2.5. Data were analyzed by non-linear regression and were best fitted to sigmoidal 
concentration/response curves. Data shown are the means ± S.E.M. of three to eight independent 
experiments performed in triplicate. The efficacy (Emax) of HA in each assay was set to 1.00 and the 
efficacies of other ligands were referred to this value. 
a Up to 100 µM, concentration-response curve for compound did not achieve saturation, therefore, 
inhibition of fMLP-stimulated O2•- production at fixed concentration of 100 µM is given (relative to HA). 
b Data were taken from Preuss et al. (2007). 
c Data were taken from Igel (2009). 
d Data were taken from Kraus et al. (2009). 
 
The inhibition of the fMLP-stimulated O2•- production by HA, AMT, DIM and 5-MHA 
was counteracted by the selective H2R antagonist FAM (Fig. 3.7). The effect of 100 µM AMT 
was only partially antagonized by 10 µM FAM. Higher concentrations of FAM were 
intentionally avoided because at concentrations above 30 µM FAM per se inhibits fMLP-
stimulated O2•- production (data not shown) (Burde et al., 1990). Incubation of neutrophil 
granulocytes in the presence of the selective H1R antagonist MEP or the H3R/H4R antagonist 
THIO did not alter the HA- or AMT-induced inhibition of O2•- production. In addition, we could 
demonstrate a H2R-mediated stimulation of cAMP accumulation by HA (Fig. 3.8). 
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Fig. 3.7 Antagonistic effects of MEP, FAM and THIO on HA-, AMT-, DIM- and 5-MHA-induced 
inhibition of O2•- production. The O2•- production in human neutrophil granulocytes (1 x 105 cells per 
well) was monitored by the determination of ferricytochrome c reduction at 550 nm as described in 
section 3.2.3. Data shown are means ± S.E.M. of three to four independent experiments, performed in 
triplicate. MEP, mepyramine at a concentration of 1 µM; FAM, famotidine at a concentration of 10 µM; 
THIO, thioperamide at a concentration of 10 µM. a The inhibition of O2•- production by HA or AMT in 
the absence of antagonists (reference value) was compared with the inhibition of O2•- production by 
HA or AMT in the presence of MEP, FAM and THIO, respectively, using one-way ANOVA, followed by 
Dunnett’s multiple comparison test (***, p < 0.001; 95 % confidence interval). b The inhibition of O2•- 
production by AMT, DIM or 5-MHA in the absence and in the presence of FAM was compared with 
unpaired two-tailed t-test (*, p < 0.05; 95 % confidence interval). 
 
 
 
 
 
Fig. 3.8 Antagonistic effects of MEP, FAM and 
THIO in the cAMP assay. cAMP accumulation 
was monitored in neutrophil granulocytes (5 x 105 
cells per cup) by HPLC-MS/MS system as 
described in sections 3.2.4 and 3.2.5. Data shown 
are from one or three (mean ± S.E.M.) independent 
experiments, performed in triplicate. MEP, 
mepyramine at a concentration of 1 µM; FAM, 
famotidine at a concentration of 10 µM; THIO, 
thioperamide at a concentration of 10 µM.  
 
Because antagonistic potencies are considered constant for a specific antagonist-
receptor interaction, irrespective of the test system used (Hill, 2006), we investigated the 
effect of H2R antagonists on neutrophil granulocytes in more detail. First of all, the potency of 
FAM for H2R in human neutrophil granulocytes was determined using Schild analysis (Schild, 
1947). The parallel shift of the concentration-response curve for histamine to the right was 
observed by applying FAM at concentrations of 0.1, 0.3, 1 and 3 µM in the cAMP assay (Fig. 
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3.9A). The maximal agonist response was depressed at very high concentrations of HA (3 
and 5 µM) which is due to an unspecific effect of HA at these concentrations on cAMP 
production, and not due to an insurmountable antagonistic activity of FAM (data not shown). 
A Schild plot of the data from Fig. 3.9A is shown in Fig. 3.9B. The slope of the regression line 
is 1.14 (95 % confidence interval from 0.83 to 1.44) and the intercept with the abscissa is      
-7.42, resulting in a pA2 value of 7.42 (95 % confidence interval from 7.14 to 7.88). This pA2 
value correlates very well with the pA2 value (7.5) for FAM determined at human neutrophil 
granulocytes more than two decades ago by Burde and coworkers (Burde et al., 1989). Here, 
the HA was used as H2R agonists as well but the O2•- assay was chosen as read out. 
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Fig. 3.9 Effect of the H2R antagonist FAM on HA-induced cAMP production in human neutrophil 
granulocytes. The cAMP level in human neutrophil granulocytes (5 x 105 cells per sample) was 
monitored by HPLC-MS/MS system as described in sections 3.2.4 and 3.2.5. (A) The effect of FAM at 
fixed concentrations (0 µM, 0.1 µM, 0.3 µM, 1 µM and 3 µM) on the HA-induced cAMP production. 
Data shown are from two independent experiments, performed in duplicate (data points are mean ± 
S.E.M.). The maximal HA-induced cAMP production in the absence of FAM was set to 1.00 and all 
other data points were referred to this value. Data were analyzed by non-linear regression and were 
best fitted to sigmoidal concentration/response curve. (B) Schild plot of the data shown in panel A. 
EC50+, EC50 value for the HA-induced cAMP production in the presence of FAM; EC50-, EC50 value for 
the HA-induced cAMP production in the absence of FAM.  
 
 
Additionally, the pKB values for FAM, TIO and ZOL were determined in the O2•- 
assay as well as in the cAMP assay by applying a submaximally effective concentration of 
HA in each assay and increasing concentrations of H2R antagonists. In Table 3.2, the results 
are summarized and compared with literature data (GTPase assay using membranes of Sf9 
insect cells expressing hH2R-GsαS) (Kelley et al., 2001). In all test systems, the pKB values 
increased in the order ZOL < TIO < FAM. Nevertheless, when pKB values of the individual 
H2R antagonists in different test systems were compared, large deviations were observed. 
Even for the same cells, neutrophils, the pKB values in the cAMP assay are for up to 0.9 log 
units higher than those determined in the O2•- assay.  
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Table 3.2 Comparison of pKB values of the H2R antagonists FAM, TIO and ZOL, determined in 
three different test systems. 
Cpd. 
O2•- assay 
(hH2R on neutrophil 
granulocytes) 
cAMP assay 
(hH2R on neutrophil 
granulocytes) 
GTPase assay 
(recombinant protein 
hH2R-GsαS)a 
pKB (pIC50 ± S.E.M.) pKB (pIC50 ± S.E.M.) pKB 
FAM 7.01 (6.68 ± 0.07) 7.90 (7.62 ± 0.14) 7.54 
TIO 6.08 (5.75 ± 0.08) 6.95 (6.68 ± 0.17) 7.22 
ZOL 5.86 (5.53 ± 0.06) 6.54 (6.27 ± 0.18) 6.00 
 
On human neutrophil granulocytes, the O2•- assay (1 x 105 cells per well) was performed as described 
in section 3.2.3 and the cAMP assay (5 x 105 cells per sample) was performed as described in 
sections 3.2.4 and 3.2.5. O2•- and cAMP production were determined at submaximally effective 
concentration of HA (25 µM and 3 µM, respectively) in the presence of increasing concentrations of 
H2R antagonists. Data were analyzed by non-linear regression and were best fitted to sigmoidal 
concentration/response curves. Data shown are from four to six independent experiments performed 
in triplicate. The pKB values were calculated from the IC50 values according to Cheng and Prusoff 
(Cheng and Prusoff, 1973). 
a Data of GTPase assays (Sf9 membranes with hH2R-GsαS fusion protein) were taken from Kelley et al. 
(2001). The reported non-logarithmic KB values were converted into logarithmic pKB values. 
 
3.3.2 Determination of H2R isoform expression in human neutrophil granulocytes 
Two isoforms of the hH2R are described in literature. The longer isoform 1 was 
identified by researchers involved in the Mammalian Gene Collection Program of the 
National Institutes of Health (Strausberg et al., 2002). This isoform encodes 397 amino acids. 
The isoform 2 was successfully cloned for the first time from human gastric fundic mucosa by 
Gantz and coworkers (Gantz et al., 1991). The second isoform, which has a truncated C-terminus 
compared to the isoform 1, encodes a protein comprising 359 amino acids.  
It is evident from the already presented results that the hH2R in neutrophil 
granulocytes behaves differently from the recombinant fusion protein hH2R-GsαS, in which 
isoform 2 of the hH2R is expressed. Therefore, the H2R isoform in human neutrophil 
granulocytes was determined. After isolation of total mRNA from neutrophils and reverse 
transcription to cDNA, primer pairs, specific for isoform 1 and isoform 2, respectively, were 
used for amplification of the cDNA by PCR. No PCR product was obtained for isoform 1 
(expected PCR product length 1197 bp), whereas the expected 1085 bp long PCR product 
could be detected with an isoform 2 specific primer pair (Fig. 3.10). Sequencing of the 
complete encoding region confirmed the presence of isoform 2 in neutrophil granulocytes 
(see supplemental data in chapter 7), and this isoform has 100 % amino acid sequence 
identity with the isoform present in the fusion protein hH2R-GsαS.   
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Fig. 3.10 Amplification of cDNA, reverse-transcribed from total RNA of human neutrophil 
granulocytes, by PCR using H2R isoform 1- and isoform 2-specific primer pairs. Isolation of total 
RNA from human neutrophil granulocytes, reverse transcription PCR and amplification of cDNA were 
performed as described in section 3.2.6. 1, DNA ladder with five fragments of differential length, the 
length of each fragment is given as number of base pairs (bp) on the left side of the figure; 2, control 
PCR without cDNA as template, using the isoform 1-specific primer pair hH2R_F and hH2R_R_Iso1; 3, 
PCR with cDNA as template, using the isoform 1-specific primer pair hH2R_F and hH2R_R_Iso1; 4, 
control PCR without cDNA as template, using the isoform 2-specific primer pair hH2R_F and 
hH2R_R_Iso2; 5, PCR with cDNA as template, using the isoform 2-specific primer pair hH2R_F and 
hH2R_R_Iso2. 
 
3.3.3 Characterisation of the β2AR on human neutrophil granulocytes with standard 
β2AR agonists 
Profound differences were found between the pharmacological profile of the hH2R in 
recombinant test system and on human neutrophil granulocytes. In order to answer the 
question whether this observation is H2R-specific or a common characteristic of Gs-coupled 
GPCRs, we additionally characterized the β2AR on human neutrophil granulocytes. By 
analogy with the hH2R, the β2AR was characterized in the O2•- assay and in the cAMP assay 
using standard β2AR agonists with efficacies varying from very weak partial to full agonism. 
Data from our study and literature data from GTPase assays using membrane preparations 
of Sf9 insect cells expressing hβ2AR-GsαS (Seifert et al., 1998; Weitl and Seifert, 2008) are 
summarized in Table 3.3.  
Potencies of ISO, ADR, SAL and DOB were higher in the O2•- assay than in the 
cAMP assay. EPH and DCI were lacking any agonistic activity in the cAMP assay at 
concentrations up to 100 µM. The efficacies of ADR and DOB were comparable in both test 
systems, but the efficacy of SAL was superior in the O2•- assay. Detailed analysis of data 
from O2•- assay, cAMP assay and GTPase assay can be summarized as follows. In general, 
the rank order of potency was cAMP assay < GTPase assay < O2•- assay whereas the rank 
order of efficacy was cAMP assay < O2•- assay ≈ GTPase assay. 
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Table 3.3 Comparison of potencies and efficacies of standard β2AR agonists, determined in 
three different test systems. 
Cpd. 
O2•- assay 
(β2AR on neutrophil 
granulocytes) 
cAMP assay 
(β2AR on neutrophil 
granulocytes) 
GTPase assay 
(recombinant protein 
hβ2AR-GsαS) 
pIC50 Emax pEC50 Emax pEC50 Emax 
ISO 8.02 ± 0.07 1.00 7.42 ± 0.10 1.00 7.50b 1.00b,c 
ADR 7.82 ± 0.09 1.01 ± 0.05 6.81 ± 0.09 1.06 ± 0.04 7.37c 1.00c 
SAL 7.16 ± 0.12 0.77 ± 0.04 6.74 ± 0.15 0.35 ± 0.03 6.70b 0.74 ± 0.04b 
DOB 7.90 ± 0.41a 0.15 ± 0.03a 4.86 ± 0.36 0.21 ± 0.05 6.70b 0.45 ± 0.07b 
EPH 5.95 ± 0.23 0.34 ± 0.04 < 4 0.01 ± 0.01 4.69b 0.31 ± 0.02b 
DCI 4.40 ± 0.26 0.32 ± 0.06 < 4 0.00 ± 0.01 7.09b 0.17 ± 0.06b 
 
On human neutrophil granulocytes, the O2•- assay (1 x 105 cells per well) was performed as described 
in section 3.2.3 and the cAMP assay (5 x 105 cells per cup) was performed as described in sections 
3.2.4 and 3.2.5. Data were analyzed by non-linear regression and were best fitted to sigmoidal 
concentration/response curves. Data shown are the means ± S.E.M. of four to nine independent 
experiments performed in triplicate. The efficacy (Emax) of ISO in each assay was set to 1.00 and the 
efficacies of other ligands were referred to this value. 
a The highest concentration used was 500 nM. DOB at concentrations higher than 500 nM causes 
reduction of ferricytochrome c per se. 
a Data were taken from Seifert et al. (1998). The reported non-logarithmic EC50 values were converted 
into logarithmic pEC50 values.  
c Data were taken from Weitl and Seifert (2008). The non-logarithmic EC50 value was converted into 
logarithmic pEC50 value. 
 
3.4 Discussion 
Drugs targeting hH2Rs and β2ARs have been used for decades in the therapy of 
humans. H2R antagonists like famotidine and ranitidine have been widely used in the 
treatment of gastroesophaegal reflux disease and peptic ulcer, whereas H2R agonistic 
activity is beneficial in the therapy of acute myeloid leukemia (van der Goot and Timmerman, 
2000; Martner et al., 2010). Numerous short- and long-acting β2AR agonists are 
indispensable as bronchodilatators in patients with asthma or chronic obstructive pulmonary 
disease (Mansfield, 2008). Despite the great success of the established therapies based on 
H2R- and β2AR-mediated effects, these receptors are still in the focus of numerous projects. 
Among others, one reason is the wide distribution of both receptors in different tissues, 
rendering it possible to employ new therapies or to reduce side effects of the existing ones. 
For example, data from literature suggest a potential use of H2R and β2AR agonists as anti-
inflammatory agents (Burde et al., 1990; Mirza et al., 2002). Therefore, we decided to 
perform a thorough characterization of both receptors on human neutrophil granulocytes 
using two distinct read-outs. Moreover, the parallel characterization of both receptors on 
neutrophil granulocytes allowed us their direct comparison.  
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3.4.1 Indications for functional selectivity of H2R and β2AR agonists 
The selectivity of GPCRs for different signaling pathways depends on more factors. 
One very important aspect is a ligand-directed trafficking of receptor signaling, also termed 
functional selectivity, ligand bias, biased agonism or stimulus trafficking in literature 
(Galandrin et al., 2007). All these terms stand for the ability of ligands to differentially activate 
distinct signaling pathways by stabilizing ligand-specific conformations of the same receptor 
protein. Functional selectivity has already been reported for numerous GPCRs such as 
dopamine D1 and D2 receptors, the histamine H3 receptor, adenosine A1 and A3 receptors, 
the α2A-adrenoceptor and the β2AR (Kenakin and Miller, 2010). Biased ligands can differently 
activate G protein-dependent and -independent signaling such as the β-arrestin pathway 
(Azzi et al., 2003; Rosethorne and Charlton, 2011), can discriminate between Gs, Gi, Gq and 
other G protein-mediated routes (Seifert and Dove, 2009) or even selectively modulate e.g. 
Gi1, Gi2 and Gi3 protein subtype activities (Mukhopadhyay and Howlett, 2005). 
Therefore, it is not surprising that any given ligand possesses multiple potencies 
and efficacies depending on the down-stream pathway analyzed (Kenakin and Miller, 2010). 
This observation was also confirmed in our study with H2R and β2AR agonists using the O2•- 
assay and the cAMP assay as read-outs and by comparison of the results with literature 
data, obtained in GTPase assays on Sf9 membranes expressing hH2R-GsαS and hβ2AR-GsαS 
(Fig. 3.11). We could rule out the possibility that different receptor isoforms are the reason for 
the divergence in potency and efficacy of H2R agonists between hH2R on neutrophils and 
hH2R-GsαS fusion protein, expressed in Sf9 insect cells (see section 3.3.2). The potency of all 
H2R agonists clearly decreased in direction GTPase assay > cAMP assay > O2•- assay 
whereas the efficacy profile of the same ligands was not uniform. For example, the efficacy 
of DIM is higher in the cAMP assay than in the GTPase assay. In contrast, the efficacy of 
IMP is more than twofold higher in the GTPase assay. By analogy, the efficacy of ADR is 
comparable in all three test systems, whereas the efficacy of SAL is drastically decreased in 
the cAMP assay and the efficacy of DOB substantially increased in the GTPase assay, 
compared to the other two test systems. Moreover, DCI is less potent in the O2•- assay than 
in the GTPase assay, in contrast to other β2AR agonist. Collectively, these data suggest that 
examined agonists are able to stabilize distinct receptor conformations of targeted receptors 
supporting the concept of functional selectivity.  
It should be noted that the vast majority of reports about functional selectivity in the 
literature originates from recombinant test systems, where receptor-G protein coupling can 
be more easily controlled (Kenakin and Miller, 2010), e.g. by expression of only receptor and 
G-proteins of interest. On the contrary, the investigation of functional selectivity in neutrophil 
granulocytes is hampered by limited possibilities to block coupling to G proteins; Gi proteins 
can be normally switched off with pertusis toxin, whereas there is no pharmacological tool 
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available for the selective inhibition of Gs and Gq coupling. However, neutrophils enable - 
although in a limited manner - the investigation of functional selectivity under more relevant 
physiological conditions.  
Moreover, our results demonstrate once more a need for the characterization of 
compounds in numerous in vitro and in vivo test systems at an early stage of development 
before extensive studies on patients are planned in order to avoid withdrawal of clinical 
studies because of unexpected drug effects. Additionally, the usage of a broad spectrum of 
test systems can be awarded with identification of additional beneficial effects of drugs. For 
example, selective activation of β2AR-mediated Gs-coupled signaling in rat cardiomyocytes 
by fenoterol had beneficial effects in congestive heart failure (Woo et al., 2009). Moreover, 
the long-acting β2AR agonist salmeterol showed beneficial anti-inflammatory effects in the 
lungs of mice by inhibiting lipopolysaccharide-induced influx of neutrophil granulocytes into 
bronchoalveolar lavage fluid (Maris et al., 2004). 
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Fig. 3.11 Pair-wise direct comparison of the potencies (A-C) and efficacies (D-E) of H2R and 
β2AR agonists in the O2•- assay, the cAMP assay and the GTPase assay. Data for H2R agonists 
were taken from Table 3.1, whereas data for β2AR agonists are from Table 3.3. H2R agonists are 
represented as blue circles and β2AR agonists as red circles. The dotted line indicates 
pharmacological identity of the two parameters compared. 
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3.4.2 Differing properties of hH2Rs and β2ARs on neutrophil granulocytes 
Substantial differences between the hH2R and the hβ2AR have been reported 
repeatedly in the literature although both receptors classically couple to Gs proteins. The 
hβ2AR fused to the long splice variant of the Gsα protein (GsαL) possessed higher apparent 
constitutive activity than hβ2AR fused to the short splice variant GsαS (Seifert et al., 1998). By 
contrast, the hH2R fused to GsαL and GsαS exhibited similar apparent constitutive activity 
(Wenzel-Seifert et al., 2001). Moreover, a decrease in potency for all examined H2R agonists 
was observed in cAMP response element (CRE)-mediated reporter gene transcription assay 
in comparison with the cAMP accumulation assay on CHO cells, stably expressing hH2R 
(Baker, 2008). Using similar experimental conditions for the characterization of the hβ2AR on 
CHO cells by the same research group, high-efficacy agonists appeared more potent in the 
cAMP assay and less efficacious agonists more potent in CRE reporter gene assay (Baker et 
al., 2003).  
By analogy with aforementioned data, obtained in recombinant test systems, the 
H2R and the β2AR behaved differently also on human neutrophil granulocytes. Extremely low 
potency of H2R agonists on the one hand and clearly higher potency of β2AR agonists on the 
other hand was determined in the O2•- assay compared to the cAMP assay. Is has been 
already mentioned in the introduction that β2ARs can couple to Gs, Gi and Gq proteins 
whereas H2R was reported to couple to Gs and Gq proteins. Although both receptors on 
neutrophils effectively couple to Gs resulting in increased cAMP turnover we cannot exclude 
the possibility that subtle Gi- or Gq-mediated effects interfere with fMLP-stimulated O2•- 
production. The second and the third intracellular loop, essential for coupling to G proteins 
(Kobilka, 1992), differ between hH2R and hβ2AR (Wang et al., 2000). In an elegant study of 
Wong and coworkers, the replacement of the second and the third intracellular loop of the 
hβ2AR with their counterparts from the hH2R decreased the ability of the hβ2AR to activate 
AC but increased the activation of PLC/PKC signaling pathway in HEK 293 cells (Wang et 
al., 2000). One could speculate that additional coupling of the hH2R to Gq protein in 
neutrophil granulocytes leads to activation of the PLC/PKC signaling pathway resulting in 
increased O2•- production. However, an early study of Leino and coworkers negated this 
speculation by reporting that HA via H2R actually inhibits Ca2+ increase induced by fMLP 
(Leino et al., 1993). 
Moreover, different compartmentation of GPCRs and their signaling partners at the 
cell membrane in microdomains like lipid rafts or caveolae can modulate subcellular signaling 
events (Ostrom and Insel, 2004; Lasley, 2011). β2AR, Gs, Gi, Gq, some AC types and PLC 
isoforms were localized in lipid rafts and caveolae of cardiac myocytes or membranes (Insel 
et al., 2005). Lipid rafts were identified also on the plasma membrane of bovine and human 
neutrophil granulocytes (Nebl et al., 2002; Shao et al., 2003). Moreover, Shao and coworkers 
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showed that membrane-bound components of NADPH-oxidase are localized in detergent 
insoluble lipid rafts. Upon neutrophil stimulation, cytosolic components of NADPH-oxidase 
and PKC were additionally recruited to the lipid rafts improving the coupling efficiency by 
juxtapose of signaling partners (Shao et al., 2003). Therefore, co-localisation of β2AR 
signaling partners could favor efficient cAMP accumulation and additional subsequent 
signaling events resulting in very effective inhibition of fMLP-stimulated O2•- production in 
neutrophils. However, in case of the hH2R, the sufficient activation of ACs but weak signaling 
transmission because of the inappropriate localization of downstream signaling partners 
could be an explanation for very modest inhibition of fMLP-stimulated O2•- production by H2R 
agonists. 
Gong and coworkers reported that ISO activated NADPH oxidase via β-arrestin-1-
dependent way using knockdown of β-arrestin-1 by RNA interference in HEK293 cells 
transfected with hβ2AR (Gong et al., 2008). Activation of cAMP/PKA-independent inhibitory 
signaling pathways could be a plausible explanation for enhanced potencies of β2AR 
agonists in the O2•- assay compared to the cAMP assay on human neutrophil granulocytes. 
Unlike in the case of β2AR agonists, lower potencies of H2R agonists in the O2•- assay than in 
the cAMP assay could be connected with the ability of the hH2R to trigger solely cAMP/PKA-
dependent inhibition of O2•- production. However, additional studies with β2AR antagonists 
and PKA inhibitors are needed to investigate this possibility. Preliminary data of ongoing 
study indicate that β2AR antagonists are able to antagonize hβ2AR-mediated O2•- production 
in neutrophils (data not shown). 
On the first glance, the lack of agonistic activity of EPH and DCI as well as the weak 
partial agonistic activity of SAL in the cAMP assay are surprising. In the O2•- assay, the 
coupling efficacy of the named ligands increases by 32 - 42 % relative to ISO. One plausible 
explanation would be that partial agonists desensitize β2ARs to a lower extent than highly 
efficacious ISO and ADR resulting in improved effectiveness of partial agonists in 
downstream inhibition of fMLP-stimulated O2•- production relative to full agonists. The 
correlation between the strength of β2AR agonist coupling and agonist-induced 
desensitization, internalization and phosphorylation has already been reported before 
(January et al., 1997; Clark et al., 1999; Baker et al., 2003). Unfortunately, direct comparison 
of H2R agonist efficacies between the O2•- assay and the cAMP assay was unfeasible 
because concentration-response curves for DIM, 5-MHA and IMP up to concentrations as 
high as 100 µM did not achieve saturation in the O2•- assay. 
It should be kept in mind that kinetics of the GPCR-G protein coupling and kinetics 
of coupling to further signaling partners (Wenzel-Seifert and Seifert, 2000), different 
expression levels of receptors as well as potential formation of homo- and heteromers 
(Hebert et al., 1996; Fukushima et al., 1997; Smith and Milligan, 2010) also add to the 
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complexity of β2AR and H2R behavior on neutrophil granulocytes. Evidently, characteristics 
of one GPCR, that classically couples to Gs, cannot be interpreted as common characteristic 
of all Gs coupled GPCRs, although the same test system is used for the characterization. 
 
3.4.3 Unexpected effects of H2R antagonists on neutrophil granulocytes 
According to the established understanding of the antagonist-GPCR interaction, 
potency of an antagonist for a given receptor is a constant irrespective of the tissue selected 
as a test system, the agonist used for the stimulation of GPCR and downstream signaling 
event monitored. Of course a prerequisite is that no chemical modification of the antagonist 
or GPCR occurs (Baker et al., 2003; Hill, 2006). Very interesting studies on this topic were 
performed by Baker and coworkers using chinese hamster ovary (CHO) cells stably 
expressing hβ2AR and hH2R, respectively (Baker et al., 2003; Baker, 2008). By monitoring 
the cAMP accumulation (incubation time 10 min) and CRE-mediated reporter gene 
transcription (incubation time 5 hours) different antagonist affinities were determined for the 
examined β2AR antagonists ICI 118,551 ((2R*,3S*)-3-(isopropylamino)-1-(7-methyl-2,3-
dihydro-1H-inden-4-yloxy)butan-2-ol), propranolol and atenolol (Baker et al., 2003). In CRE 
reporter gene assay, the β2AR antagonist affinity even depended on the agonist used for the 
stimulation of the hβ2AR. On the contrary, using similar experimental set-up (one difference 
was 30 min incubation time in cAMP accumulation assay instead of 10 min) no difference in 
H2R antagonist affinities was found between the test systems and the affinity was 
independent of the H2R agonist used (Baker, 2008). Noteworthy, also antagonists of β1- and 
β3-adrenergic receptors bind to the β1AR and the β3AR, respectively, with different affinity, 
indicating the existence of at least two distinct conformations of each receptor (Baker, 2008). 
In contrast to aforementioned results with respect of the hH2R on CHO cells 
substantial differences in pKB values were determined for H2R antagonists comparing the O2•- 
assay (incubation time 30 min) and the cAMP assay (incubation time 10 min) on neutrophil 
granulocytes (Fig. 3.12). Additionally, pKB values determined on neutrophils do not correlate 
well with pKB values for the named antagonists in recombinant test system, taken as a 
comparison (Fig. 3.12). Since HA was used as an agonist for hH2R stimulation in all three 
test systems the influence of differing agonists on pKB values of antagonists reported by 
Baker and coworkers (Baker et al., 2003) can be excluded. Like other GPCRs the H2R can 
be phosphorylated, desensitized and internalized upon incubation with an agonist (Hill, 
2006). Therefore, one could speculate that the reduced pKB values of FAM, TIO and ZOL in 
the O2•- assay are the consequence of a larger chemical modification (phosphorylation) of the 
hH2R during 30 min incubation time in the presence of the agonist HA in comparison with 
chemical modification during the cAMP assay, where incubation time is only 10 min. The use 
of a phosphorylation-deficient mutant of the β2AR revealed that the ISO-induced 
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phosphorylation of the hβ2AR is responsible for reduced affinity of the antagonist ICI 118,551 
in CRE gene reporter assay (Baker et al., 2003). However, it should be noted here that the 
incubation time in the gene reporter assay in case of the β2AR was 10-fold longer than the 
incubation time for the hH2R in the O2•- assay. Moreover, no divergence in hH2R antagonist 
affinities was found by the same research group comparing the immediate event of cAMP 
accumulation and further downstream CRE gene reporter assay in recombinant test system 
(Baker, 2008). 
 
 
Fig. 3.12 Web of pKB values for H2R antagonists FAM, TIO and ZOL. On human neutrophil 
granulocytes, the O2•- assay (1 x 105 cells per well) was performed as described in section 3.2.3, and 
the cAMP assay (5 x 105 cells per cup) was performed as described in sections 3.2.4 and 3.2.5. O2•- 
and cAMP production were determined at submaximally effective concentration of HA (25 µM and 3 
µM, respectively) in the presence of increasing concentrations of H2R antagonists. Data were 
analyzed by non-linear regression and were best fitted to sigmoidal concentration/response curves. 
Data shown are from four to six independent experiments performed in triplicate. The pKB values were 
calculated from the IC50 values according to Cheng and Prusoff (Cheng and Prusoff, 1973). Data for 
GTPase assay (Sf9 membranes with hH2R-GsαS fusion protein) were taken from Kelley et al. (Kelley et 
al., 2001); the reported non-logarithmic KB values were converted into logarithmic pKB values. 
 
 
In the history of drug research, discrepancies in the binding affinities or the 
pharmacological behavior of ligands played a pivotal role in the identification of new receptor 
subtypes. One prominent example with respect to the identification of a novel receptor 
subtype was the discovery of the H2R by the late Sir James Black and his coworkers (Black 
et al., 1972). However, on the basis of the data presented in this study the postulation of the 
existence of distinct H2R subtypes on neutrophils seems unjustifiable, although the described 
differential effects of examined H2R antagonists on cAMP production and O2•- accumulation 
in neutrophils are unequivocal. We could show that FAM, at a concentration of 10 µM, was 
 Discussion  65 
able to completely antagonize the effect of 100 µM HA, proving that the HA-induced inhibition 
of O2•- production is indeed H2R-mediated.  
Examination of β2AR antagonists on neutrophil granulocytes to find out whether pKB 
values of β2AR antagonists also differ in the cAMP assay and the O2•- assay is subject of 
ongoing work. Moreover, studies with PKA inhibitors are planned in order to gain deeper 
insight into the signaling events between cAMP accumulation and O2•- production.  
 
3.4.4 Conclusions 
As the activation of the H2R and the β2AR could have beneficial anti-inflammatory 
effects both aminergic GPCRs were characterized on human neutrophil granulocytes, cells of 
the innate immune system. For comprehensive characterization the influence of the H2R and 
the β2AR on fMLP-stimulated O2•- production and cAMP accumulation, respectively, was 
assessed. Collectively, this work revealed (I) indications for functional selectivity of examined 
H2R and β2AR agonists, (II) distinct pharmacological profile of the hH2R and the hβ2AR on 
neutrophil granulocytes and (III) divergence in pKB values for H2R antagonist affinities 
between the O2•- assay and the cAMP assay. Further studies are needed to mechanistically 
explain some findings of the present study. 
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with the N-terminus of the histamine H2 receptor and 
their effects on human neutrophil granulocytes  
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4.1 Introduction 
Histamine H2 receptor (H2R) antagonists such as cimetidine, ranitidine and 
famotidine (FAM) have been well established drugs in the therapy of gastroduodenal ulcers 
and gastroesophaegal reflux disease for decades (van der Goot and Timmerman, 2000). 
Histamine dihydrochloride in combination with interleukin-2 (Ceplene®) has come on the 
market very recently as an “H2R agonist” for maintenance immunotherapy of acute myeloid 
leukemia in adults (Martner et al., 2010). Besides the beneficial effect in acute myeloid 
leukemia, new H2R agonists could be also advantageous as anti-inflammatory agents (Burde 
et al., 1990) and positive inotropic drugs in the therapy of heart failure (Baumann et al., 1984; 
Felix et al., 1995).  
NG-acylated hetarylpropylguanidines are a new class of potent H2R agonists (Xie et 
al., 2006; Ghorai et al., 2008; Kraus et al., 2009; Birnkammer, 2011). This group of 
compounds was derived from guanidine-type analogues of impromidine (IMP) and 
arpromidine (ARP) in order to reduce basicity, improve oral bioavailability and to allow the 
penetration across blood-brain barrier (Xie et al., 2006; Ghorai et al., 2008). The most potent 
monovalent NG-acylated hetarylpropylguanidines show potencies in the low two-digit nM 
range (Xie et al., 2006; Ghorai et al., 2008; Kraus et al., 2009). Recently, bivalent NG-
acylated hetarylpropylguanidines were synthesized with some of them having potencies even 
in the one-digit nM range (Birnkammer, 2011). Whereas monovalent NG-acylated 
imidazolylpropylguanidines show antagonistic and/or partial agonistic activity at the hH1R, 
hH3R and hH4R (Xie et al., 2006; Ghorai et al., 2008; Igel et al., 2009), NG-acylated 
aminothiazolylpropylguanidines are selective partial to full hH2R agonists (Kraus et al., 2009). 
The same selectivity pattern was observed for bivalent NG-acylated hetarylpropylguanidines 
(Birnkammer, 2011). 
In general, bivalent ligands are compounds containing two pharmacophoric moieties 
joined by a spacer, and they are synthesized with the intention to increase affinity, potency 
and selectivity compared to the monovalent counterparts and to investigate receptor homo- 
and heterodimers (Smith and Milligan, 2010; Shonberg et al., 2011). The bivalent ligand 
approach has been successfully applied in studies of numerous GPCRs, e.g. dopamine 
receptors, serotonin receptors, gonadotropin-releasing hormone receptors, opioid receptors 
and others (Halazy et al., 1996; Decker and Lehmann, 2007; Bonger et al., 2008; Zhang et 
al., 2009; Kühhorn et al., 2011; Shonberg et al., 2011). Also in our research group the 
bivalent ligand approach resulted in very potent agonists at the hH2R and gpH2R with 
substantially increased potency in comparison to monovalent NG-acylated 
hetarylpropylguanidines (Birnkammer, 2011). Nevertheless, structure-activity relationship 
studies on bivalent NG-acylated hetarylpropylguanidines revealed that spacer length of the 
most potent ligands is insufficient to allow simultaneous occupation of two neighboring 
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receptors (Portoghese, 2001; Birnkammer, 2011). It is, therefore, conceivable that the 
second pharmacophoric moiety binds to an additional (allosteric) binding site on the same 
receptor.  
Characteristic of monovalent and bivalent NG-acylated hetarylpropylguanidines is 
also enhanced potency and efficacy at the guinea pig (gp) H2R compared to the human (h) 
H2R ortholog as determined in GTPase assay using membrane preparations of Sf9 insect 
cells expressing gpH2R-GsαS and hH2R-GsαS (Xie et al., 2006; Ghorai et al., 2008; Kraus et al., 
2009; Birnkammer, 2011). As shown in Fig. 4.1, hH2R and gpH2R possess very high overall 
sequence identity of 86 %, even higher identity within transmembrane domains (96 %), but 
very low homology in the N-terminal sequence (66 %). Therefore, using mutagenesis study, 
we assessed the contribution of the N-terminus to different behavior of NG-acylated 
hetarylpropylguanidines at the hH2R and gpH2R as well as the potential role of this receptor 
domain as an accessory binding site of bivalent H2R agonists.  
 
 
Fig. 4.1 Comparison of the amino acid sequences of the hH2R and the gpH2R. Amino acid 
sequences of the wild-type hH2R (Gantz et al., 1991) and the wild-type gpH2R (Traiffort et al., 1995) 
are given in one-letter code. TM I-VII, seven transmembrane domains; I1-3, first, second and third 
intracellular loop; E1-3, first, second and third extracellular loop. Dots in the sequence of the gpH2R 
indicate identical amino acids with the hH2R. Amino acids with grey shading represent the most 
conserved amino acids among aminergic G protein-coupled receptors (Shi and Javitch, 2002) and 
amino acids in bold indicate interaction sites of HA with the H2R (Gantz et al., 1992; Nederkoorn et al., 
1996). Amino acids marked with downward-facing triangle (▼) at the hH2R were replaced by the 
corresponding amino acids of the gpH2R by the generation of chimeric receptor hgpNTH2R in this study. 
Amino acids marked with circle (●) were reported to determine the species-selectivity of monovalent 
guanidines and NG-acylguanidines (Kelley et al., 2001; Preuss et al., 2007a) whereas amino acids 
marked with diamond (♦) do not influence the species-selectivity of the same class of ligands (Preuss 
et al., 2007b). 
 
Moreover, regarding the hH2R, the ligands of interest were so far only characterized 
in recombinant test systems, namely the hH2R-GsαS fusion protein in Sf9 cell membranes. To 
make one step forward, a set of representative NG-acylated hetarylpropylguanidines was 
additionally characterized on isolated human neutrophil granulocytes. Neutrophil 
granulocytes endogenously express H2Rs and were therefore used as a test system for 
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characterization of H2R ligands in the past (Burde et al., 1990). The H2R agonistic activity of 
acylguanidines was assessed by monitoring the inhibition of N-formyl-L-methionyl-L-leucyl-L-
phenylalanine (fMLP)-stimulated O2•- production and cyclic adenosine 3',5'-monophosphate 
(cAMP) accumulation in neutrophils. The signaling pathway of the fMLP-induced O2•- 
production and the interference of the latter with the signaling pathway of the H2R in human 
neutrophil granulocytes are described in section 3.1. 
 
4.2 Materials and Methods 
4.2.1 Materials 
Histamine (HA) and thioperamide (THIO) were obtained from Tocris Bioscience 
(Avonmouth, Bristol, UK). Mepyramine (MEP) and FAM were from Sigma-Aldrich Chemie 
(Steinheim, Germany). Compound 1 (Kraus et al., 2009) and ligands 2-17 (Birnkammer, 
2011) were synthesized in our laboratory as described. The structures of the synthesized 
compounds 2-17 were confirmed by 1H NMR, 13C-NMR and mass spectroscopy spectra 
(HR-MS). Purity of compounds was ≥ 95 % as determined by analytical HPLC (compound 
purities were calculated as the percentage peak area of the analyzed compound by UV 
detection at 210 nm). Chemical structures of ligands 1-17 are depicted in Fig. 4.2 and an 
overview of potencies and efficacies, determined in recombinant test system, is given in 
Table 4.1. Stock solutions of HA, MEP, THIO and compound 1 (10 mM each) were prepared 
in Millipore water. 2 mM stock solution of FAM was dissolved in 2 mM HCl. 2 mM stock 
solutions of 2-17 were prepared in 20 % dimethyl sulfoxide (DMSO) (v/v). For GTPase 
assay, dilution series of HA and ligands 1, 5, 6, 10, 11, 12 and 17 were prepared in 
water/DMSO mixture in defined ratio to achieve constant final concentration of 1 % DMSO 
(v/v) in test tubes. For the O2•- assay and the cAMP assay, all ligands were diluted with 
Millipore water; final concentration of DMSO in experiments was maximally 0.01 % (v/v).  
The generation of pGEM-3Z-SF-hH2R-His6-GsaS has been described previously 
(Kelley et al., 2001). DNA primers for PCR were purchased by MWG Biotech (Ebersberg, 
Germany). Phusion high-fidelity DNA polymerase was obtained from Finnzymes (Espoo, 
Finland). Restriction enzymes and T4-DNA ligase were from New England Biolabs (Ipswich, 
MA, USA). Insect Xpress medium was from Lonza (Walkersville, MD, USA), fetal calf serum 
from Biochrom (Berlin, Germany) and gentamicin from Cambrex Bio Science (Walkersville, 
MD, USA). BaculoGOLD transfection kit was purchased from BD PharMingen (San Diego, 
CA, USA). EDTA and leupeptin were from Merck (Darmstadt, Germany). Adenosine 5’-
triphosphate (ATP), guanosine 5’-triphosphate (GTP), adenosine 5’-[β,-imido]triphosphate 
and creatine kinase were purchased from Roche (Mannheim, Germany). Benzamidine was 
obtained from Acros Organics (Geel, Belgium). Phenylmethylsulfonyl fluoride, creatine 
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phosphate and bovine serum albumin were from Sigma-Aldrich Chemie (Steinheim, 
Germany)). [-33P]GTP was synthesized using guanosine 5’-diphosphate (GDP) and [-33P]Pi 
(3,000 Ci/mmol orthophosphoric acid) by analogy with the synthesis of [-32P]GTP described 
before (Walseth and Johnson, 1979). GDP was purchased from Sigma-Aldrich Chemie 
(Steinheim, Germany) and [-33P]Pi from Hartmann Analytic (Braunschweig, Germany).  
 
 
Fig. 4.2 Structures of the examined NG-acylated hetarylpropylguanidine type histamine H2 
receptor agonists. Laboratory code for each ligand is given in parenthesis. 
 
10 x Dulbecco’s phosphate buffered saline (DPBS) without Ca2+ and Mg2+ (pH 6.5 – 
7.0) was purchased from PAN Biotech (Aidenbach, Germany) and Biocoll separating solution 
from Biochrom (Berlin, Germany). Trypan blue solution, ferricytochrome c, cytochalasin B, 
fMLP and 3-isobutyl-1-methylxanthine (IBMX) were from Sigma-Aldrich Chemie (Steinheim, 
Germany). Solvents for extraction and HPLC analysis were purchased as follows: HPLC-
gradient grade water and methanol from J. T. Baker (Deventer, The Netherlands), 
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ammonium acetate from Sigma-Aldrich Chemie (Steinheim, Germany) and acetic acid from 
Riedel-de Haen (Hannover-Seelze, Germany). cAMP (> 99 %) was obtained from Biolog Life 
Science Institute (Bremen, Germany) and tenofovir from the National Institute of Health 
(Bethesda, MD, USA). Morphological investigation of neutrophil granulocytes was performed 
with Zeiss microscope Axiovert 200M (Göttingen, Germany).  
 
4.2.2 Construction of the cDNA for the hgpNTH2R-GsαS fusion protein 
The cDNA for hgpNTH2R-GsαS was generated by sequential overlap-extension PCR, 
using pGEM-3Z-SF-hH2R-His6-GsaS as template, by analogy with a previously described 
approach (Preuss et al., 2007b). In PCR 1A, the DNA region encoding the cleavable signal 
peptide from influenza hemagglutinin (S), the FLAG epitope (F) recognized by the M1 
monoclonal antibody and the N-terminus of gpH2R was amplified. The sense primer 
annealed with 27 bp of pGEM-3Z in front of the 5’-end of SF. The antisense primer with the 
sequence 5’-TATACGGTAAAGTCCATGCAAAAGGAAGGGACTGTGCCATTGAATGCCAT 
GGCGTCATCATCGTC-3’ was used to generate Pro3→Phe3, Ala7→Val7, Ser8→Pro8, 
Leu12→Met12, Ser14→Phe14, Ala16→Val16 and Cys17→Try17 mutations in the region of 
N-terminus and a new Bst Z17I restriction site (GTATAC). Amino acids at positions 16 (Ala) 
and 17 (Cys) in the hH2R are, according to Kelley and colleagues (Kelley et al., 2001), 
located in TM I (Fig. 4.1), but were included in the mutagenesis study because of the close 
proximity to the N-terminus. In PCR 1B, the DNA sequence of guinea pig N-terminus, the 
rest of hH2R, hexahistidine tag (His6) and GsaS was amplified. The sense primer encoded the 
sequence  5’-TTCAATGGCACAGTCCCTTCCTTTTGCATGGACTTTACCGTATACAAGAT 
CACCATCACCGTGGTCC-3’ to generate Pro3→Phe3, Ala7→Val7, Ser8→Pro8, 
Leu12→Met12, Ser14→Phe14, Ala16→Val16 and Cys17→Try17 mutations in the region of 
N-terminus and a new Bst Z17I restriction site. The antisense primer annealed with 21 bp of 
pGEM-3Z behind the stop codon and downstream to Xba I site. In PCR 2, using the sense 
primer of PCR 1A and the antisense primer of PCR 1B, the products of PCR 1A and 1B 
annealed in the region of newly created canine N-terminus and a new Bst Z17I restriction 
site. The product of PCR 2 encoded the complete cDNA for SF-hgpNTH2R-His6-GsαS protein. 
This product was double-digested with Sac I and Xba I and cloned into the pGEM-3Z-SF-
hH2R-His6-GsaS plasmid digested with the same enzymes. The pGEM-3Z-SF-hgpNTH2R-His6-
GsaS DNA was digested with Sac I and Xba I and cloned into the baculovirus transfer vector 
pVL1392-SF-hH2R-His6-GsaS digested with the same enzymes. The sequence of SF-
hgpNTH2R-His6-GsaS, cloned into the pGEM-3Z plasmid, was verified by restriction enzyme 
analysis and sequencing (Entelechon, Regensburg, Germany). 
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4.2.3 Sf9 insect cell culture, generation of recombinant baculoviruses and 
membrane preparation 
Sf9 insect cell culture and generation of recombinant baculoviruses have been 
described recently (Schneider et al., 2009; Schnell et al., 2010). Sf9 cells were cultured in 
250- or 500-ml disposable Erlenmeyer flasks at 28 °C under rotation at 150 rpm in Insect 
Xpress medium supplemented with 5 % (v/v) fetal calf serum and 0.1 mg/ml gentamicin. 
Cells were maintained at a density of 0.5 – 6.0 x 106 cells/ml. Recombinant baculoviruses 
encoding the hgpNTH2R-GsαS were generated in Sf9 insect cells using the BaculoGOLD 
transfection kit according to manufacturer’s instructions. After initial transfection, high-titer 
virus stocks were generated by two sequential virus amplifications. In the first amplification, 
cells were seeded at 2.0 x 106 cells/ml and infected with a 1:100 dilution of the supernatant 
fluid from the initial transfection. Cells were cultured for 7 days, resulting in death of virtually 
the entire cell population. The supernatant of this infection was harvested and stored under 
light protection at 4 °C. In a second amplification, cells were seeded at 3.0 x 106 cells/ml and 
infected with a 1:20 dilution of the supernatant fluid from the first amplification. Cells were 
cultured for 48 hours and afterwards, the supernatant fluid was harvested. After the 48 hours 
culture period, the most of cells showed signs of infection (altered morphology), but the 
majority of cells was still intact. The supernatant fluid from the second amplification was 
stored under light protection at 4 °C and used as virus stock for membrane preparation.  
Before infection, Sf9 cells were sedimented by centrifugation and suspended in 
fresh medium. Cells were seeded at a density of 3.0 x 106 cells/ml and infected with high-titer 
baculovirus stock encoding hgpNTH2R-GsαS (1:100 dilution). Cells were cultured for 48 h at 28 
C under rotation at 150 rpm before the membrane preparation was performed as described 
before (Seifert et al., 1998). All steps during membrane preparation were performed at 4 °C. 
After 48 hours culture period, cells were washed by centrifugation step at 170 x g for 10 min, 
discarding the supernatant and resuspending the cell pellet in 50 ml of PBS buffer (137 mM 
NaCl, 2.6 mM KCl, 0.5 mM MgCl2, 0.9 mM CaCl2, 1.5 mM KH2PO4 and 0.8 mM Na2HPO4, pH 
7.4). After repeating the centrifugation step, the supernatant was removed and the pellet 
suspended in 15 ml of lysis buffer, containing 1 mM EDTA, 10 mM Tris/HCl pH 7.4, 0.2 mM 
phenylmethylsulfonyl fluoride, 10 μg/ml benzamidine and 10 μg/ml leupeptin, and 
homogenized in a Dounce homogenizer with 25 strokes. After centrifugation at 40 x g for 5 
min, the supernatant contained the membranes and the pellet nuclei and unbroken cells. The 
supernatant was then transferred to a plastic tube and centrifuged at 38,500 x g for 20 min. 
The pellet containing the membranes was resuspended in 20 ml of lysis buffer and 
centrifuged once again at 38,500 x g for 20 min. The membrane pellet was then suspended 
in 25 ml of binding buffer (12.5 mM MgCl2, 1 mM EDTA and 75 mM Tris/HCl, pH 7.4) and 
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homogenized by a syringe with 20 strokes. Aliquots of membranes (1 ml) were stored at -80 
°C until use. 
 
4.2.4 Steady-state GTPase activity assay 
Steady-state GTPase activity assays, using [-33P]GTP as radioligand, were 
essentially conducted as described (Preuss et al., 2007b). The membranes were thawed, 
sedimented by centrifugation (18,000 x g, 10 min, 4°C) and resuspended in 10 mM Tris/HCl, 
ph 7.4. Assay tubes contained membranes expressing hgpNTH2R-GsαS fusion protein (5-10 μg 
of protein per tube), 1.0 mM MgCl2 (final concentration after the addition of [-33P]GTP), 100 
µM EDTA, 100 µM ATP, 100 nM GTP, 100 µM adenosine 5’-[β,-imido]triphosphate, 1.2 mM 
creatine phosphate, 1 µg creatine kinase, 0.2 % (w/v) bovine serum albumin in 50 mM 
Tris/HCl, pH 7.4 and ligands at investigated concentrations. Reaction mixtures (80 µl) were 
incubated for 2 min at 25 °C before the addition of 20 µl of [33P]GTP (0.05 µCi per tube). 
Reactions were conducted for 20 min at 25°C and terminated by the addition of 900 µl of 
slurry consisting of 5 % (w/v) activated carcoal (absorbs nucleotides, but not Pi) and 50 mM 
NaH2PO4, pH 2.0. Reaction mixtures were then centrifuged at room temperature (7 min, 
15,000 x g). Six hundert µl of resulting supernatant was removed and 33Pi was determined by 
liquid scintillation counting using OptiPhase Supermix Cocktail (PerkinElmer, Groningen, The 
Netherlands). Enzyme activities were corrected for spontaneous degradation of [-33P]GTP, 
which was determined in tubes containing all of the above described components and 
additionally a high concentration of unlabeled GTP (1 mM) that, by competition with [-
33P]GTP, prevents [-33P]GTP hydrolysis by enzymatic activities present in Sf9 membranes. 
Spontaneous [-33P]GTP degradation normally amounted to < 1 % of the total amount of 
radioactivity added. The experimental conditions ensured that no more than 16 % of the total 
amount of [-33P]GTP added were converted to 33Pi. 
 
4.2.5 Isolation of human neutrophils  
See section 3.2.2. 
 
4.2.6 Superoxide anion generation (O2•- assay) 
See section 3.2.3. 
 
4.2.7 cAMP accumulation and extraction from neutrophils (cAMP assay) 
See section 3.2.4.   
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4.2.8 Quantitation of cAMP by HPLC-MS/MS  
See section 3.2.5. 
 
4.2.9 Miscellaneous 
Protein concentrations were determined using the Bio-Rad DC protein assay kit 
(Hercules, CA). Chromatograms, obtained during the HPLC-MS/MS analysis, were analyzed 
with the Analyst Software 1.5.1 (AB Sciex, Foster City, CA). Data from GTPase assay, O2•- 
assay and cAMP assay were analyzed with the Prism 5.01 software (GraphPad, San Diego, 
CA). The means ± S.E.M. were always determined by the analysis of at least three 
independent experiments, performed in duplicate or triplicate, if not indicated otherwise. 
pEC50 and Emax values in Table 4.1, respectively, were statistically analyzed using one-way 
ANOVA, followed by Bonferroni’s multiple comparison test. Statistical significance was 
defined as p  0.05 (95 % confidence interval). 
 
4.3 Results 
4.3.1 Characterization of HA and NG-acylated hetarylpropylguanidines at the 
hgpNTH2R-GsαS in steady-state GTPase assay 
In order to assess the potential involvement of the N-terminus in different 
characteristics of monovalent as well as bivalent NG-acylated hetarylpropylguanidines at 
hH2R-GsαS and gpH2R-GsαS (Kraus et al., 2009; Birnkammer, 2011), the chimeric fusion 
receptor hgpNTH2R-GsαS was constructed by overlap-extension PCR, in which the N-terminal 
amino acid sequence of the hH2R was exchanged by the counterpart sequence of the gpH2R 
(Fig. 4.1). Afterwards, Sf9 membranes, expressing hgpNTH2R-GsαS fusion protein, were 
characterized with the series of seven NG-acylated hetarylpropylguanidines (compounds 1, 5, 
6, 10, 11, 12 and 17) and with the standard agonist HA in the steady-state GTPase assay. 
For hgpNTH2R-GsαS, basal GTPase activities ranged from 3.3 to 3.8 pmol/mg/min and GTPase 
activity after stimulation with 100 µM HA from 9.0 to 11.4 pmol/mg/min.  
Potencies and efficacies of the examined ligands at the hgpNTH2R-GsαS as well as 
comparison with potencies and efficacies at the hH2R-GsαS and the gpH2R-GsαS are shown in 
Table 4.1. For HA, 10, 12 and 17, statistical analysis of the data revealed a difference neither 
in potency nor in efficacy, when the mutant receptor hgpNTH2R-GsαS was compared with the 
hH2R-GsαS. Interestingly, the pEC50 value of the monovalent (2-amino-4-
methylthiazolyl)propylguanidine 1 and the Emax value of the symmetrical bivalent (2-
aminothiazolyl)propylguanidine 6 at the hgpNTH2R-GsαS were significantly lower than the 
respective pEC50 and Emax values at the hH2R-GsαS. On the contrary, in case of the 
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symmetrical bivalent triazolylpropylguanidine 11, the pEC50 and Emax of at the hH2R-GsαS tend 
to those determined at the gpH2R-GsαS. The Emax value of the symmetrical bivalent (2-amino-
4-methylthiazolyl)propylguanidine 5 even reaches the same efficacy as at the gpH2R-GsαS. 
 
Table 4.1 Potencies and efficacies of HA and NG-acylated hetarylpropylguanidines on hH2R-
GsαS, gpH2R-GsαS and hgpNTH2R-GsαS fusion proteins, determined in steady-state GTPase assay.   
Cpd. 
hH2R-GsαSa gpH2R-GsαSa hgpNTH2R-GsαSb 
pEC50  Emax 
pEC50  
(pKB) 
Emax pEC50  Emax 
HAc 6.01 ± 0.02 1.00 6.10 ± 0.08 1.00 5.93 ± 0.04 1.00 
1c 7.68 ± 0.08 0.79 ± 0.01 8.13 ± 0.03** 0.76 ± 0.01 7.31 ± 0.03*,+++ 0.82 ± 0.01+ 
2 7.24 ± 0.22 0.68 ± 0.03 8.56 ± 0.30 0.90 ± 0.01 n.d. n.d. 
3 7.30 ± 0.25 0.62 ± 0.03 9.20 ± 0.16 0.81 ± 0.03 n.d. n.d. 
4 7.45 ± 0.15 0.43 ± 0.04 8.57 ± 0.16 0.92 ± 0.04 n.d. n.d. 
5c 8.11 ± 0.25 0.53 ± 0.04 9.41 ± 0.14** 0.74 ± 0.05* 7.94 ± 0.05++ 0.73 ± 0.01* 
6c 7.53 ± 0.02 0.81 ± 0.01 8.87 ± 0.28*** 1.00 ± 0.03*** 7.40 ± 0.04+++ 0.73 ± 0.02*,+++ 
7 7.67 ± 0.07 0.76 ± 0.03 8.30 ± 0.22 0.94 ± 0.01 n.d. n.d. 
8 6.67 ± 0.34 0.68 ± 0.04 7.98 ± 0.11 1.01 ± 0.02 n.d. n.d. 
9 7.36 ± 0.22 0.77 ± 0.12 8.49 ± 0.34 1.18 ± 0.01 n.d. n.d. 
10c 8.18 ± 0.04 0.88 ± 0.05 8.93 ± 0.06*** 1.05 ± 0.05* 8.10 ± 0.03+++ 0.87 ± 0.01 
11c 6.82 ± 0.05 0.48 ± 0.02 7.97 ± 0.02*** 0.96 ± 0.05*** 7.10 ± 0.03*,+++ 0.62 ± 0.02*,++ 
12c 8.13 ± 0.04 0.79 ± 0.06 9.33 ± 0.12*** 1.03 ± 0.04* 8.14 ± 0.06+++ 0.79 ± 0.01+ 
13 7.85 ± 0.16 0.79 ± 0.03 8.47 ± 0.30 0.89 ± 0.04 n.d. n.d. 
14 7.68 ± 0.11 0.58 ± 0.03 8.15 ± 0.10 0.94 ± 0.04 n.d. n.d. 
15 6.63 ± 0.23 0.74 ± 0.03 7.86 ± 0.06 0.83 ± 0.06 n.d. n.d. 
16 7.32 ± 0.06 0.60 ± 0.03 (7.91 ± 0.02)  n.d. n.d. 
17c 7.84 ± 0.09 0.60 ± 0.03 8.70 ± 0.05*** 0.89 ± 0.04*** 7.81 ± 0.05+++ 0.60 ± 0.01+++ 
 
a pEC50 (pKB) and Emax values at hH2R-GsαS and gpH2R-GsαS were taken from Preuss et al. (2007b) for 
HA, from Kraus et al. (2009) for  compound 1 and from Birnkammer (2011) for compounds 2-17. 
b GTPase activity in Sf9 membranes (5 to 10 µg protein per tube), expressing hgpNTH2R-GsαS fusion 
protein, was determined as described in section 4.2.4. Data were analyzed by non-linear regression 
and were best fitted to sigmoidal concentration/response curves. Data shown are the means ± S.E.M. 
of three independent experiments performed in duplicate. The efficacy (Emax) of HA was set to 1.00 
and the efficacies of other ligands were referred to this value.  
c pEC50 and Emax values were compared using one-way ANOVA, followed by Bonferroni`s multiple 
comparison test (pEC50 or Emax significantly different to: *hH2R-GsαS, +gpH2R-GsαS; one symbol: p < 
0.05, two symbols: p < 0.01, three symbols: p < 0.001). 
n.d. Not determined. 
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4.3.2 Characterization of HA and NG-acylated hetarylpropylguanidines on neutrophil 
granulocytes in the O2•- assay  
We aimed at characterizing the NG-acylated hetarylpropylguanidine group of H2R 
ligands in a physiologically relevant test system. Neutrophil granulocytes express H2Rs and 
sufficient amount of neutrophils can be isolated from human blood effectively. Therefore, we 
choose these white blood cells for the verification of the very potent agonistic activity of NG-
acylated hetarylpropylguanidine, determined for the hH2R in recombinant test system. 
Superoxide anion production, stimulated by fMLP via formyl peptide receptor on neutrophil 
granulocytes, is inhibited by elevated levels of cAMP in cells (Burde et al., 1989; Burde et al., 
1990). The H2R is Gs-coupled receptor and that is why the agonistic activity of examined 
compounds at the H2R can be monitored as an inhibition of fMLP-stimulated O2•- production 
(Fig. 4.3, Table 4.2).  
 
 
 
 
 
 
 
 
 
Fig. 4.3 Concentration-response curves for HA and compound 10 in the O2•- assay. O2•- 
production in human neutrophil granulocytes (1 x 105 cells per well) was monitored by measurement of 
superoxide dismutase-inhibitable reduction of ferricytochrome c at 550 nm as described in section 
3.2.3. Data shown are from three (compound 10) and eight (HA) independent experiments, performed 
in triplicate (data points are means ± S.E.M.). Data were analyzed by non-linear regression and were 
best fitted to sigmoidal concentration/response curves.  
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Table 4.2 Comparison of potencies and efficacies of HA and selected NG-acylated 
hetarylpropylguanidines in different test systems. 
Compound 
O2•- assay 
(hH2R on neutrophil 
granulocytes) 
cAMP assay 
(hH2R on neutrophil 
granulocytes) 
GTPase assay 
(recombinant protein 
hH2R-GsαS) 
pIC50 Emax pEC50 Emax pEC50 Emax 
HA 4.65 ± 0.06 1.00 5.47 ± 0.03 1.00 6.01 ± 0.02b 1.00 
1 4.16 ± 0.11 0.86 ± 0.02a 7.08 ± 0.20 0.33 ± 0.03 7.65c 0.78 ± 0.02c 
5 no effect 7.28 ± 0.20 0.25 ± 0.02 8.11 ± 0.25d 0.53 ± 0.04d 
10 no effect 7.36 ± 0.12 0.31 ± 0.02 8.21 ± 0.07d 0.81 ± 0.02d 
12 no effect 7.55 ± 0.21 0.26 ± 0.03 8.12 ± 0.04d 0.76 ± 0.05d 
 
On human neutrophil granulocytes, the O2•- assay (1 x 105 cells per sample) was performed as 
described in section 3.2.3 and cAMP assay (5 x 105 cells per cup) was performed as described in 
sections 3.2.4 and 3.2.5. Data were analyzed by non-linear regression and were best fitted to 
sigmoidal concentration/response curves. Data shown are the means ± S.E.M. of three to eight 
independent experiments performed in triplicate. The efficacy (Emax) of HA was set to 1.00 and the 
efficacies of other ligands were referred to this value. 
a Up to 100 µM, concentration-response curve for compound 1 did not achieve saturation, therefore 
inhibition of fMLP-stimulated O2•- production at fixed concentration 100 µM (relative to HA) is listed. 
b Data were taken from Preuss et al. (2007b). 
c Data were taken from Kraus et al. (2009). 
d Data were taken from Birnkammer (2011). 
 
Both, HA (100 µM) and the monovalent (2-amino-4-methylthiazolyl)propylguanidine 
1 (100 µM), reduced the fMLP-stimulated O2•- production by 66 % on average (Table 4.3). A 
drastic decrease in potency was observed for both ligands compared to the data from 
GTPase assay (Table 4.2). No significant inhibition of the fMLP-stimulated O2•- production 
was detected in case of bivalent ligands 2-16 at a concentration of 1 µM (Table 4.3). The 
bivalent ligands were screened for their effect at 1 µM because of two reasons. Firstly, in 
steady-state GTPase assay, these ligands showed 4.3-130-fold higher potency than HA at 
the hH2R-GsαS. And secondly, bivalent ligands of acylguanidine type are cytotoxic at higher 
concentrations (see also section 4.4.2). Some bivalent ligands (10, 12) were tested at 
concentrations up to 500 µM (data not shown). At higher concentrations (100 µM, 500 µM), 
O2•- production in neutrophil granulocytes was reduced; this did not happen via specific 
inhibition of O2•- production but was due to cell death. This was evident from the 
morphological examination of neutrophil granulocytes (Fig. 4.4).   
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Table 4.3 Effects of HA and NG-acylated hetarylpropylguanidines 1-16 on fMLP-stimulated O2•- 
production in neutrophil granulocytes.  
Compound 
O2•- production 
(relative to fMLP-
stimulated O2•- production) 
Compound
O2•- production 
(relative to fMLP-
stimulated O2•- production) 
HA  0.34 ± 0.03   
1 0.34 ± 0.03 9 0.92 ± 0.01 
2 0.97 ± 0.04 10 0.95 ± 0.01 
3 0.99 ± 0.03 11 0.98 ± 0.01 
4 1.00 ± 0.04 12 0.96 ± 0.01 
5 0.97 ± 0.03 13 0.97 ± 0.01 
6 1.00 ± 0.07 14 0.84 ± 0.15 
7 0.97 ± 0.02 15 0.99 ± 0.01 
8 0.98 ± 0.01 16 1.01 ± 0.01 
 
O2•- production was monitored in human neutrophil granulocytes (1 x 105 cells per well) as described in 
section 3.2.3. Data shown are the means ± S.E.M. of three independent experiments performed in 
triplicate, except in case of HA, where 25 independent experiments in triplicate were conducted. The 
fMLP-stimulated O2•- production was set to 1.00 and the O2•- production in the presence of examined 
compounds was referred to this value. Inhibition of fMLP-stimulated O2•- production was measured at a 
fixed concentration of 100 µM for HA or compound 1 and at a fixed concentration of 1 µM for 
compounds 2-16. 
 
 
 
Fig. 4.4 Morphology of neutrophil granulocytes after the performance of the O2•- assay. The O2•- 
assay in human neutrophil granulocytes (1 x 105 cells per well) was performed as described in section 
3.2.3. Cells were imaged approximately 1-2 hours after begin of the O2•- assay. The O2•- assay was 
performed under control conditions (A) and in the presence of ligands at concentrations as follows: 
1mM HA (B), 1 mM compound 1 (C) and 500 µM compound 12 (D).  
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The effect of 100 µM HA was completely counteracted by FAM (10 µM), but not by 
MEP (1 µM) and THIO (10 µM), indicating solely H2R-mediated inhibition of O2•- production 
by the endogenous ligand HA (see section 3.3.1). Additionally, the effect of HA could be 
almost completely antagonized by symmetrical bivalent acylguanidine 5 (Fig. 4.5A and B). 
On the contrary, the effect of monovalent acylguanidine 1 could not be antagonized by 10 µM 
FAM (Fig. 4.5A).  
It is also noteworthy that all examined ligands in our study did neither cause 
reduction of ferricytochrome c nor stimulation of O2•- production per se (data not shown).  
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Fig. 4.5 Antagonistic effect of compound 5 and FAM on HA- or compound 1-induced inhibition 
of O2•- production. The O2•- production in human neutrophil granulocytes (1 x 105 cells per well) was 
monitored by measurement of ferricytochrome c reduction at 550 nm as described in section 3.2.3. 
Data shown are means (± S.E.M.) of one to four experiments, performed in triplicate. (A) Effect of 
compound 5 (1 µM) and FAM (10 µM) at fixed concentrations. a The inhibition of O2•- production by HA 
in the absence and in the presence of compound 5 and the inhibition of O2•- production by compound 1 
(10 µM) in the absence and in the presence of FAM, respectively, were compared with the unpaired 
two-tailed t-test (**, p < 0.01). (B) Effect of increasing concentrations of compound 5. O2•- production 
was determined at fixed concentration of HA (25 µM, submaximally effective concentration) in the 
presence of increasing concentrations of compound 5.  
 
4.3.3 Characterisation of HA and NG-acylated hetarylpropylguanidines on neutrophil 
granulocytes in the cAMP assay 
Because of the lack of H2R agonistic activity of examined acylguanidines 2-16 in the 
O2•- assay, we decided to determine the effect of these compounds on cAMP generation in 
neutrophil granulocytes. Production of cAMP in cells is an event rather proximal to ligand-
H2R receptor interaction whereas monitoring of the O2•- production is a rather indirect way to 
assess agonistic activity at the H2R (see section 3.1).  
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As summarized Table 4.4, NG-acylated hetarylpropylguanidines 1-16 acted as very 
weak to moderate hH2R agonists. On the basis of these screening results at fixed 
concentrations, we decided to investigate the effect of HA and compounds 1, 5, 10 and 12 in 
more detail. Compound 1 is a very potent monovalent NG-acylated 
aminothiazolylpropylguanidine at the hH2R-GsαS fusion protein (Kraus et al., 2009) and 
compounds 5, 10 and 12 are the most potent bivalent NG-acylated hetarylpropylguanidines in 
one-digit nM range, characterized at the hH2R-GsαS so far (Birnkammer, 2011). The potency 
of HA is reduced compared to the potency determined in GTPase assay, but still higher than 
the potency in O2•- assay (Table 4.2). For compounds 1, 5, 10 and 12, lower potency in two-
digit nM range and drastic drop in efficacy (2.3 - 2.9-fold) compared to the data in 
recombinant test system was observed (Table 4.2, Fig. 4.6). 
 
Table 4.4 Effects of HA and NG-acylated hetarylpropylguanidines 1-16 on cAMP accumulation in 
neutrophil granulocytes.  
Compound 
cAMP accumulation 
(relative to HA) 
Compound
cAMP accumulation 
(relative to HA) 
HA  1.00   
1 0.33 ± 0.06 9 0.39 ± 0.06 
2 0.07 ± 0.01 10 0.28 ± 0.02 
3 0.18 ± 0.06 11 0.09 ± 0.05 
4 0.14 ± 0.04 12 0.26 ± 0.05 
5 0.22 ± 0.03 13 0.18 ± 0.04 
6 0.30 ± 0.04 14 0.07 ± 0.03 
7 0.25 ± 0.03 15 0.13 ± 0.04 
8 0.12 ± 0.03 16 0.07 ± 0.05 
 
cAMP accumulation was monitored in neutrophil granulocytes (5 x 105 cells per sample) by HPLC-
MS/MS system as described in sections 3.2.4 and 3.2.5. Data shown are the means ± S.E.M. of three 
to five independent experiments performed in triplicate. The cAMP production at fixed concentration of 
100 µM for HA was set to 1.00 and the cAMP production at fixed concentrations of other examined 
compounds (10 µM for 1; 1 µM for 2-16) was referred to this value.  
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Fig. 4.6 Concentration-response curves for HA and compound 10 in the cAMP assay. cAMP 
concentration in human neutrophil granulocytes (5 x 105 cells per sample) was monitored by HPLC-
MS/MS system as described in sections 3.2.4 and 3.2.5 Data shown are from three (compound 10) 
and five (HA) independent experiments, performed in duplicate or triplicate (data points are mean ± 
S.E.M.). Data were analyzed by non-linear regression and were best fitted to sigmoidal 
concentration/response curves.  
 
In Fig. 4.7, the antagonistic effect of MEP, FAM and THIO on compound 1- and 
compound 10-mediated cAMP elevation in neutrophil granulocytes is shown. In case of 
compound 10, cAMP level could be almost completely reduced with FAM, whereas MEP and 
THIO did not influence the cAMP production. In contrast to the results of the O2•- assay, 
stimulation of cAMP production by compound 1 could be at least partially reduced by FAM. 
 
Fig. 4.7 Antagonistic effect of MEP, FAM and 
THIO on compound 1- and compound 10-
induced cAMP accumulation in neutrophil 
granulocytes. cAMP accumulation was monitored 
in neutrophil granulocytes (5 x 105 cells per 
sample) by HPLC-MS/MS system as described in 
sections 3.2.4 and 3.2.5. Data shown are means 
of two to four experiments, performed in triplicate. 
MEP, mepyramine at a concentration of 1 µM; 
FAM, famotidine at a concentration of 10 µM; 
THIO, thioperamide at a concentration of 10 µM.   
a The cAMP production by 1 µM of compound 1 in 
the absence and in the presence of 10 µM FAM 
and the cAMP production by 10 µM of compound 
1 in the absence and in the presence of 10 µM 
FAM, respectively, were compared with unpaired 
two-tailed t-test (no significant difference found). b 
The stimulation of cAMP production by compound 
10 in the absence of antagonists (reference value) was compared with the stimulation of cAMP 
production by compound 10 in the presence of MEP, FAM and THIO, respectively, using one-way 
ANOVA, followed by Dunnett’s multiple comparison test (**, p < 0.01).  
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4.4 Discussion 
NG-acylated hetarylpropylguanidines, synthesized in our laboratory, are very potent 
H2R agonists as determined in GTPase and adenylate cyclase assays using membrane 
preparations of Sf9 insect cells expressing hH2R or gpH2R and on isolated spontaneously 
beating guinea pig right atrium (Xie et al., 2006; Ghorai et al., 2008; Kraus et al., 2009; 
Birnkammer, 2011). The intention of this study was firstly, to assess a potential involvement 
of the N-terminus in behavior of these ligands at the hH2R and gpH2R and secondly, to 
characterize them in a physiologically relevant test system, on human neutrophil 
granulocytes.  
 
4.4.1 Ambivalent role of the H2R N-terminus  
The N-terminus of many peptidergic GPCRs is involved in binding of large peptide 
ligands, e.g. in case of complement factor 5a receptor (Chen et al., 1998) and chemokine 
receptor CXCR4 (Rana and Baranski, 2010). On the contrary, the N-terminus of the 
aminergic GPCRs is normally considered just as an inert element of the receptor and there 
are only few reports about its functional role (Strasser et al., 2008). 
Several studies were already performed in order to explain the species-selective 
profile of acylguanidines at the hH2R and gphH2R. Amino acids at positions 17 in TM I (Cys 
at the hH2R and Tyr at the gpH2R) and 271 in TM VII (Ala at the H2R and Asp at the gpH2R) 
(Fig. 4.1), forming interhelical H-bond at the gpH2R but not at the hH2R, are just partially 
responsible for distinct potencies and efficacies of monovalent and bivalent acylguanidine-
type ligands between species (Preuss et al., 2007a; Birnkammer, 2011). The second 
extracellular loop (E2-loop), reported to be in close contact to ligands in the orthosteric 
binding pocket for some other GPCRs (Palczewski et al., 2000; Peeters et al., 2011), was 
studied also at the H2R. However, mutual exchange of four non-conserved amino acids at 
positions 167, 169, 171 and 172 of the hH2R and the gpH2R (Fig. 4.1), respectively, resulted 
in similar potencies and efficacies of monovalent NG-acylguanidines at the mutant and 
corresponding wild-type receptors (Preuss et al., 2007b). The E2-loop was also analyzed as 
a putative accessory binding site of bivalent ligands. Hence, mutagenesis studies revealed 
only minor influence of the E2-loop onto the potency of some bivalent 2-amino-4-
methylthiazolyl ligands, but no effect with respect to other types of bivalent compounds 
(Birnkammer, 2011). 
Molecular modeling of N-terminus of GPCRs is even more challenging than 
modeling of already highly flexible extracellular loops. Hence, mutagenesis studies are a 
better alternative to study this flexible domain. By the generation of receptor chimera 
hgpNTH2R-GsαS, no shift in charge was introduced in the area of N-terminus, but few 
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alterations in polarity and flexibility of this domain (Fig. 4.1). Because of the close proximity to 
the N-terminus also Cys-17 in the TM I of the hH2R was replaced by Tyr-17 of the gpH2R. As 
already mentioned before amino acid at position 17 together with amino acid at position 271 
is involved in species-selective profile of NG-acylguanidines (Preuss et al., 2007a; 
Birnkammer, 2011), but because of the lack of Asp at position 271 in the hgpNTH2R-GsαS, a 
crucial interhelical H-bond cannot be formed. The characterization of NG-acylguanidines at 
the hgpNTH2R-GsαS indicates ambivalent influence of the altered N-terminus. Therefore, no 
general trend for the behavior of examined ligands could be observed at the hgpNTH2R-GsαS 
(Table 4.1).  
The N-terminus of the hH2R and gpH2R on its own is not a key player in determining 
the species-selective profile of acylguanidines. Nevertheless, in a three-dimensional 
homology model of hH2R a putative interaction of the second extracellular loop and N-
terminus was suggested (Preuss et al., 2007b). Moreover, activation of thyroid stimulating 
hormone receptor was influenced by cooperative action of more extracellular domains 
(Kleinau et al., 2008). Molecular dynamic simulation at the hH1R also revealed an importance 
of H-bond network between N-terminus, E1-loop and E2-loop for conformation and flexibility 
of the E2-loop (Strasser et al., 2008). A complex network of interactions between 
extracellular domains should be kept in mind, when molecular determinants influencing the 
receptor activation process are discussed (Peeters et al., 2011). The species-specificity, 
especially of the bivalent NG-acylated hetarylpropylguanidines, cannot be explained by 
exchanging only the N-terminus of the H2R. But it can be speculated that an interaction 
between the N-terminus and two or more extracellular loops is prerequisite for the high 
activity at the gpH2R.  
 
4.4.2 Unexpected effects of NG-acylated hetarylpropylguanidines on neutrophil 
granulocytes 
Although monovalent and bivalent NG-acylated hetarylpropylguanidines are very 
potent H2R agonists and therefore interesting tools for further pharmacological studies, these 
compounds have some drawbacks. Because of their cationic-amphiphilic character, they are 
susceptible to interaction with biological membranes and off-targets (Schreier et al., 2000). 
Hemolytic activity was detected for several rather lipophilic monovalent acylguanidines at a 
concentration of 100 µM and for bivalent ligands with a longer lipophilic spacer (n ≥ 14) at a 
concentration of 10 µM (Birnkammer, 2011). Cytotoxic effects were detectable at 
concentrations ≥ 10 µM (Birnkammer, 2011). Acylguanidines also bound strongly to serum 
albumin (generally ≥ 90 %) (Birnkammer, 2011). The aforementioned properties of the title 
compounds have to be taken into consideration, when studies on the cellular level or in vivo 
are planned. 
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In general, the development of bivalent ligands as potential drugs is compromised 
by unfavorable physicochemical properties (bulkyness and high molecular weight) and 
unfavorable pharmacokinetic properties (Shonberg et al., 2011). However, besides their 
usefulness as pharmacological tools for investigation of receptor dimers in vitro, several 
examples from literature demonstrate that the bivalent ligand approach can result also in 
beneficial effects in vivo. One prominent example is a study published by Daniels et al. 
(2005). Hybrid compounds combining the pharmacophoric moieties of both the δ-opioid 
receptor antagonist naltrindole, reported to suppress antinociceptive tolerance, and the μ-
opioid receptor agonist oxymorphone, connected with a 21-atom linker, revealed improved 
antinociceptive properties in mice compared to morphine. Additionally, this opioid receptor 
ligand did not induce tolerance and physical dependence upon chronic administration. 
Moreover, in vitro and in vivo studies on bivalent ligand with two sumatriptan molecules as 
pharmacophores revealed superior potency at 5-HT1B receptor compared to the monovalent 
counterpart sumatriptan, which is currently used in the treatment of migraine (Perez et al., 
1998). These examples prove that the applicability of bivalent ligands is not restricted to 
recombinant test systems. 
The effects of the acylguanidines on neutrophil granulocytes are difficult to explain. 
Neutrophil granulocytes are a much more complex test system for the characterization of 
H2R agonists than Sf9 insect cell membranes, where only the receptor of interest is 
expressed. Previously, reduced potency in the O2•- assay on human neutrophil granulocytes 
(Burde et al., 1990) compared to the GTPase assay on hH2R-GsαS (Preuss et al., 2007b) was 
reported for the monovalent guanidines IMP and ARP. The potency of IMP and ARP differed 
13- and 140-fold, respectively, between both assays. Nevertheless, IMP and ARP were still 
full agonists in the O2•- assay (Burde et al., 1990) whereas bivalent NG-acylguanidines were 
lacking of any agonistic activity at a concentration (1 µM) corresponding to – in some cases - 
more than 100-fold the EC50 value determined in the GTPase assay (Table 4.3). Moreover, 
inhibition of fMLP-stimulated O2•- production by the guanidine ARP could be competitively 
antagonized by famotidine (Burde et al., 1990) whereas, in our study, the agonistic effect of 
acylguanidine 1 could not be reversed by the same H2R antagonist (Fig. 4.5). 
Monovalent as well as bivalent ligands stimulated cAMP accumulation in neutrophil 
granulocytes in a H2R-dependent manner, although with reduced potency and efficacy 
compared to that observed in a recombinant test system (Table 4.2). Results of structure-
activity relationship studies with bivalent acylguanidines at the hH2R-GsαS (Birnkammer, 
2011) are - at least in part - in agreement with the results of the cAMP assay on neutrophil 
granulocytes. A decanedioyl spacer between pharmacophoric groups is the common 
structural motif of the most potent H2R agonists in both test systems. 
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It should be noted here that due to the disappointing results regarding effects of 
bivalent NG-acylguanidines in functional assays on neutrophil granulocytes, we were aiming 
at detecting of hH2R molecules on these cells. In our laboratory, red fluorescent H2R ligands 
were synthesized and successfully characterized on HEK293 cells, expressing recombinant 
hH2Rs (Erdmann, 2011). Unfortunately, preliminary experiments revealed unsuitability of 
these ligands for binding studies on neutrophil granulocytes. Unexpectedly, flow cytometric 
experiments and confocal microscopy were hampered by penetration of the fluorescent H2R 
ligands into the cells as well as by pronounced red autofluorescence of neutrophils (Lopuch, 
2011). The presence of phagocyte-specific cytochrome b-245 (absorption maxima at 426, 528 
and 558 nm) in neutrophils could at least partially account for the latter problem (Seifert and 
Schultz, 1991). 
Another concern with respect to different activities of the title compounds in different 
test systems is the artificial nature of the hH2R-GsαS fusion protein, expressed in Sf9 cells, 
resulting in high potencies. Nevertheless, in the study of Xie and coworkers, IMP and ARP 
were examined at the hH2R-GsαS fusion protein in GTPase assay and at non-fused hH2R in 
adenylate cyclases assay, using Sf9 cells as expression system in both cases (Xie et al., 
2006). The potencies of two above-mentioned ligands were even ~2.5-fold higher in adenylyl 
cyclase assay than in GTPase assay, ruling out the role of the GsαS as a potency-intensifier 
at least in case of the guanidines. Moreover, representative bivalent acylguanidines were 
characterized also at the spontaneously beating guinea pig right atrium, which is a standard 
organ for the investigation of H2R ligands. Here, the EC50 and Emax values of the most potent 
agonists correlated well with the data, determined at the gpH2R-GsαS in recombinant test 
system (Birnkammer, 2011).  
As mentioned before, inhibition of fMLP-stimulated O2•- production in neutrophil 
granulocytes is a very indirect way of assessing H2R agonistic activity. Upon exposure to 
fMLP, formyl peptide receptors are activated and couple to Gi proteins (Gierschik et al., 1989; 
Wenzel-Seifert et al., 1999). Further signaling events including activation of phospholipase C 
and protein kinase C result in O2•- production, catalyzed by NADPH oxidase (Burde et al., 
1989). Activation of the H2R leads to cAMP increase and O2•- production is presumably 
inhibited by cAMP-dependent protein kinases (Seifert and Schultz, 1991). In this complex 
signaling event, where NADPH oxidase can be activated by numerous stimuli acting through 
different pathways, not only via formyl peptide receptors (Seifert and Schultz, 1991), it is 
difficult to find an explanation for unspecific (non-H2R-mediated) suppression of O2•- 
production by amphiphilic monovalent acylguanidine 1 (Fig. 4.5). It is known from the 
literature that lipophilic ARP-like guanidines and cationic amphiphilic HA-derivative are 
capable of stimulating Gi proteins in a receptor-independent manner, resulting in O2•- 
elevation in neutrophils and HL-60 cells (Hagelüken et al., 1995). Also in general, numerous 
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cationic amphiphilic molecules are known to stimulate G proteins in a receptor-independent 
way by passing cell membrane (Mousli et al., 1990). Thus, compound 1 may be able to enter 
the cell and inhibit O2•- generation on different levels of the above described cascade of 
events. Furthermore, the direct interaction of basic heterocycle of compound 1 with 
cytochrome b-245 of neutrophils or ferricytochrome c cannot be excluded. The former will 
result in reduced O2•- production (Seifert and Schultz, 1991), the latter in diminished reduction 
of ferricytochrome c (Burde et al., 1990). In both cases the results can be mis-interpretated 
as H2R agonistic activity. Further studies on this topic would be needed to explain the effect 
of compound 1.  
Another point that should be discussed are tissue-specific properties of H2Rs. 
Remarkable dissociation of H2R-mediated agonistic effects was observed for the series of 
IMP analogues between guinea pig right atrium and guinea pig gastric fundus (Sterk et al., 
1987). Moreover, also within one organ, different behavior of H2R ligands was reported. The 
positive inotropic response in guinea pig papillary muscle differed from positive chronotropic 
effect in the isolated guinea pig right atrium for some ARP-like H2R agonists (Buschauer, 
1989). Tissue specific behavior of one and the same receptor subtype can be influenced by 
different compartmentation of signaling partners at the plasma membrane (Lasley, 2011), by 
formation of homo- or heteromers (Smith and Milligan, 2010), by variable susceptibility to 
receptor desensitization and internalization (Tobin et al., 2008) as well as by different 
expression level and receptor reserve. Additionally, surface properties of different cell types 
are also highly relevant in case of amphiphilic molecules. The selectivity of amphiphilic 
peptides for some cell types strongly depends on extent of the negative charge on the cell 
surface (Mousli et al., 1990). For example, negatively charged sialic acid residues on the cell 
surface were suggested to be involved in interaction of amphiphilic substance P with mast 
cell membrane (Mousli et al., 1989). Sialic acid content dynamically changes during 
maturation and activation process of neutrophil granulocytes (Cross et al., 2003; Sakarya et 
al., 2004). It is conceivable, that interactions of amphiphilic acylguanidines with sialic acid 
and other negatively charged residues on the surface of neutrophil granulocytes diminishes 
number of ligands, which can specifically interact with H2R, resulting in reduced potency. 
Therefore, acylguanidines have less perspective as anti-inflammatory drugs, but might be 
useful in the treatment of acute congestive heart failure or have beneficial effect in other 
tissues expressing H2R. The next rational step would be the characterization of NG-acylated 
hetarylpropylguanidines at the guinea pig neutrophil granulocytes to get more insight into the 
tissue specific behavior of those ligands at the same species. However, the limiting factor 
with respect of extensive studies is isolation of sufficient amounts of neutrophils from this 
small laboratory animal. 
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4.4.3 Conclusions 
The aim of this study was to broaden our knowledge about the pharmacological 
profile of potent H2R agonists, monovalent and bivalent NG-acylated hetarylpropylguanidines. 
Mutagenesis study revealed rather marginal contribution of the N-terminus to the species-
selective profile of acylguanidines at the hH2R and gpH2R. Furthermore, the characterization 
of title compounds on neutrophil granulocytes revealed (I) unspecific inhibition of fMLP-
stimulated O2•- production by monovalent ligand 1, (II) lack of inhibitory effect of bivalent 
acylguanidines on fMLP-stimulated O2•- production and (III) weak H2R-mediated stimulation 
of cAMP production by monovalent and bivalent ligands compared to the Sf9/baculovirus 
system. In conclusion, further in vitro investigations and in vivo studies of representative 
compounds are needed to assess the potential therapeutic value of acylguanidine-type H2R 
agonists. 
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Role of the second and third extracellular loops of 
the histamine H4 receptor in receptor activation    
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5.1 Abstract 
The histamine H4 receptor subtype (H4R) belongs to the class 1 of G protein-
coupled receptors and is involved in inflammatory and immunological processes. The aim of 
this study was to elucidate the importance of extracellular regions for the large species 
differences between the human (h) and canine (c) H4R. Therefore, chimeric receptors were 
generated by replacing corresponding domains of the hH4R with the canine N-terminus 
(hcNTH4R) and three canine extracellular loops, respectively (hcE1H4R, hcE2H4R and hcE3H4R). 
Wild-type and chimeric H4 receptors were expressed in Sf9 insect cells and subsequently 
characterized in [3H]histamine binding experiments and in steady-state GTPase activity 
assays, where standard H4R ligands histamine, 5-methylhistamine, thioperamide, 1-[(5-
chloro-1H-indol-2-yl)carbonyl]-4-methylpiperazine (JNJ7777120) and clozapine were 
examined. The exchange of N-terminus or first extracellular loop did not influence hH4R 
pharmacology. The effect of altered second extracellular loop (E2-loop) and third 
extracellular loop (E3-loop) was rather ligand-specific than agonist/inverse agonist-specific. 
At the hcE3H4R, the potency of histamine and 5-methylhistamine significantly decreased. The 
efficacy of the inverse agonist thioperamide was strongly reduced at the hcE2H4R and the 
hcE3H4R. Surprisingly, JNJ7777120 as weak inverse agonist at the hH4R exhibited partial 
agonistic activity at the hcE2H4R and the hcE3H4R. Molecular dynamic simulations suggest that 
the E2- and E3-loops are independently of each other involved in partial/inverse agonism of 
JNJ7777120 and that E2- as well as E3-loop do not directly interact with JNJ7777120 in the 
binding pocket. In conclusion, our study indicates an involvement of E2- and E3-loop in H4R 
activation process after binding of some but not all examined ligands. 
 
5.2 Introduction 
There are four histamine receptor subtypes known (histamine H1, H2, H3 and H4 
receptor), which belong to the class 1 (rhodopsin-like class) of G protein-coupled receptors 
(GPCR) (Foord et al., 2005; Thurmond et al., 2008). The latest identified histamine receptor 
subtype, histamine H4 receptor (H4R), couples to pertussis toxin-sensitive Gi/o proteins, 
leading to increases in intracellular calcium and inhibition of cAMP production (Thurmond et 
al., 2008; Leurs et al., 2009). The H4R is mainly expressed on cells of haematopoietic origin, 
like mast cells, dendritic cells, monocytes, eosinophils, basophils and T cells, and thereby 
plays a role in modulation of immune and inflammatory processes (Thurmond et al., 2008; 
Zampeli and Tiligada, 2009). The H4R is regarded as a very promising drug target in respect 
of therapy of asthma, chronic pruritus and autoimmune disorders like rheumatoid arthritis 
(Zampeli and Tiligada, 2009). 
 Introduction  99 
Full-length human H4R (hH4R) consists of 390 amino acids, with an extracellular N-
terminus, seven transmembrane domains (TM I-VII), intertwined by three extracellular and 
three intracellular loops, and an intracellular C-terminus. One characteristic of the hH4R is 
quite low amino acid homology to other species, for instance 65 %, 68 % and 69 % to the 
guinea pig, mouse and rat H4R, respectively (Liu et al., 2001). These structural differences 
are translated into differing pharmacological profiles (Lim et al., 2010; Schnell et al., 2011). 
Consequently, the evaluation of H4R ligands, potentially beneficial in therapy of humans, is 
limited in animal models. Thus, there is a need to identify structural determinants, 
responsible for differences in pharmacology of the hH4R and H4R of other species, used as 
animal models. 
In 2008, the canine H4R (cH4R) from Canis familiaris was cloned (Jiang et al., 
2008). Testing of standard H4R ligands at the cH4R revealed major differences in binding 
affinity and potency compared to the hH4R (Jiang et al., 2008; Lim et al., 2010; Schnell et al., 
2011). Very recently, also an agonistic activity of thioperamide (THIO) and 1-[(5-chloro-1H-
indol-2-yl)carbonyl]-4-methylpiperazine (JNJ7777120) at the cH4R, expressed in Sf9 insect 
cells, was reported (Schnell et al., 2011). These two ligands exhibit inverse agonistic activity 
at the hH4R. The cH4R is composed of 395 amino acids and shares 71 % of an overall 
sequence identity with the hH4R and 83 % of sequence identity in transmembrane area (Fig. 
5.1A). Many amino acids in transmembrane regions of the hH4R, identified as crucial for 
histamine (HA) binding, receptor activation and G-protein coupling, are identical at the cH4R 
(Jiang et al., 2008). This gives rise to a question, whether the regions other than 
transmembrane domains are important for species differences, observed for the hH4R and 
the cH4R.  
For numerous aminergic GPCRs, like α1A- and α1B-adrenergic receptors, the            
β2-adrenergic receptor, M1, M2, M3 and M4 muscarinic acetylcholine receptors, 5-HT1D and   
5-HT1B receptors, adenosine A2A and A2B receptors as same as the histamine H1 receptor 
(Shi and Javitch, 2002; Lawson and Wheatley, 2004; Strasser et al., 2008b; Peeters et al., 
2011a; Peeters et al., 2011b), extracellular regions are functionally important parts of the 
receptor. Most importantly, small-molecule ligands with different modes of action (agonists, 
antagonists or inverse agonists) stabilize distinct extracellular surface conformations of        
β2-adrenergic receptor, indicative of a role of extracellular domains as modulators of receptor 
function (Bokoch et al., 2010). In case of the H4R, comparison of four extracellular regions of 
human and canine receptor revealed sequence identity of 63 %, 55 %, 48 % and 20 % for N-
terminus, first extracellular loop (E1-loop), second extracellular loop (E2-loop) and third 
extracellular loop (E3-loop), respectively. It is also noteworthy, that the E2-loop of the cH4R is 
six amino acids longer than the E2-loop of the hH4R (Fig. 5.1A). Therefore, in the present 
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study, we were aiming at evaluating the relevance of differing extracellular domains for 
differences in the pharmacology of the hH4R and the cH4R. 
 
 
Fig. 5.1 Human, canine and chimeric histamine H4 receptors. (A) Alignment of the amino acid 
sequences of the wild-type hH4R and cH4R (Jiang et al., 2008). TM I-VII, seven transmembrane 
domains; I1-3 loop, first, second and third intracellular loop; E1-3 loop, first, second and third 
extracellular loop. Dots in the sequence of the cH4R indicate identical amino acids with the hH4R. 
Hyphens stand for missing amino acids and underlined amino acids indicate putative glycosylation 
sites in extracellular regions. Amino acids with grey shading represent the most conserved amino 
acids among aminergic G protein-coupled receptors (Shi and Javitch, 2002). Amino acids in bold were 
exchanged by the generation of chimeric H4 receptors; hcNTH4R, with downward-facing triangle (▼) 
marked amino acids at the hH4R were replaced by corresponding amino acids of the cH4R; hcE1H4R, 
with circle (●) marked amino acids at the hH4R were replaced by corresponding amino acids of the 
cH4R; hcE2H4R, with diamond (♦) marked amino acids at the hH4R were replaced by corresponding 
amino acids of the cH4R or inserted; hcE3H4R, with upward-facing triangle (▲) marked amino acids at 
the hH4R were replaced by corresponding amino acids of the cH4R. (B) Schematic depiction of wild-
type hH4R, cH4R as well as generated H4R chimeras. The parts of the human H4R are shown in grey 
and the parts of the canine H4R are shown in black. 
 
For this reason, we generated chimeric H4R receptors by replacing corresponding 
extracellular domains of the hH4R with the canine N-terminus (hcNTH4R) and three canine 
extracellular loops, respectively (hcE1H4R, hcE2H4R and hcE3H4R) (Fig. 5.1B). Wild-type hH4R 
and cH4R as well as chimeric H4 receptors were expressed in Sf9 insect cells together with G 
protein subunits Gi2 and G12 and characterized in [3H]HA binding experiments and in 
steady-state GTPase activity assays. Here, standard H4R ligands HA, 5-methylhistamine (5-
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MHA), THIO, JNJ7777120 and clozapine were tested (Fig. 5.2). To obtain detailed insight 
into the influence of the E2-loop and E3-loop with regard to ligand binding and receptor 
activation, molecular modelling studies were performed.  
 
5.3 Materials and Methods 
5.3.1 Materials 
The pcDNA 3.1 plasmid with the sequence of the hH4R was obtained from UMR 
cDNA Resource Center at the University of Missouri-Rolla (Rolla, MO). The pCIneo plasmid 
containing the sequence of the cH4R was kindly provided by Dr. R. Thurmond (Johnson  
Johnson Pharmaceutical RD, San Diego, CA). The generation of pGEM-3Z-SF-hH4R-His6, 
pVL1392-SF-hH4R-His6-Gi2 and pVL1392-SF-cH4R-His6 was described previously 
(Schneider et al., 2009; Schnell et al., 2011). Baculovirus encoding Gi2 was donated by Dr. 
A. G. Gilman (Department of Pharmacology, University of Southwestern Medical Center, 
Dallas, TX). Baculovirus encoding the unmodified versions of the G12 subunits was kindly 
provided by Dr. P. Gierschik (Department of Pharmacology and Toxicology, University of 
Ulm, Germany). The anti-Flag IgG (M1 monoclonal antibody) was from Sigma (St. Louis, 
MO). The antibody selective for Gi1/2 was purchased from Calbiochem (La Jolla, CA). The 
DNA primers for PCR were purchased by MWG Biotech (Ebersberg, Germany). Phusion 
high-fidelity DNA Polymerase was obtained from Finnzymes (Espoo, Finland). Restriction 
enzymes and T4-DNA ligase were from New England Biolabs (Ipswich, MA). [3H]HA (14.2 
Ci/mmol) was from Perkin Elmer (Boston, MA). [-32P]GTP was synthesized using GDP and 
[-32P]Pi (8,500-9,100 Ci/mmol orthophosphoric acid) as described previously (Walseth and 
Johnson, 1979). Analogously, [-33P]GTP was synthesized using GDP and [-33P]Pi (3,000 
Ci/mmol orthophosphoric acid). GDP was purchased from Sigma-Aldrich (St. Louis, MO), [-
32P]Pi from Perkin Elmer (Boston, MA) and [-33P]Pi from Hartmann Analytic (Braunschweig, 
Germany). All other reagents were from standard suppliers and had the highest purity 
available. Radioactive samples were counted in a PerkinElmer Tricarb 2800TR liquid 
scintillation analyzer. 
HA, 5-MHA and THIO were obtained from Tocris (Avonmouth, Bristol, UK), 
clozapine from Research Biochemicals International (Natick, MA) and JNJ7777120 from 
Axon Medchem (Groningen, Netherlands). Chemical structures of ligands are depicted in 
Fig. 5.2. Stock solutions and dilutions of HA, 5-MHA and THIO were prepared in millipore 
water. 10 mM stock solutions of JNJ7777120 and clozapine were dissolved in dimethyl 
sulfoxide (DMSO) and dilution series, used in assays, were prepared in 10 % DMSO (v/v) to 
achieve final DMSO concentration of 1 % (v/v) in each assay tube. 
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Fig. 5.2 Structures of the tested H4R ligands. Using Sf9 insect cells as expression system and 
steady-state GTPase activity assay as read-out, histamine (HA), 5-methylhistamine (5-MHA) and 
clozapine show agonistic activity at the hH4R as same as at the cH4R. In contrast, thioperamide 
(THIO) and JNJ7777120 exhibit species-specific mode of action; they act as inverse agonists at the 
hH4R and as agonists at the cH4R (Schnell et al., 2011).  
 
5.3.2 Construction of the cDNA for the hcNTH4R  
The cDNA for the hcNTH4R was generated by sequential overlap-extension PCR, 
using pGEM-3Z-SF-hH4R-His6 as template, by analogy with approaches described before 
(Preuss et al., 2007; Strasser et al., 2008b).  In PCR 1A, the DNA region encoding for 
cleavable signal peptide from influenza hemagglutinin (S; ATGAAGACGATCATCGCCCT 
GAGCTACATCTTCTGCCTGGTATTCGCC), the FLAG epitope (F; GACTACAAGGACGAT 
GATGACGCC) recognized by the M1 monoclonal antibody and the N-terminus of cH4R was 
amplified. The sense primer annealed with 24 bp of pGEM-3Z prior to the 5’-end of SF. The 
antisense primer with the sequence 5’-TACGCGTGCTTAGTGGTAAAGTGATTGT 
TCCATTAGTAGCTGACATGGCGTCATCATCGTCCTTGTAG-3’ was used to generate 
Pro2→Ser2, Asp3→Ala3, Ser6→Gly6, Asn9→Thr9, Ser11→Pro11 and Val16→Ile16 
mutations in the region of N-terminus and a new Mlu I restriction site (ACGCGT). In PCR 1B, 
the DNA sequence of canine N-terminus, the rest of the hH4R and a hexahistidine tag 
(CACCATCATCACCATCAC) was amplified. The hexahistidine tag allows future purification 
and provides additional protection against proteolysis. The sense primer encoded the 
sequence  5’-TCAGCTACTAATGGAACAATCACTTTACCACTAAGCACGCGTATTACTTT 
AGCATTTTTTATGTCCTTAGTAG-3’ to generate Pro2→Ser2, Asp3→Ala3, Ser6→Gly6, 
Asn9→Thr9, Ser11→Pro11 and Val16→Ile16 mutations and a new Mlu I restriction site. The 
antisense primer annealed with 18 bp of pGEM-3Z after the stop codon and after an Xba I 
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site. In PCR 2, using the sense primer of PCR 1A and the antisense primer of PCR 1B, the 
products of PCR 1A and 1B annealed in the region of newly created canine N-terminus and a 
new Mlu I restriction site. The product of PCR 2 encoded the complete cDNA for SF-hcNTH4R-
His6 protein. This product was double-digested with Sac I and Xba I and cloned into pGEM-
3Z-SF-hH4R-His6 digested with the same enzymes. pGEM-3Z-SF-hcNTH4R-His6 was digested 
with Sac I and Xba I and cloned into the baculovirus transfer vector pVL1392-SF-hH4R-His6 
digested with the same enzymes. The sequence of SF-hcNTH4R-His6, cloned into the pGEM-
3Z plasmid, was verified by restriction enzyme analysis and sequencing (Entelechon, 
Regensburg, Germany).  
 
5.3.3 Construction of the cDNA for the hcE1H4R, hcE2H4R, hcE3H4R and hcE3H4R-Gi2. 
The cDNAs for the hcE1H4R, hcE2H4R and hcE3H4R were generated by analogy with 
the generation of cDNA for the hcNTH4R, using pGEM-3Z-SF-hH4R-His6 as template. For 
construction of the hcE1H4R cDNA, the antisense primer 5’-GCGCAGAGTTTATTTCCAAAA 
TCCCAATCGAA CAGCGTGTGAGGGATG-3’ was used in PCR 1A and the sense primer 5’-
TTGGGATTTTGGAAATAAACTCTGCGCATTTTGGCTCACTACTGACTATCTG-3’ was used 
in PCR 1B in order to generate mutations Glu79→Asp79, Lys84→Asn84, Glu85→Lys85, 
Ile86→Leu86 and Val88→Ala88 in the region of E1-loop and a new Fsp I restriction site 
(TGCGCA).  
In case of the hcE2H4R, the antisense primer 5’-CCTGGTGAAAAATCCAGGTTC 
ACAATCCTTCTCCTCCACGACTCCGAAACTGGAATTCTTCCAAGACTCTGAAACTAGAA 
TCATTGG-3’ was used in PCR 1A and the sense primer  5’-AATTCCAGTTTCGGAGTC 
GTGGAGGAGAAGGATTGTGAACCTGGATTTTTCACCAGGTGGTACATCCTTGCCATCA 
CATCATTC-3’ was used in PCR 1B in order to generate mutations Asp159→Asn159, 
Glu160→Ser160, Gly161→Glu167, Ser162→Lys168, Glu163→Asp169, Ser170→Thr176 
and Glu171→Arg177 in the region of E2-loop and a new Dra III restriction site 
(CACNNNGTG) and to insert 6 amino acids in the region of E2-loop (Ser161, Phe162, 
Gly163, Val164, Val165, Glu166). Amino acids at positions 170 (Ser) and 171 (Glu) in the 
hH4R are according to (Jiang et al., 2008) located already in TM V (Fig. 5.1A), but were 
included in the mutagenesis study because of the close proximity to E2-loop. 
For construction of the hcE3H4R cDNA, the antisense primer 5’-ATTTGTGGAC 
GCTGTTCTAGTGGATAAATTGAAAGGACAATTGTGAACAGAG-3’ was used in PCR 1A 
and the sense primer 5’-ATTTATCCACTAGAACAGCGTCCACAAATAGTTTGGTATAG 
AATTGCATTTTGG-3’ was used in PCR 1B in order to generate mutations Phe328→Ile334, 
Ser330→Pro336, Ser331→Leu337, Ala332→Glu338, Thr333→Gln339, Gly334→Arg340, 
Lys336→Gln342 and Ser337→Ile343 in the region of E3-loop and a new Xcm I restriction 
site (CCANNNNNNNNNTGG). 
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The same primers as by the generation of the hcE3H4R were used in synthesis of 
cDNA for the fusion protein hcE3H4R-Gi2. However, here pVL1392-SF-hH4R-His6-Gi2 was 
used as template. 
 
5.3.4 Generation of recombinant baculoviruses, Sf9 insect cell culture and 
membrane preparation 
Generation of recombinant baculoviruses and Sf9 insect cell culture was described 
recently (Schneider et al., 2009). Before infection, Sf9 cells were sedimented and suspended 
in fresh medium. Cells were seeded at a density of 3.0 x 106 cells/ml and infected with high-
titer baculovirus stocks encoding different histamine H4 receptors, Gi2 and G12 (1:100 
dilution), if not indicated otherwise. Cells were cultured for 48 h at 28 C under rotation at 150 
rpm and afterwards, membrane preparation was performed as described (Seifert et al., 
1998a). Here, 1 mM EDTA, 0.2 mM phenylmethylsulfonyl fluoride, 10 μg/ml benzamidine, 
and 10 μg/ml leupeptin were used as protease inhibitors. Membranes were suspended in 
binding buffer (12.5 mM MgCl2, 1 mM EDTA and 75 mM Tris/HCl, pH 7.4) and stored in 
aliquots at -80 °C. 
In order to analyze the effect of HA or THIO on the expression level of the hH4R and 
the hcE2H4R, mini-membrane preparations were conducted as reported recently (Schneider et 
al., 2009). Briefly, 15 x 106 Sf9 cells were seeded in 15 ml cell culture medium (75 cm2 
culture flasks). By control expression, no ligand was added to the flask. To other flasks, 100 
µM THIO or 1 mM HA solutions were added to yield final concentration of 1 µM for THIO or 
10 µM for HA, respectively. Furthermore, the baculovirus stocks (hH4R or hcE2H4R + Gi2 + 
G12) were added to achieve 1:100 dilution. Cells were cultured for 48 h at 28 C. HA (10 
µM) was additionally added after 24 h to decompensate degradation. After 48 hours, cells 
were harvested, centrifuged and washed with phosphate-buffered saline. After additional 
centrifugation, the cells were homogenised in 0.5 ml lysis buffer, used also by regular 
membrane preparation. Then, centrifugation and additional wash step with 1 ml lysis buffer 
followed. At the end, membranes were re-suspended in 2 ml binding buffer and stored in 
aliquots at -80 °C. Three washes during mini-membrane preparation and one additional wash 
step before performance of [3H]HA binding experiments and steady-state GTPase activity 
assays assured removal of HA or THIO from the membranes.  
 
5.3.5 [3H]HA binding experiments 
Prior to experiments, Sf9 membranes were thawed and sedimented by a 10 min 
centrifugation step at 4 C and 13,000 rpm. Membranes were then re-suspended in binding 
buffer (12.5 mM MgCl2, 1 mM EDTA and 75 mM Tris/HCl, pH 7.4). Each tube contained 100 
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µg of protein in a total volume of 250 µl or 200 µg protein in a total volume of 500 µl. For 
saturation binding, Sf9 membranes were incubated in binding buffer in the presence of 
[3H]HA (0.78-100 nM) and 0.2 % (m/v) bovine serum albumin. For competition binding, Sf9 
membranes in binding buffer, 20 nM [3H]HA, 0.2 % (m/v) bovine serum albumin and 
examined ligands at various concentrations were used. Non-specific binding was determined 
in the presence of 100 µM THIO. Incubations were performed for 60 min at room 
temperature and 250 rpm. Bound [3H]HA was separated from free [3H]HA by filtration through 
GF/C filters, pretreated with 0.3 % (m/v) polyethyleneimine, followed by three washes with 2 
ml ice-cold binding buffer (4 C). Filter-bound radioactivity was measured by liquid 
scintillation counting.  
 
5.3.6 Steady-state GTPase activity assay  
Steady-state GTPase activity assays, using [-32P]GTP as radioligand (0.1 µCi per 
tube), were essentially conducted as already described (Preuss et al., 2007), but with 5.0 
mM MgCl2, 1.2 mM creatine phosphate and 1 µg creatine kinase in the samples. Each 
sample contained 10-20 µg of membrane protein. GTPase activity was measured in the 
presence of 100 mM NaCl. In the same manner, some experiments were performed using [-
33P]GTP as radioligand (0.05 µCi per tube). No shift in pEC50 and Emax values was observed 
after substitution of [-32P]GTP with [-33P]GTP.  
 
5.3.7 Molecular Modelling  
For construction of several receptor models, the technique of homology modelling 
was used. Based on the crystal structure of the human 2-adrenergic receptor (protein data 
bank code 2RH1) (Cherezov et al., 2007; Rasmussen et al., 2007; Rosenbaum et al., 2007) 
a homology model of the inactive hH4R was generated as described previously (Deml et al., 
2009; Schneider et al., 2010). For construction of the homology models of the active cH4R, 
hcE2H4R and hcE3H4R the crystal structure of opsin co-crystallized with the C-terminal part of 
G (protein data bank code 3DQB) (Scheerer et al., 2008) was used as a template. The 
most recent crystal structure of an active state of the 2-adrenergic receptor, 3P0G 
(Rasmussen et al., 2011), is nanobody-stabilized. This nanobody, interacting with the 
receptor in the intracellular part, is more voluminous than the C-terminus of G, which 
interacts with a GPCR. Thus, the outward movement of TM VI is larger in 3P0G than in 
3DQB. This may lead to a structural artefact in the intracellular part of the receptor. 
Furthermore, unnatural intracellular part may have influence onto the conformation of the 
whole receptor. Thus, we decided to use opsin as template for modelling the active state 
conformation of H4Rs. 
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JNJ7777120 was docked manually into the binding pocket of each receptor model. 
Subsequently, molecular dynamic (MD) simulations were performed, as described previously 
(Strasser et al., 2008a), including the natural surroundings of the receptor, like lipid bilayer 
and water. Simulation parameters were used as described (Strasser et al., 2008a). For all 
MD simulations, the software Gromacs (http://www.gromacs.org) was used (Oostenbrink et 
al., 2004). 
 
5.3.8 Miscellaneous  
Protein concentrations were determined using Bio-Rad DC protein assay kit 
(Hercules, CA). SDS-PAGE and immunoblot analysis was performed as described 
(Schneider et al., 2009). Data obtained from radioligand binding and GTPase experiments 
were analysed with the Prism 5.01 software (GraphPad, San Diego, CA). All values are given 
as mean ± S.E.M. of at least three independent experiments. If not indicated otherwise, 
significance was calculated using one-way ANOVA, followed by Dunnett’s or Bonferroni’s 
multiple comparison test. Data from Fig. 5.4 were analyzed with Dunnett’s method in order to 
compare Bmax value for the hH4R or the hcE2H4R after expression in the absence of ligands 
(reference value) with Bmax value after expression in the presence of HA or THIO for the 
same receptor. By analogy, data from Table 5.1 were also analyzed with Dunnett’s method in 
order to compare relative GTPase activities of the hH4R or the hcE2H4R, respectively, after 
expression under different conditions. Data from Table 5.2 (KD and Bmax values), Table 5.3 
(pKi values) and Table 5.4 (pEC50 and Emax values) were analyzed with Bonferroni’s method, 
where constants (KD, Bmax, pKi, pEC50 and Emax, respectively) at different receptors (hH4R, 
cH4R and four H4R chimeras) were compared with each other. Statistical significance was 
defined as p  0.05 (95 % confidence interval). 
 
5.4 Results 
5.4.1 Immunological detection of recombinant proteins  
Histamine H4 wild-type receptors (hH4R, cH4R) and chimeric receptors (hcNTH4R, 
hcE1H4R, hcE2H4R, hcE3H4R) were expressed in Sf9 insect cells together with G protein 
subunits Gi2 and G12. All studied H4 receptors were N-terminally tagged with FLAG-
epitope and therefore could be detected with M1 anti-FLAG antibody. The hH4R appeared as 
a diffuse band at 40 kDa (Fig. 5.3A, lane 1), which is in agreement with literature data 
(Schneider et al., 2009; Schneider and Seifert, 2009). Receptor chimeras were also well 
expressed and exhibited migration properties similar to those of the hH4R (Fig. 5.3A, lane 3-
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6). Nevertheless, the cH4R migrated as two bands in SDS-PAGE and occurred at somewhat 
higher molecular masses than the diffuse band representing the hH4R (Fig. 5.3A, lane 2).  
The expression of Gi2 in membranes from the batch of Sf9 cells, used also for 
detection of FLAG-tagged H4Rs (Fig 5.3A), was confirmed using anti-Gi1/2 antibody. Gi2 
appeared at the expected molecular mass of 41 kDa (Fig. 5.3B) (Kleemann et al., 2008). 
 
 
Fig. 5.3 Immunological analysis of recombinant proteins, expressed in Sf9 insect cell 
membranes. Sf9 cell membranes, expressing different histamine H4 receptors together with Gi2 and 
G12, were analysed as described under 5.3.8. In each lane of the gels, 10 µg of protein was loaded. 
Membranes, shown in the same panel, are from the same membrane preparation. Numbers on the left 
of each panel indicate the molecular masses of marker proteins in kDa. (A) Detection of FLAG-tagged 
proteins hH4R, cH4R, hcNTH4R, hcE1H4R, hcE2H4R and hcE3H4R, using M1 monoclonal antibody (anti-
FLAG Ig). (B) Detection of Gi2, using anti-Gi1/2 antibody. (C) Detection of hH4R and hcE2H4R, 
expressed in Sf9 insect cells under control conditions and in the presence of 1 µM THIO, with M1 
monoclonal antibody (anti-FLAG Ig). 
 
5.4.2 Structural instability of the hcE2H4R  
Expression of the hcE2H4R was confirmed by immunoblotting, where the band 
representing the hcE2H4R had only slightly reduced intensity compared to the band for the 
hH4R (Fig. 5.3A, lane 1 and 5). However, preliminary [3H]HA saturation binding experiments, 
using two membranes from independent membrane preparations, expressing the hcE2H4R (+ 
Gi2 + G12), revealed very low specific binding of [3H]HA. Bmax value for the hcE2H4R was 
0.13 ± 0.01 pmol/mg, which is almost 15-fold lower than Bmax for the hH4R (1.77 ± 0.05 
pmol/mg). Moreover, in steady-state GTPase assays, an agonistic effect of HA and inverse 
agonistic effect of THIO could be detected, but because of the low signal-to-noise ratio it was 
impossible to obtain reproducible pEC50 values. Those findings indicate a high structural 
instability of the chimeric hcE2H4R.  
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Some structurally labile receptors could be stabilized by expression in the presence 
of ligands (Gether et al., 1997; Pauwels and Tardif, 2002; Roth et al., 2008). Also, the 
agonist HA and the inverse agonist THIO were able to increase the Bmax value of [3H]HA 
binding to the wild-type hH4R (Schneider et al., 2009). Therefore, we decided to investigate 
the effect of ligands HA and THIO on stabilization of the structurally labile hcE2H4R during 
expression. The hH4R and the hcE2H4R (+ Gi2 + G12) were expressed in Sf9 cells under 
control conditions, in the presence of 10 µM HA or in the presence of 1 µM THIO. Mini-
membrane preparations were performed as described in section 5.3.4. Specific binding of 
[3H]HA (100 nM) increased only slightly (15 %), when the hH4R was expressed with HA or 
THIO (Fig. 5.4). At the hcE2H4R, the amount of specific [3H]HA binding sites was significantly 
(3.6 fold) higher after the expression in the presence of ligands (Fig. 5.4). While non-specific 
binding of [3H]HA at the hH4R was constantly 15 % of total binding, irrespective of expression 
conditions, the non-specific binding at the hcE2H4R was reduced from 70 % (control 
expression) to 40 % (HA or THIO expression). 
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Fig. 5.4 Influence of different expression conditions on the Bmax value of [3H]HA binding to the 
hH4R and the hcE2H4R. The hH4R (white bars) and the hcE2H4R (black bars) were expressed in Sf9 
insect cells together with Gi2 and G12 in the absence of ligands (-), in the presence of 10 µM HA (+ 
HA) or in the presence of 1 µM THIO (+ THIO). Sf9 cell membranes (60 to 100 µg protein per tube) 
were incubated with 100 nM [3H]HA as described in section 5.3.5. Data shown are the means ± S.E.M. 
of at least three independent experiments performed in triplicate. Membranes used were from 
independent mini-membrane preparations. Bmax values were compared using one-way ANOVA, 
followed by Dunnett`s multiple comparison test; Bmax value after expression in the presence of HA or 
THIO was compared with Bmax value after expression in the absence of ligands (ns, not significant; **, 
p < 0.01). 
 
Additionally, the effect of different expression conditions on maximal receptor 
stimulation (HA, 100 µM) and maximal receptor inhibition (THIO, 100 µM) was studied. As 
shown in Table 5.1, addition of ligands during the expression did not significantly improve 
relative HA-induced stimulation and THIO-induced inhibition of GTPase activity at the wild-
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type hH4R. At the hcE2H4R, small relative stimulatory effect of HA (+14.2 %, compared to 
basal GTPase activity) and small relative inhibitory effect of THIO (-5.12 %) in control 
expression was non-significantly increased by the expression in the presence of HA (+25.5 
% and -11.7 %, respectively). Better improvement of signal-to-noise ratio was achieved by 
expression of the hcE2H4R in the presence of THIO. Here, 100 µM THIO caused significantly 
stronger reduction of GTPase activity than at the hcE2H4R, expressed in the absence of THIO 
(-19.2 % vs. -5.12 %; p < 0.05). Furthermore, significant increase of GTPase activity after 
stimulation with 100 µM HA was observed, compared to the hcE2H4R, expressed under 
control conditions (+43.5 % vs. +14.2 %; p < 0.001). 
 
Table 5.1 Influence of different expression conditions on the GTPase activity in Sf9 cell 
membranes expressing the hH4R or the hcE2H4R.  
GTPase activity 
hH4R + Gi2 + G12 hcE2H4R + Gi2 + G12 
- + HA - + HA - + HA 
basal 
[pmol/(mgmin)] 
1.45        
± 0.25 
1.58       
± 0.10 
1.41       
± 0.17 
0.96       
± 0.17 
1.47        
± 0.12 
1.23       
± 0.26 
   
ago. stim.  
[% of basal] 
+ 21.4      
± 2.46 
+ 15.4     
± 2.69ns 
+ 23.3     
± 2.17ns 
+ 14.2     
± 2.48 
+ 25.5      
± 0.55ns 
+ 43.5      
± 4.90*** 
   
inv. ago. inh.     
[% of basal] 
- 20.8       
± 1.92 
- 20.0      
± 2.04ns 
- 26.6      
± 3.79ns 
- 5.12      
± 1.11 
- 11.7       
± 3.31ns 
- 19.2      
± 5.73* 
The hH4R and the hcE2H4R were expressed in Sf9 insect cells together with Gi2 and G12 in the 
absence of ligands (-), in the presence of 10 µM HA (+ HA) or in the presence of 1 µM THIO (+ THIO). 
Steady-state GTPase experiments were conducted as described in section 5.3.6. GTPase activity in 
Sf9 cell membranes was measured under basal conditions (basal), after maximal stimulation with an 
agonist (HA, 100 µM, ago. stim.) and after maximal inhibition with an inverse agonist (THIO, 100 µM, 
inv. ago. inh.). Membranes used were from independent mini-membrane preparations. Data shown 
are the means ± S.E.M. of three to four independent experiments performed in triplicate. Relative 
GTPase activity [% of basal] of the hH4R and the hcE2H4R, respectively, after stimulation with an 
agonist or after inhibition with an inverse agonist was compared using one-way ANOVA, followed by 
Dunnett`s multiple comparison test; relative GTPase activity after expression in the presence of HA or 
THIO was compared with relative GTPase activity after expression in the absence of ligands (ns, not 
significant; *, p < 0.05; ***, p < 0.001). 
 
Because THIO was superior to HA as an additive during receptor expression with 
respect to increasing the signal-to-noise ratio in GTPase assay, the hcE2H4R expressed in the 
presence of THIO was further characterized. Immunoblot analysis revealed comparable 
expression levels of both the hH4R and the hcE2H4R, recognized with M1 anti-FLAG antibody, 
independent of the presence or absence of THIO during expression (Fig. 5.3C). It is 
noteworthy, that not only properly folded receptors but also unfunctional receptors with 
accessible epitope are detected by the M1 anti-FLAG antibody. Unaltered expression level, 
assessed by immunoblotting, and increased Bmax value of [3H]HA binding for the hcE2H4R 
after expression in the presence of hydrophilic THIO indicate a ligand-induced 
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conformational stabilization of the already membrane-integrated hcE2H4R (Schneider et al., 
2009).  
 
5.4.3 [3H]HA saturation binding experiments at H4R wild-type and chimeric isoforms  
Results of saturation binding experiments are shown in Table 5.2 and Fig. 5.5. Data 
for the hH4R and the cH4R were taken from Schnell et al. (Schnell et al., 2011), where GAIP 
(regulator of G protein signalling 19) was additionally co-expressed, and were generated in 
parallel with data for chimeric H4Rs. Co-expression of GAIP did not alter the binding 
properties of [3H]HA to H4Rs (data not shown) (Schneider and Seifert, 2009). Comparison of 
KD values revealed no significant difference in [3H]HA binding to the hH4R, cH4R and 
chimeric H4R. The KD value for the cH4R is about 1.5-fold higher than KD value for the hH4R 
(Schnell et al., 2011) and determined KD values for the hcNTH4R, hcE1H4R, hcE2H4R and 
hcE3H4R were in the range between KD values of the hH4R and the cH4R. The Bmax values of 
the hH4R and the hcNTH4R were in the same range and the Bmax value of the hcE1H4R was 
even significantly higher than the Bmax at hH4R. In contrast, specific binding of [3H]HA to the 
cH4R, hcE2H4R and hcE3H4R significantly decreased compared to the hH4R. 
 
Table 5.2 [3H]HA saturation binding at the hH4R, cH4R and four H4R chimeras. Receptors were 
co-expressed in Sf9 insect cells with Gi2 and G12. 
 KD [nM] Bmax [pmol/mg] 
hH4Ra 9.78 ± 0.89 1.77 ± 0.05 
cH4Ra 15.5 ± 1.09 0.37 ± 0.01** 
hcNTH4R 10.9 ± 0.98 2.08 ± 0.23+++ 
hcE1H4R 15.2 ± 0.95 2.73 ± 0.34*,+++ 
hcE2H4Rb 10.8 ± 1.20 0.66 ± 0.07**,••, ### 
hcE3H4R 15.2 ± 2.52 0.48 ± 0.04**,•••, ### 
In membranes, expressing the hH4R or the cH4R, GAIP (regulator of G protein signalling 19) was 
additionally co-expressed. Co-expression of GAIP does not alter the binding properties of [3H]HA to H4 
receptors (see section 5.4.3). Sf9 cell membranes (100 to 200 µg protein per tube) were incubated 
with 0.78 to 100 nM [3H]HA as described in section 5.3.5. The binding data were analyzed by non-
linear regression and were best fitted to one-site (monophasic) saturation curves. Data shown are the 
means ± S.E.M. of three independent experiments performed in triplicate. KD and Bmax values were 
compared using one-way ANOVA, followed by Bonferroni`s multiple comparison test (Bmax significantly 
different to: *hH4R, +cH4R, •hcNTH4R or #hcE1H4R; one symbol: p < 0.05, two symbols: p < 0.01, three 
symbols: p < 0.001). 
a Data were taken from Schnell et al. (Schnell et al., 2011) and were generated in parallel with the data 
on chimeric receptors to allow direct comparison. 
b Expression in the presence of 1 µM THIO (see section 5.4.2). 
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Fig. 5.5 [3H]HA saturation binding curves for the hH4R (A), cH4R (B), hcNTH4R (C), hcE1H4R (D), 
hcE2H4R (E) and hcE3H4R (F). Receptors were co-expressed in Sf9 cells with Gi2 and G12. In 
membranes, expressing the hH4R or the cH4R, GAIP (regulator of G protein signalling 19) was 
additionally co-expressed; those data are taken from Schnell et al. (Schnell et al., 2011) but were 
generated in parallel with the data on chimeric receptors. Co-expression of GAIP does not alter the 
binding properties of [3H]HA to H4 receptors (see section 5.4.3). The hcE2H4R was expressed in the 
presence of 1 µM THIO (see section 5.4.2). The saturation binding experiments were performed as 
described in section 5.3.5, using Sf9 cell membranes (100 to 200 µg protein per tube) and [3H]HA at 
concentrations, indicated on the abscissa. Data were analyzed by non-linear regression and were best 
fitted to one-site (monophasic) saturation curves. Data shown are the means ± S.E.M. of three 
independent experiments performed in triplicate. The open cycle () shows the data for total binding, 
the square (■) the data for non-specific binding and the triangle (▲) the data for specific binding. 
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5.4.4 [3H]HA competition binding experiments at H4R wild-type and chimeric 
isoforms 
The affinities (pKi values) of standard H4R ligands, determined in the [3H]HA 
competition binding experiments, are shown in Table 5.3. HA, 5-MHA, JNJ7777120 and 
clozapine showed significantly lower affinity at the cH4R than at the hH4R, which is in 
accordance with recently published data (Jiang et al., 2008; Lim et al., 2010; Schnell et al., 
2011). Nevertheless, the absolute pKi values for JNJ7777120 at the hH4R and the cH4R, 
determined in our study, differ from pKi values, determined at the hH4R and the cH4R, 
expressed in HEK 293T cells (Lim et al., 2010), although the same radioligand was used in 
both studies. We have no explanation for this discrepancy between data, but it should be 
kept in mind, that especially in case of JNJ7777120, affinity and potency in different test 
systems can differ greatly (for a comprehensive overview of pharmacological data regarding 
characterisation of JNJ7777120 in different in vitro test systems cf. Seifert et al. (2011)). 
 
Table 5.3 Affinities of standard H4R ligands at the hH4R, cH4R, hcNTH4R, hcE1H4R, hcE2H4R and 
hcE3H4R, co-expressed with Gi2 and G12 in Sf9 cell membranes.  
 pKi 
HA 5-MHA THIO JNJ7777120 clozapine 
hH4R 7.89 ± 0.01  7.61 ± 0.06  6.94 ± 0.05  7.49 ± 0.07  6.34 ± 0.15  
cH4R 7.59 ± 0.01**   6.93 ± 0.11*** 6.72 ± 0.04 6.76 ± 0.05***  3.81 ± 0.09***  
hcNTH4R 7.86 ± 0.03++ 7.53 ± 0.04++ 7.02 ± 0.04 7.46 ± 0.06+++ 6.23 ± 0.02+++ 
hcE1H4R 7.72 ± 0.06  7.38 ± 0.04+  7.14 ± 0.06+  7.25 ± 0.06+++  6.18 ± 0.06+++  
hcE2H4Ra 7.81 ± 0.01+  7.27 ± 0.05  6.77 ± 0.05  7.27 ± 0.03+++  6.21 ± 0.06+++  
hcE3H4R 7.77 ± 0.05  7.07 ± 0.10**,  6.74 ± 0.12 7.76 ± 0.07+++,, 6.15 ± 0.07+++  
Competition binding was determined in Sf9 membranes (100 µg protein per tube) in the presence of 
20 nM [3H]HA as described in section 5.3.5. Data were analyzed by non-linear regression and were 
best fitted to one-site (monophasic) competition curves. Data shown are the means ± S.E.M. of three 
to four independent experiments performed in duplicate. pKi values were calculated according to 
Cheng and Prusoff (Cheng and Prusoff, 1973) and compared using one-way ANOVA, followed by 
Bonferroni`s multiple comparison test (pKi significantly different to: *hH4R, +cH4R, hcNTH4R, #hcE1H4R 
or hcE2H4R; one symbol: p < 0.05, two symbols: p < 0.01, three symbols: p < 0.001). 
a Expression in the presence of 1 µM THIO (see section 5.4.2). 
 
The pKi value for THIO was comparable between both wild-type receptors as 
already reported (Jiang et al., 2008; Schnell et al., 2011). Generally, the alteration of 
extracellular domains at the hH4R did not significantly influence binding of examined ligands. 
pKi values for HA, 5-MHA, THIO, JNJ7777120 and clozapine were in the same range at 
chimeric receptors (hcNTH4R, hcE1H4R, hcE2H4R, hcE3H4R) and at the wild-type hH4R. One 
exception is a significantly lower affinity of 5-MHA at the hcE3H4R compared to the hH4R. 
Interestingly, some significantly different pKi values were identified, when affinity of examined 
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ligands was compared within receptor chimeras (e.g. pKi value for THIO at the hcE1H4R and 
the hcE2H4R). This could indicate a subtle influence of individual extracellular domains onto 
the binding of some ligands, which remain uncovered, when pKi values for receptor chimeras 
are compared solely with the wild-type hH4R. Moreover, affinity of numerous ligands for 
chimeric receptors differed significantly from affinity at the wild-type cH4R. In general, this 
can be explained by the similarity between the hH4R and H4R chimeras with respect to ligand 
binding.   
 
5.4.5 Functional analysis of wild-type and chimeric H4 receptors by steady-state 
GTPase activity assay   
In order to study the influence of altered extracellular regions of the hH4R on 
receptor activity, we determined potencies (pEC50 values) and efficacies (Emax values) of H4R 
standard ligands HA, 5-MHA, THIO, JNJ7777120 and clozapine at wild-type and chimeric H4 
receptors (Table 5.4 and Fig. 5.6). In agreement with recently published data, endogenous 
full agonist HA had lower potency at the cH4R than at the hH4R (Jiang et al., 2008; Schnell et 
al., 2011). While the potency of HA at the hcNTH4R and the hcE1H4R was similar to the potency 
at the hH4R, the potency of HA slightly (non-significantly) decreased at the hcE2H4R (2-fold) 
and significantly decreased at the hcE3H4R (3-fold). 5-MHA exhibited full agonistic activity at 
all H4 receptors, and the same potency-pattern was observed as for the full agonist HA 
(comparable pEC50 value for the hH4R, hcNTH4R and hcE1H4R, slightly decreased pEC50 at the 
hcE2H4R and significantly decreased pEC50 at the hcE3H4R and the cH4R). At the hH4R and 
chimeric H4Rs clozapine acted as partial agonist, but showed no stimulation of GTPase 
activity at cH4R. Interestingly, the potency of clozapine at the hcE1H4R and the hcE3H4R was 
by more than 0.5 log units lower than at the hcNTH4R, although neither of chimeric H4 
receptors significantly differs from the hH4R in pEC50 value for clozapine. 
Additionally, we examined two ligands with inverse agonistic activity at the hH4R. 
THIO acts at the hH4R as almost full inverse agonist and JNJ7777120 as weak inverse 
agonist (Schneider et al., 2009). In accordance with recently published data (Schnell et al., 
2011), we observed a shift from inverse agonistic activity at the hH4R to agonistic activity at 
the cH4R for both THIO and JNJ7777120 (Table 5.4). The mode of action and the Emax 
values for THIO and JNJ-7777120 were not altered at the hcNTH4R and the hcE1H4R in 
comparison with the hH4R. However, a decrease in inverse agonistic activity of THIO was 
observed in the series hH4R  hcE2H4R  hcE3H4R. Moreover, JNJ7777120 acted as partial 
agonist at the hcE2H4R and the hcE3H4R, but with significantly lower efficacy than at the cH4R.  
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Fig. 5.6 Concentration-response curves for HA (●), THIO (■) and JNJ7777120 (▲) at the hH4R 
(A), cH4R (B), hcNTH4R (C), hcE1H4R (D), hcE2H4R (E) and hcE3H4R (F), determined in steady-state 
GTPase activity assay. Receptors were co-expressed in Sf9 cells with Gi2 and G12. The hcE2H4R 
was expressed in the presence of 1 µM THIO (see section 5.4.2). GTP hydrolysis in Sf9 membranes 
was measured as described in section 5.3.6. Reaction mixtures contained Sf9 membranes (10 to 20 
µg protein per tube) and ligands at concentrations indicated on the abscissa. Data shown are means ± 
S.E.M. of at least three independent experiments performed in duplicate or triplicate. Data were 
analyzed by non-linear regression and were best fitted to sigmoidal concentration-response curves. 
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5.4.6 Functional analysis of the hH4R-Gi2 and the hcE3H4R-Gi2 fusion proteins by 
steady-state GTPase assay  
When co-expression system is used for the pharmacological characterization of one 
GPCR, we cannot assure a constant receptor/G-protein ratio (Schneider and Seifert, 2010). 
Consequently, coupling efficiency of receptor to G-protein might be influenced. In contrast, 
when the C-terminus of the GPCR is fused to the N-terminus of the G-protein, close 
proximity of both interaction partners enables increased interaction efficiency. In addition, 
fusion proteins assure characterization of receptor/G-protein coupling in a system with 
defined 1:1 stoichiometry (Schneider and Seifert, 2010). 
When we consider the data from functional assays (Table 5.4), the hcE3H4R differed 
in pharmacological profile from the hH4R the most among all chimeric receptors. Therefore, 
we decided to analyze the influence of potentially unequal H4 receptor/Gi2 ratio on the 
different pharmacological characteristics of the hcE3H4R and the hH4R. For this reason, fusion 
proteins hH4R-Gi2 and hcE3H4R-Gi2 were co-expressed with G12 in Sf9 insect cells and 
characterized by steady-state GTPase assay (Table 5.5). Afterwards, potencies and 
efficacies of HA, 5-MHA and THIO were compared to the corresponding parameters from co-
expression system (hH4R or hcE3H4R + Gi2 + G12), shown in Table 5.4. Statistical analysis 
revealed no significant alteration of potency for HA, 5-MHA and THIO neither for the hH4R 
nor for the hcE3H4R, when they were fused to Gi2 (Table 5.5). Interestingly, the efficacy of the 
inverse agonist THIO markedly (1.9-fold) increased at the fusion protein hH4R-Gi2, 
indicating an increased constitutive GTPase activity related to the total ligand-regulated 
GTPase activity. This can be explained by the stabilizing effect of Gi2 on hH4R active 
conformation in a fusion protein, where interaction partners are in close proximity to each 
other (Schneider et al., 2009). In contrast, the efficacy of the inverse agonist THIO was not 
significantly increased at the hcE3H4R-Gi2 compared to co-expression system. Thus, very 
low THIO-sensitive constitutive GTPase activity of the hcE3H4R relative to the total ligand-
regulated GTPase activity is not due to inefficient interaction with Gi2. In summary, the 
altered pharmacological profile of the hcE3H4R compared to the hH4R is not due to the 
unequal receptor/G-protein ratio, but due to differences in the E3-loop. 
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Table 5.5 Potencies and efficacies of HA, 5-MHA and THIO at the hH4R-Gi2 and hcE3H4R-Gi2 
fusion proteins, co-expressed with G12 in Sf9 cell membranes.  
Compound 
hH4R-Gi2 hcE3H4R-Gi2 
pEC50a Emaxb pEC50a Emaxb 
HA 7.53 ± 0.05 1.00 7.05 ± 0.01 1.00 
5-MHA 7.33 ± 0.08 1.19 ± 0.14 6.42 ± 0.01 0.98 ± 0.05 
THIO 6.81 ± 0.07 -1.67 ± 0.30* 6.84 ± 0.14 -0.37± 0.03 
GTPase activity was determined in Sf9 membranes (10 to 20 µg protein per tube) as described in 
section 5.3.6. Data were analyzed by non-linear regression and were best fitted to sigmoidal 
concentration/response curves. Data shown are the means ± S.E.M. of three to four independent 
experiments performed in duplicate or triplicate. The efficacy (Emax) of HA was set to 1.00 and the 
efficacies of other ligands were referred to this value. pEC50 and Emax values for HA, 5-MHA and THIO 
at the hH4R-Gi2 fusion protein were compared to corresponding parameters at the hH4R (data from 
Table 5.4) and pEC50 and Emax values for HA, 5-MHA and THIO at the hcE3H4R-Gi2 fusion protein 
were compared to corresponding parameters at the hcE3H4R (data from Table 5.4) using unpaired two-
tailed t test (95 % confidence interval). 
a Comparison with the pEC50 at the hH4R; no significant difference. 
b Comparison with the Emax at the hH4R; *, p  0.05. 
c Comparison with the pEC50 at the hcE3H4R; no significant difference. 
d Comparison with the Emax at the hcE3H4R; no significant difference. 
 
5.4.7 Binding of JNJ7777120 to the hH4R, hcE2H4R, hcE3H4R and cH4R  
Since JNJ7777120 acts as inverse agonist at the hH4R, but as partial agonist at the 
hcE2H4R, hcE3H4R and cH4R, JNJ7777120 was studied within the inactive model of the hH4R 
and within the active state models of the hcE2H4R, hcE3H4R and cH4R. The MD simulations 
revealed stable binding modes of JNJ7777120 at the hH4R, hcE2H4R, hcE3H4R and cH4R. 
However, there were significant differences between the binding of JNJ7777120 at the hH4R 
on the one hand and at the hcE2H4R, hcE3H4R and cH4R on the other hand. 
A MD snapshot of JNJ7777120 in the binding pocket of the inactive hH4R is given in 
Fig. 5.7A. The basic amine moiety of JNJ7777120 establishes a stable electrostatic 
interaction with the highly conserved Asp3.32. The indole moiety of JNJ7777120 is embedded 
in an aromatic pocket, established by Tyr3.33, Trp6.48 and Tyr6.51. The Trp6.48, discussed to be 
involved in the rotamer toggle switch during receptor activation (Crocker et al., 2006) is 
stabilized in a more vertical conformation, corresponding to the inactive state. 
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A  hH4R B  cH4R 
  
C  hE2-loop D  cE2-loop 
  
D  hE3-loop E  cE3-loop 
  
 
Fig. 5.7 Binding mode of JNJ777120 at the hH4R and the cH4R and influence of E2- and E3-loop 
onto the binding pocket. (A) Binding mode of JNJ7777120 at the hH4R; (B) binding mode of 
JNJ7777120 at the cH4R; (C) influence of the human E2-loop onto the binding pocket (amino acids 
Glu163-Pro166 of the E2-loop presented as van der Waals spheres); (D) influence of the canine E2-
loop onto the binding pocket (amino acids Glu167-Pro172 of the E2-loop presented as van der Waals 
spheres); (E) influence of the human E3-loop onto the binding pocket; (F) influence of the canine E3-
loop onto the binding pocket. Molecular modeling studies were performed as described in section 
5.3.7. 
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In contrast, at the hcE2H4R, hcE3H4R and cH4R, the JNJ7777120 stabilizes the active 
receptor conformation. The MD simulations revealed no significant differences for the binding 
mode of JNJ7777120 at the hcE2H4R, hcE3H4R and cH4R. Representative for the hcE2H4R, 
hcE3H4R and cH4R, the binding mode of JNJ7777120 at the cH4R is given in Fig. 5.7B. As 
already observed at the hH4R, the positively charged amine moiety of JNJ7777120 interacts 
electrostatically with the highly conserved Asp3.32. The indole moiety of JNJ7777120 is 
embedded in an aromatic pocket, established by Tyr3.33, Trp6.48 and Tyr6.51. In contrast to the 
binding mode of JNJ7777120 at the inactive hH4R, the Trp6.48 shows a more horizontal 
conformation, corresponding to the active receptor state. The orientation of the indole moiety 
of JNJ7777120 restrains the Trp6.48 in its active conformation, due to a stacked aromatic 
interaction. 
The differences between human and canine E2-loop are shown in Fig. 5.7C (human 
E2-loop) and Fig. 5.7D (canine E2-loop). For the human E2-loop, the amino acids Glu163, 
Cys164, Glu165 and mainly Pro166 are in close contact to Tyr3.33. The interaction between 
this part of the human E2-loop and Tyr3.33 forces the Tyr3.33 away from the binding pocket 
(Fig. 5.7C). The corresponding interaction is quite different for the canine E2-loop. Here, 
Glu167, Lys168, Asp169, Cys170, Glu171 and Pro172 are in close contact to Tyr3.33. This 
more polar interaction surface forces the Tyr3.33 in direction of JNJ7777120 in the binding 
pocket, enabling a stronger interaction between JNJ7777120 and Tyr3.33. Furthermore, this 
conformation of Tyr3.33 stabilizes the ligand-receptor complex in the active state. 
The different influence of human and canine E3-loop is shown in Fig. 5.7E (human 
E3-loop) and Fig. 5.7F (canine E3-loop). The E3-loop is in close contact to an aromatic 
channel, passing from the extracellular part into the binding pocket. This channel is formed 
by Phe6.54, Tyr6.51, Tyr7.35 and Phe7.39 at the hH4R as well as at the cH4R. A proline (Pro335 at 
the hH4R, Pro341 at the cH4R) is in close contact to the entry of this aromatic channel, 
established by Phe6.54 and Tyr7.35. Nevertheless, the conformations of the E3-loop differ 
between the hH4R and the cH4R. Thus, it is suggested that the conformation of the E3-loop, 
especially, the orientation of the proline (Pro335 at the hH4R, Pro341 at the cH4R), is 
responsible for the different conformations of the aromatic channel between TM VI and TM 
VII, leading from the extracellular part into the binding pocket.  
Additionally, it should be noted that JNJ7777120 can be docked into both, the 
inactive and the active hH4R (Seifert et al., 2011). Since the differences between the binding 
pockets of the hH4R, the cH4R and the chimeras are not very large, it is reasonable to 
assume that JNJ7777120 can be docked in inactive and active models of the cH4R and the 
chimeras. However, the docking studies would not give information about the thermodynamic 
stability of the corresponding ligand-receptor complexes. Therefore, molecular dynamic 
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simulations in combination with calculation of Gibbs energies would be appreciated. 
Unfortunately, up to now, a reliable prediction of Gibbs energies is not possible.  
 
5.5 Discussion 
Numerous H4R species were pharmacologically characterized in various 
recombinant test systems (Liu et al., 2001; Jiang et al., 2008; Lim et al., 2008; Lim et al., 
2010; Schnell et al., 2011). The aforementioned studies revealed differences in binding 
affinity, potency and efficacy of ligands at H4R species orthologs and sometimes even 
discrepancies in mode of action (agonistic, antagonistic or inverse agonistic activity) (Schnell 
et al., 2011). Searching for structural determinants, responsible for these differing 
pharmacological characteristics, we focused on four extracellular regions of the H4R, i.e. N-
terminus and three extracellular loops. So far, relatively little attention has been paid to 
extracellular regions of biogenic amine GPCRs, although the number of studies is increasing 
(Shi and Javitch, 2002; Lawson and Wheatley, 2004; Peeters et al., 2011b). One of the 
reasons for the insufficient evaluation of extracellular domains is that, based on crystal 
structures, only a snapshot-conformation of the highly flexible extracellular part of receptors 
is available. Thus, information about dynamics of the extracellular part is lost. However, it is 
possible to address the dynamics of the extracellular part of GPCRs by MD simulations. 
Pharmacological characterization of chimeric receptors in combination with MD simulation is 
a very useful approach. In our study, human/canine chimeric H4Rs were used to assess the 
importance of extracellular domains for H4R species differences. The results may contribute 
to broaden the knowledge about the functional role of extracellular regions of aminergic 
GPCRs.  
 
5.5.1 Ligand-induced stabilization of the hcE2H4R during expression  
In order to evaluate the potential involvement of single extracellular regions in 
differences between hH4R and cH4R pharmacology, four human/canine H4R chimeras were 
constructed (hcNTH4R, hcE1H4R, hcE2H4R and hcE3H4R). Among them, the chimeric receptor 
hcE2H4R showed high structural instability. Presumably, additional 6 amino acids in the E2-
loop of the hcE2H4R and a few shifts in charge of amino acids compared to the hH4R are 
responsible for disruption of receptor-stabilizing constraints. Nevertheless, further 
pharmacological analysis of the hcE2H4R became feasible because we could stabilize the 
hcE2H4R by expression in the presence of the inverse agonist THIO. Structural instability of 
GPCRs and their stabilization by ligands has been observed repeatedly (Gether et al., 1997; 
Pauwels and Tardif, 2002; Roth et al., 2008; Schneider et al., 2009). 
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It is interesting that expression of the hcE2H4R with HA or THIO increases the 
number of high-affinity [3H]HA binding sites to the same extent, whereas the improvement of 
signal-to-noise ratio in GTPase assay was superior in case of expression in the presence of 
THIO. Both hydrophilic ligands can interact with receptors, which are already present on the 
membrane surface. After binding of ligands during expression, interactions in the receptor 
structure and those of receptor with environment are rearranged, resulting in increased 
stability of inherently unstable receptors. Obviously, the hcE2H4R adopts similar receptor 
conformation (similar equilibrium between active and inactive state) after washing out of HA 
or THIO, which is equally recognized by [3H]HA. But still, stabilization of the hcE2H4R with 
THIO presumably rearranges additional important interactions and allows receptors to more 
intensively undergo transitions between active and inactive state after incubation with an 
agonist or inverse agonist, respectively. Superior effects of the inverse agonist ICI 118,551 
((2R*,3S*)-3-(isopropylamino)-1-(7-methyl-2,3-dihydro-1H-inden-4-yloxy)butan-2-ol) vs. the 
agonist isoproterenol were already observed in denaturation studies with a constitutively 
active and structurally unstable mutant of the 2-adrenergic receptor (Gether et al., 1997). 
Additionally, the question arose whether the pharmacological characteristics of the 
hcE2H4R change due to expression in the presence of THIO. Because of the low signal-to-
noise ratio at the hcE2H4R expressed under control conditions, comparison of efficacies and 
potencies of HA and THIO with those at the hcE2H4R, expressed in the presence of THIO, 
was impossible. Nevertheless, expression with THIO did not influence pEC50 and Emax values 
for HA and THIO at the hH4R, determined in steady-state GTPase assay (data not shown). 
Additionally, the expression of wild-type histamine H2 receptor in the presence of ranitidine 
did neither significantly affect the binding of [125I]aminopotentidine nor change pEC50 and Emax 
values of the histamine-induced cAMP production (Alewijnse et al., 2000). Furthermore, KD 
value of [3H]RX821002  (2-(2-methoxy-2,3-dihydrobenzo[b][1,4]dioxin-2-yl)-4,5-dihydro-1H-
imidazole) binding to mutated 2A adrenergic receptor (Thr373Lys 2AAR) was neither 
affected by the expression of receptor in the presence of inverse agonist nor in the presence 
of antagonist or agonist (Pauwels and Tardif, 2002). Based on these data, indicating 
unaltered receptor properties after expression with various ligands, we decided to express 
the hcE2H4R in the presence of 1 µM THIO to allow its further pharmacological 
characterization. 
 
5.5.2 Irrelevance of the N-terminus and E1-loop for differences between the hH4R 
and the cH4R 
The N-terminus of aminergic GPCRs is generally considered to be a 
pharmacologically inert element. One notable exception is the N-terminus of the histamine H1 
receptor, where the alteration of hydrogen bond network between N-terminus and E2-loop 
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influenced binding of histaprodifens (Strasser et al., 2008b). Also mutations of two amino 
acids in the E1-loop of adenosine A2B receptor lead to changes in constitutive activity and 
potency of agonists (Peeters et al., 2011a). Our study revealed that the N-terminus and E1-
loop are not responsible for different characteristics of the hH4R and the cH4R. One reason 
could be a relative high amino acid homology for N-terminus and E1-loop between the hH4R 
and the cH4R. Besides the intracellular C-terminus, extracellular regions are generally the 
most variable elements of GPCRs. Additionally, only a few shifts in charge were caused by 
the generation of hcNTH4R (Asp3→Ala3) and hcE1H4R mutants (Lys84→Asn84, 
Glu85→Lys85). Charged residues in E1-loop were crucial for activation of some other 
GPCRs (Peeters et al., 2011b).  
 
5.5.3 Binding characteristics of the hcE2H4R and the hcE3H4R  
Several studies report about versatile roles of E2-loop in aminergic GPCRs, like 
“gatekeeping” of the binding crevice, recognition of ligands and allosteric modulation 
(Peeters et al., 2011b). Importance of E2-loop for receptor subtype and species selectivity 
was reported amongst others for 1-adrenergic receptor and 5-HT1D receptor (Shi and 
Javitch, 2002). Also reports about involvement of E3-loop in ligand recognition process and 
activation mechanism of aminergic GPCRs are increasing (Lawson and Wheatley, 2004; 
Peeters et al., 2011b). 
We assessed the importance of E2- and E3-loop of H4R for ligand binding and 
receptor activation, using chimeric receptors hcE2H4R and hcE3H4R. Worthy of note is lower 
species sequence homology for E2-loop (48 %) and E3-loop (20 %) than for N-terminus and 
E1-loop. Binding experiments revealed no major impact of E2- and E3-loop on affinity of 
examined ligands. In contrast, a single amino acid (Phe169) in E2-loop is responsible for 
difference in agonist binding to the human and mouse H4R (Lim et al., 2008). Phe169 is 
present at equivalent position at the hH4R and at the cH4R.  
A striking discrepancy was found between Bmax values from [3HA] radioligand 
binding studies and relative density of bands, obtained by immunoblotting when the hH4R 
was compared with the hcE2H4R and the hcE3H4R. Bmax for [3H]HA binding at the hcE2H4R and 
the hcE3H4R is 2.7- and 3.7-fold lower than at the hH4R, which is not reflected in relative 
densities of bands from immunoblot studies. Proteolysis of H4R chimeras does not account 
for the discrepancies since no bands with lower mass than the predicted receptor mass were 
detected. Hence, there are two plausible explanations for this phenomenon. Firstly, 
membrane integrated hcE2H4R and hcE3H4R are structurally unstable and therefore unable to 
bind [3H]HA (Schneider et al., 2009).  Secondly, the proportion of low-affinity binding sites for 
the agonist [3H]HA is increased in case of E2- and E3-loop mutant. Unfortunately, in binding 
experiments with [3H]HA, low-affinity binding sites cannot be easily detected. By contrast, in 
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functional GTPase experiments, low-affinity ligand-receptor interactions can be readily 
recognized (Wenzel-Seifert et al., 1999), but for H4R chimeras, we did not obtain evidence 
for such low-affinity interaction. 
Generally, the best way to distinguish between high- and low-affinity agonist binding 
sites would be an additional application of radiolabeled antagonist. In competition studies 
with a radiolabeled antagonist, low-affinity agonist binding sites can be readily detected 
(Seifert et al., 1998a; Seifert et al., 1998b; Seifert et al., 2001).  [3H]JNJ7777120 was 
previously used as H4R antagonist radioligand (Lim et al., 2005). In our study, 
[3H]JNJ7777120 cannot be used because JNJ7777120 acts as partial agonist at the hcE2H4R 
and the hcE3H4R. An alternative approach to investigate high- and low-affinity binding sites 
are studies with an non-hydrolysable analogue of GTP, guanosine 5’-[-thio]triphosphate 
(GTPS). Binding of GTPS to G-protein causes uncoupling of receptor and G-protein, 
resulting in a reduction of high-affinity binding sites (De Lean et al., 1980). But even here, the 
problems occur in case of the H4R. High-affinity receptor state of the hH4R is insensitive to 
GTPS (Schneider et al., 2009).  
 
5.5.4 Involvement of the E2- and E3-loop in H4R activation process 
For the H4R, we provide for the first time evidence about the importance of E2- and 
E3-loop with respect to receptor activity. Specifically, our study revealed a crucial role of E2- 
and E3-loop in the paradoxical agonistic activity of THIO and JNJ7777120 at the cH4R 
(Schnell et al., 2011). Efficacy of both ligands at the hcE2H4R and the hcE3H4R is substantially 
shifted toward efficacy at the cH4R. By analysis of receptor-Gi2 fusion proteins we could 
unequivocally demonstrate that this effect is not due to insufficient coupling of chimeric H4Rs 
to Gi2.  
THIO exhibits strong inverse agonistic activity at the highly constitutive active hH4R 
(Schneider et al., 2009), which is reduced in case of the hcE2H4R and the hcE3H4R.  At the less 
constitutively active cH4R, THIO elevates GTP hydrolysis in Sf9 insect cell membranes 
(Schnell et al., 2011). Given that the affinity of THIO to both species as same as to the 
hcE2H4R and the hcE3H4R is comparable, the cause of variable THIO efficacy profile lies in a 
conformational change of receptor after binding of THIO. Here, different constitutive activity 
of receptors could be relevant. Altered E2-loop and E3-loop at the hcE2H4R and the hcE3H4R, 
respectively, reduce pronounced constitutive activity of the wild-type hH4R and consequently 
equilibrium between active (R*) and inactive state (R) is partially shifted toward the inactive 
state. Therefore, after binding of THIO, the equilibrium R*/R cannot be shifted toward the R 
state to the same extent as in the case of the hH4R (regarded relative to basal GTPase 
activity). Furthermore, the basal GTPase activity at the cH4R is already so low that similar 
R*/R equilibrium as at the hH4R after binding of THIO is seen as agonism (Kenakin, 2007; 
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Schnell et al., 2011). All in all, we suggest the E2- and E3-loop to be involved in fine tuning of 
constitutive activity of H4Rs. 
Based on the efficacy profile of JNJ7777120 at the hH4R, hcE2H4R, hcE3H4R and 
cH4R, we also suggest that the E2- and E3-loops are involved in inverse or partial agonistic 
behaviour of JNJ7777120 at H4Rs. Since the exchange of E2-loop or E3-loop at the hH4R for 
the corresponding canine loops does not lead to a complete shift of efficacy toward the cH4R, 
the inverse/partial agonistic behaviour of JNJ7777120 cannot be attributed to these moieties 
alone. Additional differences between the sequences of the hH4R and the cH4R might play a 
role as well as a co-operative action of E2- and E3-loop. The molecular modelling studies 
also suggest that E2- and E3-loop affect the pharmacology of JNJ7777120 at the H4R 
independently of each other.  
The segment of the E2-loop starting from the cysteine (Cys164 at the hH4R, Cys170 
at the cH4R) in direction to TM V exhibits the same length at the hH4R and the cH4R. The 
cysteine (Cys164 at the hH4R, Cys170 at the cH4R) establishes a disulfide bridge to Cys3.25. 
Thus, the position of this part of the E2-loop is restrained and no significant differences in 
conformation between the hH4R and the cH4R were observed within the MD simulations. In 
contrast, there is a significant difference with regard to length of the segment of the E2-loop 
from TM IV to Cys164 at the hH4R and Cys170 at the cH4R, respectively. Thus, completely 
different conformations of this part of the E2-loop were observed during the MD simulations. 
Consequently, the contact surfaces of E2-loop to Tyr3.33 are completely different, on the one 
hand with regard to volume, on the other hand with regard to surface properties. This has 
strong impact onto the conformation of Tyr3.33, which is in close contact to the bound 
JNJ7777120. In case of the cH4R, Tyr3.33 is shifted more towards the binding pocket, 
compared to the hH4R. Thus, at the cH4R or the hcE2H4R JNJ7777120 bound in the active 
receptor conformation is preferred. 
There are no differences in length of human and canine E3-loop, but significant 
differences in amino acid sequence. Only a tyrosine (Tyr329 at the hH4R, Tyr335 at the 
cH4R) and a proline (Pro335 at the hH4R, Pro341 at the cH4R) are found in the E3-loops of 
both H4R orthologs. The MD simulations revealed differences in conformation of E3-loop 
between the hH4R and the cH4R. Additionally, the proline (Pro335 at the hH4R, Pro341 at the 
cH4R) is in close contact to an aromatic channel, established by TM VI and TM VII, leading 
from the extracellular area into the binding pocket. There, Tyr6.51 interacts with the bound 
JNJ7777120. Thus, the E3-loop may have an indirect effect onto the conformation of Tyr6.51 
and in this way on the binding mode of JNJ7777120.  
In general, molecular modelling studies enable a deeper insight into ligand-GPCR 
interactions on a molecular level. However, in contrast to the transmembrane domains, the 
loops are highly flexible, rendering the modelling of loops much more challenging than 
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modelling of transmembrane domains. Nonetheless, molecular modelling studies, especially 
MD simulations, can provide useful hints with regard to the influence of the extracellular 
loops on ligand binding. Still, it is not clear, whether single amino acids in the region of E2- 
and E3-loop or the E2- and E3-loops as a whole are responsible for the surprising efficacy 
profile of JNJ7777120 at the hH4R and the cH4R.  
 
5.5.5 Conclusions 
The present study revealed for the first time an involvement of E2- and E3-loop in 
the activation process of the H4Rs, especially with regard to the surprising efficacy profile of 
JNJ7777120 at the hH4R and the cH4R. MD simulations provide important suggestions about 
the influence of E2- and E3-loops onto the inverse/partial agonistic behaviour of JNJ7777120 
at the hH4R and the cH4R on molecular level. Besides, the modelling studies suggest an 
independent influence of E2-loop and E3-loop onto the binding of JNJ7777120. Thus, this 
work is broadening our knowledge about structural determinants responsible for the species-
selective efficacy profile of JNJ7777120 at H4Rs. 
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6.1 Summary 
About one third of the drugs currently available on the market address cell 
membrane-integrated G protein-coupled receptors (GPCRs). As such, the histamine H2 
receptor (H2R) and the β2-adrenergic receptor (β2AR) have been successfully targeted in the 
treatment of frequently occurring gastric disorders and asthma, respectively. The novel 
histaminergic GPCR, the histamine H4 receptor (H4R), is currently in the focus of clinical trials 
as a promising target in the therapy of asthma and allergic rhinitis. However, being involved 
in many (patho)physiological functions, the H2R, H4R and 2AR gain great interest in 
academia and industry because of their potential to both, enable novel and to improve 
established therapeutic interventions.  
The first aim of this thesis was the dissection and comparison of the H2R- and β2AR-
mediated effects on isolated human neutrophil granulocytes. Activation of both receptors on 
neutrophils results in an inhibition of inflammatory responses such as superoxide anion (O2•-) 
production, which could be therapeutically exploited. Although both, the H2R and the β2AR, 
preferentially couple to Gs proteins, a distinct behavior was observed in respect of their 
influence on cyclic adenosine 3',5'-monophosphate (cAMP) accumulation and O2•- production 
in neutrophils and a discrepancy with literature data, obtained in recombinant test systems, 
was noticed. In addition, ligand-directed signaling was detected, indicative of the concept of 
functional selectivity and suggesting that signaling events between the cAMP accumulation 
and the O2•- production are much more complex than assumed so far. Moreover, untypical 
behavior of H2R antagonists on neutrophils does not fit to the conventional understanding of 
antagonist/GPCR interaction. Possible reasons for described observations are discussed, 
although more detailed analyses of the signaling events in neutrophils are needed to 
mechanistically explain the divergence between the H2R and the β2AR and to better 
understand the multiplicity of GPCR-mediated signaling. 
The second aim of the present work was to characterize NG-acylated 
hetarylpropylguanidines, highly potent (partial) human H2R-agonists in Sf9 insect cell 
membranes, in physiologically more relevant human neutrophil granulocytes. In general, new 
H2R agonists are developed as valuable pharmacological tools and are regarded as novel 
drug candidates, e.g. in the therapy of acute myeloid leukemia. In contrast to histamine, the 
O2•- production by activated neutrophils was not affected by bivalent acylguanidines, whereas 
a monovalent ligand reduced O2•- production in a H2R-independent way. However, the 
ligands of interest stimulated cAMP accumulation in an H2R-dependent manner, albeit with 
drastically diminished agonistic activity compared with that in the respective recombinant test 
system. These results point to a drawback of acylguanidines, e.g. their amphiphilic character, 
and suggest that their drug-likeness needs to be further improved. Moreover, a contribution 
to the understanding of molecular interactions between the H2R and NG-acylated 
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hetarylpropylguanidines was made. Mutagenesis studies revealed a rather marginal 
contribution of the extracelluar N-terminus to the species-selective profile of acylguanidines 
at the human H2R and the guinea pig H2R.  
Preclinical investigation of therapeutically interesting compounds in translational 
animal models is indispensable in drug research and development. Thus, identification and 
understanding of substantial pharmacological differences between H4R species orthologs at 
the molecular level is essential. In the third part of this thesis, the importance of extracellular 
regions for the species-specific pharmacology of the H4R was evaluated, using chimeric 
receptor approach and Sf9 insect cells as expression system. This study indicates that the N-
terminus and the first extracellular loop are not responsible for the species differences 
between human and canine H4Rs. On the contrary, for the first time evidence is provided that 
the second and the third extracellular loop are involved in the H4R activation process. 
Mutagenesis studies revealed that low amino acid sequence homologies of the latter two 
loops contribute to the divergence between the inverse agonistic activity of JNJ7777120 (1-
[(5-chloro-1H-indol-2-yl)carbonyl]-4-methylpiperazine) at the human and partial agonistic 
activity at the canine H4R, reported previously. Using a molecular dynamic simulation 
approach, suggestions about the involvement of the second and third extracellular loops in 
the inverse/partial agonistic behavior of JNJ7777120 are made at the molecular level. 
Taken together, this work broadens our knowledge about the therapeutically 
relevant H2R, β2AR and H4R at the cellular and/or molecular level.  
 
 
 
134 
6.2 Zusammenfassung 
Ein Drittel der derzeit auf dem Markt befindlichen Arzneimittel bindet an G Protein-
gekoppelte Rezeptoren (GPCR). Drei Vertreter dieser GPCR-Familie standen im Mittelpunkt 
dieser Arbeit: der Histamin H2 Rezeptor (H2R), der β2-adrenerge Rezeptor (β2AR) und der 
Histamin H4 Rezeptor (H4R). Die H2R Antagonisten werden zur Therapie von peptischen 
Ulcera eingesetzt, die β2AR Agonisten in der Behandlung des Asthma bronchiale. Der erste 
H4R-Antagonist befindet sich gerade in der klinischen Prüfung zur Therapie des Asthma 
bronchiale und der allergischen Rhinitis. Weil alle drei GPCRs an vielen 
(patho)physiologischen Prozessen beteiligt sind, sind sie als Zielstrukturen für die 
Verbesserung bestehender Therapien und für die Etablierung neuer Therapieansätze 
interessant.  
Ein erstes Ziel dieser Arbeit war die Analyse und der Vergleich H2R- und β2AR- 
induzierter Effekte an isolierten humanen neutrophilen Granulozyten. Aktivierung beider 
Rezeptoren in diesen Zellen führt zu einer Hemmung entzündlicher Prozesse, z. B. der 
Superoxid-Anionen (O2•-) Bildung. Obwohl beide Rezeptoren klassisch an Gs Proteine 
koppeln, beeinflussten die aktivierten H2R und β2AR die Akkumulation von zyklischem 
Adenosin-3',5'-monophosphat (cAMP) und die O2•- Produktion in Neutrophilen sehr 
unterschiedlich. Ebenso wurden Unterschiede zu Daten aus rekombinanten Testsystemen 
gefunden. Ferner ergaben sich Hinweise auf Ligand-spezifische Rezeptorkonformationen, 
die für das Konzept der funktionellen Selektivität sprechen. Die Ergebnisse deuten darauf 
hin, dass die Beziehung zwischen der cAMP-Akkumulation und der Hemmung der O2•- 
Produktion in Neutrophilen komplexer ist als bisher angenommen. Das in dieser Arbeit 
beobachtete atypische Verhalten der H2R-Antagonisten ist mit der klassischen Vorstellung 
der Interaktion zwischen einem GPCR und einem Antagonisten nicht vereinbar. Mögliche 
Erklärungen für die beobachteten H2R- und β2AR-induzierten Effekte werden diskutiert, 
wobei zusätzliche Untersuchungen notwendig sind, um die Unterschiede in den untersuchten 
Signalwegen in Neutrophilen mechanistisch zu verstehen. 
Das zweite Ziel der Arbeit war die Charakterisierung monovalenter und bivalenter 
NG-acylierter Hetarylpropylguanidine, hochpotenter (partieller) Agonisten am humanen H2R 
in Sf9 Insektenzellen-Membranen, an humanen neutrophilen Granulozyten, da diese Zellen 
ein physiologisch relevanteres Testsystem darstellen. Diese H2R Agonisten wurden zunächst 
als pharmakologische Werkzeuge entwickelt, könnten aber auch therapeutischen Nutzen 
haben, z. B. in der Therapie der akuten myeloischen Leukämie. In Gegensatz zu Histamin 
hemmten bivalente Acylguanidine die O2•- Produktion in den aktivierten Neutrophilen nicht. 
Ein monovalenter Ligand zeigte eine hemmende Wirkung auf die O2•- Produktion, die aber 
H2R-unabhängig verlief. Dennoch stimulierten die untersuchten Liganden die cAMP 
Produktion über den H2R, aber mit einer stark reduzierten agonistischen Wirkung im 
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Vergleich mit den im rekombinanten Testsystem bestimmten Wirkungen. Die ungünstigen 
physikalisch-chemischen Eigenschaften der NG-acylierten Hetarylpropylguanidine (z. B. 
amphiphiler Charakter) müssten wahrscheinlich verbessert werden, um bessere Wirkungen 
am H2R an Neutrophilen zu erzielen. Zusätzlich trägt diese Arbeit dazu bei, die Interaktionen 
der Acylguanidine mit dem H2R auf molekularer Ebene besser zu verstehen. So zeigten die 
Untersuchungen des mutierten H2R, dass der extrazelluläre N-Terminus bezüglich der 
unterschiedlichen Potenz und intrinsischen Aktivität der Acylguanidine am H2R des 
Menschen und des Meerschweinchens nur eine marginale Rolle spielt.  
Die präklinische Untersuchung neuer Wirkstoffe in translationalen Tiermodellen ist 
in der Arzneistoffforschung und -entwicklung unverzichtbar. Die Identifizierung und das 
Verständnis wesentlicher pharmakologischer Unterschiede zwischen H4R Speziesorthologen 
ist daher essentiell. Im dritten Teil dieser Arbeit wurde die Bedeutung von extrazellulären 
Domänen für die unterschiedlichen pharmakologischen Eigenschaften des humanen (h) und 
des caninen (c) H4R untersucht. Dafür wurden h/c-H4R-Chimären generiert und in Sf9 
Insektenzellen exprimiert. Unsere Daten deuten darauf hin, dass der N-Terminus und die 
erste extrazelluläre Schleife keinen Einfluss auf die Speziesunterschiede zwischen hH4R  
und cH4R haben. Dass die zweite und dritte extrazelluläre Schleife bei der H4R-Aktivierung 
beteiligt sind, konnte erstmals gezeigt werden. Zum Beispiel ist die sehr niedrige Homologie 
der Aminosäuren im Bereich der letzten zwei extrazellulären Schleifen zumindest teilweise 
für die unterschiedlichen Effekt des Liganden JNJ7777120 (1-[(5-Chloro-1H-indol-2-
yl)carbonyl]-4-methylpiperazin) am hH4R (inverser Agonist) und cH4R (partieller Agonist) 
verantwortlich. Die vorgeschlagene Hypothese, dass die zweite und die dritte extrazelluläre 
Schleife in die inverse agonistische/agonistische Wirkung des JNJ7777120 involviert sind 
basiert auf molekulardynamischen Simulationen.  
Insgesamt trägt diese Arbeit zur Erweiterung unserer Kenntnisse über die 
therapeutisch wichtigen H2R, β2AR und H4R auf molekularer und/oder zellulärer Ebene bei. 
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                *         *         *         *         *         *         *         *         *         * 
  1701 TAGTTGTCACATTGGGAGCAGAGAAGAAGCAACCAGGGGCCCTGATCAGGGGACTGAGCCGTAGAGTCCCAGGATGGCACCCAATGGCACAGCCTCTTCC 1800   
                                               |||||#|#||||||||||||||||||||||||||||||||||||||||||||||||||||        
     4 ----------------------------------------CCTganCnggGgaCtgagCCGTAGaGTCCcAGGaTGGCACCCAATGGCACAGCCTCTTCC 63     
                                                     *         *         *         *         *         *    
 
                *         *         *         *         *         *         *         *         *         * 
  1801 TTTTGCCTGGACTCTACCGCATGCAAGATCACCATCACCGTGGTCCTTGCGGTCCTCATCCTCATCACCGTTGCTGGCAATGTGGTCGTCTGTCTGGCCG 1900   
       ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||        
    64 TTTTGCCTGGACTCTACCGCATGCAAGATCACCATCACCGTGGTCCTTGCGGTCCTCATCCTCATCACCGTTGCTGGCAATGTGGTCGTCTGTCTGGCCG 163    
             *         *         *         *         *         *         *         *         *         *    
 
                *         *         *         *         *         *         *         *         *         * 
  1901 TGGGCTTGAACCGCCGGCTCCGCAACCTGACCAATTGTTTCATCGTGTCCTTGGCTATCACTGACCTGCTCCTCGGCCTCCTGGTGCTGCCCTTCTCTGC 2000   
       ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||        
   164 TGGGCTTGAACCGCCGGCTCCGCAACCTGACCAATTGTTTCATCGTGTCCTTGGCTATCACTGACCTGCTCCTCGGCCTCCTGGTGCTGCCCTTCTCTGC 263    
             *         *         *         *         *         *         *         *         *         *    
 
                *         *         *         *         *         *         *         *         *         * 
  2001 CATCTACCAGCTGTCCTGCAAGTGGAGCTTTGGCAAGGTCTTCTGCAATATCTACACCAGCCTGGATGTGATGCTCTGCACAGCCTCCATTCTTAACCTC 2100   
       ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||        
   264 CATCTACCAGCTGTCCTGCAAGTGGAGCTTTGGCAAGGTCTTCTGCAATATCTACACCAGCCTGGATGTGATGCTCTGCACAGCCTCCATTCTTAACCTC 363    
             *         *         *         *         *         *         *         *         *         *    
 
                *         *         *         *         *         *         *         *         *         * 
  2101 TTCATGATCAGCCTCGACCGGTACTGCGCTGTCATGGACCCACTGCGGTACCCTGTGCTGGTCACCCCAGTTCGGGTCGCCATCTCTCTGGTCTTAATTT 2200   
       ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||        
   364 TTCATGATCAGCCTCGACCGGTACTGCGCTGTCATGGACCCACTGCGGTACCCTGTGCTGGTCACCCCAGTTCGGGTCGCCATCTCTCTGGTCTTAATTT 463    
             *         *         *         *         *         *         *         *         *         *    
 
                *         *         *         *         *         *         *         *         *         * 
  2201 GGGTCATCTCCATTACCCTGTCCTTTCTGTCTATCCACCTGGGGTGGAACAGCAGGAACGAGACCAGCAAGGGCAATCATACCACCTCTAAGTGCAAAGT 2300   
       ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||        
   464 GGGTCATCTCCATTACCCTGTCCTTTCTGTCTATCCACCTGGGGTGGAACAGCAGGAACGAGACCAGCAAGGGCAATCATACCACCTCTAAGTGCAAAGT 563    
             *         *         *         *         *         *         *         *         *         *    
 
                *         *         *         *         *         *         *         *         *         * 
  2301 CCAGGTCAATGAAGTGTACGGGCTGGTGGATGGGCTGGTCACCTTCTACCTCCCGCTACTGATCATGTGCATCACCTACTACCGCATCTTCAAGGTCGCC 2400   
       ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||        
   564 CCAGGTCAATGAAGTGTACGGGCTGGTGGATGGGCTGGTCACCTTCTACCTCCCGCTACTGATCATGTGCATCACCTACTACCGCATCTTCAAGGTCGCC 663    
             *         *         *         *         *         *         *         *         *         *    
 
                *         *         *         *         *         *         *         *         *         * 
  2401 CGGGATCAGGCCAAGAGGATCAATCACATTAGCTCCTGGAAGGCAGCCACCATCAGGGAGCACAAAGCCACAGTGACACTGGCCGCCGTCATGGGGGCCT 2500   
       ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||        
   664 CGGGATCAGGCCAAGAGGATCAATCACATTAGCTCCTGGAAGGCAGCCACCATCAGGGAGCACAAAGCCACAGTGACACTGGCCGCCGTCATGGgGGCCT 763    
             *         *         *         *         *         *         *         *         *         *    
 
                *         *         *         *         *         *         *         *         *         * 
  2501 TCATCATCTGCTGGTTTCCCTACTTCACCGCGTTTGTGTACCGTGGGCTGAGAGGGGATGATGCCATCAATGAGGTGTTAGAAGCCATCGTTCTGTGGCT 2600   
       ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||        
   764 TCATCATCTGCTGGTTTCCCTACTTCACCGCGTTTGTGTACCGTggGCTGAGAGGGGATGATGCCATCAATGAGGTGTTAGaAGCCAtCGTTCTGTGGCT 863    
             *         *         *         *         *         *         *         *         *         *    
 
                *         *         *         *          *         *         *         *         *          
  2601 GGGCTATGCCAACTCAGCCCTGAACCCCATCCTGTATGCTGCGCT-GAACAGAGACTTCCGCACCGGGTACCAACAGCTCTTCTGCTGCAGGCTGGCCAA 2699   
       ||||||||||||||||||||||||||||||||||||||||||||| ||||##|||||||||||||||||||||||||   ||||  |     |||             
   864 GGGCTATGCCAACTCAGcCCTGAACCCCATCCTGTATGCTGCgCttgAACnnaGaCTTCcgCACCgGGTACCAAcag---TTCT--T-----CTG----- 948    
             *         *         *         *         *         *         *         *                        
 
       *         *         *         *         *         *         *         *         *         *          
  2700 CCGCAACTCCCACAAAACTTCTCTGAGGTCCAACGCCTCTCAGCTGTCCAGGACCCAAAGCCGAGAACCCAGGCAACAGGAAGAGAAACCCCTGAAGCTC 2799   
                             |||    |                                                                              
   949 ----------------------CTG----C~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 952    
                              * 
 
       *         *         *         *         *         *         *         *         *         *          
  2800 CAGGTGTGGAGTGGGACAGAAGTCACGGCCCCCCAGGGAGCCACAGACAGGTAATAGCCCTAGCCATTGGTGCACAGGATGGGGGCAATGGGAGGGGATG 2899   
                                                                                                                   
   952 ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 952    
 
       *         *         *         *         *         *         *         *         *         *          
  2900 CTACTGATGGGAATGATTAAGGGAGCTGCTGTTTAGGTGGTGCTGGTTTATGTTCTAGGAACTCTTCATGAGCACTTTGTAAACACCCTCTTGCTTAATC 2999   
                                                                                                                   
   952 ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 952    
 
Fig. 7.1 Annealing of the nucleotide sequence of the hH2R isoform 2 from NCBI database with 
the nucleotide sequence, obtained in sequencing using primer hH2R_F_Iso2_seq. The encoding 
region of the hH2R isoform 2 from NCBI database is shown in red (START and STOP codon are 
underlined) and part of the region before START and after STOP codon in black. The nucleotide 
sequence, obtained in sequencing, is shown in blue. 
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                *         *         *         *         *         *         *         *         *         * 
  1701 TAGTTGTCACATTGGGAGCAGAGAAGAAGCAACCAGGGGCCCTGATCAGGGGACTGAGCCGTAGAGTCCCAGGATGGCACCCAATGGCACAGCCTCTTCC 1800   
                                                                                                                   
   829 ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 829    
 
                *         *         *         *         *         *         *         *         *         * 
  1801 TTTTGCCTGGACTCTACCGCATGCAAGATCACCATCACCGTGGTCCTTGCGGTCCTCATCCTCATCACCGTTGCTGGCAATGTGGTCGTCTGTCTGGCCG 1900   
                                                                                                                   
   829 ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 829    
 
                *         *         *         *         *         *         *         *         *         * 
  1901 TGGGCTTGAACCGCCGGCTCCGCAACCTGACCAATTGTTTCATCGTGTCCTTGGCTATCACTGACCTGCTCCTCGGCCTCCTGGTGCTGCCCTTCTCTGC 2000   
                                                                                                                   
   829 ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 829    
 
                *         *         *         *         *         *         *         *         *         * 
  2001 CATCTACCAGCTGTCCTGCAAGTGGAGCTTTGGCAAGGTCTTCTGCAATATCTACACCAGCCTGGATGTGATGCTCTGCACAGCCTCCATTCTTAACCTC 2100   
                                                                                    |||||||||#||||||#|||||#        
   829 ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~gCACAGCCtncattctnaACctn 807    
                                                                                             *         *    
 
                *         *         *         *         *         *         *         *         *         * 
  2101 TTCATGATCAGCCTCGACCGGTACTGCGCTGTCATGGACCCACTGCGGTACCCTGTGCTGGTCACCCCAGTTCGGGTCGCCATCTCTCTGGTCTTAATTT 2200   
       |#||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||#|        
   806 tnCATGATCAGccTCGACCgGTACTGCGCTGTCATGGACCcACTGCGGTACCCTgtgcTGGTCACCcCAGTTCGGGTCGCCATCTCTCtggTCTTAATnT 707    
             *         *         *         *         *         *         *         *         *         *    
 
                *         *         *         *         *         *         *         *         *         * 
  2201 GGGTCATCTCCATTACCCTGTCCTTTCTGTCTATCCACCTGGGGTGGAACAGCAGGAACGAGACCAGCAAGGGCAATCATACCACCTCTAAGTGCAAAGT 2300   
       ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||        
   706 GgGTCATCTCCATTACCCTGTCCTTTCTGTCTATCCACCTGGGGTGGAACAGCAGGAACGAGACCAGCAAGGGCAATCATACCACCTCTAAGTGCAAAGT 607    
             *         *         *         *         *         *         *         *         *         *    
 
                *         *         *         *         *         *         *         *         *         * 
  2301 CCAGGTCAATGAAGTGTACGGGCTGGTGGATGGGCTGGTCACCTTCTACCTCCCGCTACTGATCATGTGCATCACCTACTACCGCATCTTCAAGGTCGCC 2400   
       ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||        
   606 CCAGGTCAATGAAGTGTACGGGCTGGTGGATGGGCTGGTCACCTTCTACCTCCCGCTACTGATCATGTGCATCACCTACTACCGCATCTTCAAGGTCGCC 507    
             *         *         *         *         *         *         *         *         *         *    
 
                *         *         *         *         *         *         *         *         *         * 
  2401 CGGGATCAGGCCAAGAGGATCAATCACATTAGCTCCTGGAAGGCAGCCACCATCAGGGAGCACAAAGCCACAGTGACACTGGCCGCCGTCATGGGGGCCT 2500   
       ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||        
   506 CGGGATCAGGCCAAGAGGATCAATCACATTAGCTCCTGGAAGGCAGCCACCATCAGGGAGCACAAAGCCACAGTGACACTGGCCGCCGTCATGGGGGCCT 407    
             *         *         *         *         *         *         *         *         *         *    
 
                *         *         *         *         *         *         *         *         *         * 
  2501 TCATCATCTGCTGGTTTCCCTACTTCACCGCGTTTGTGTACCGTGGGCTGAGAGGGGATGATGCCATCAATGAGGTGTTAGAAGCCATCGTTCTGTGGCT 2600   
       ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||        
   406 TCATCATCTGCTGGTTTCCCTACTTCACCGCGTTTGTGTACCGTGGGCTGAGAGGGGATGATGCCATCAATGAGGTGTTAGAAGCCATCGTTCTGTGGCT 307    
             *         *         *         *         *         *         *         *         *         *    
 
                *         *         *         *         *         *         *         *         *         * 
  2601 GGGCTATGCCAACTCAGCCCTGAACCCCATCCTGTATGCTGCGCTGAACAGAGACTTCCGCACCGGGTACCAACAGCTCTTCTGCTGCAGGCTGGCCAAC 2700   
       ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||        
   306 GGGCTATGCCAACTCAGCCCTGAACCCCATCCTGTATGCTGCGCTGAACAGAGACTTCCGCACCGGGTACCAACAGCTCTTCTGCTGCAGGCTGGCCAAC 207    
             *         *         *         *         *         *         *         *         *         *    
 
                *         *         *         *         *         *         *         *         *         * 
  2701 CGCAACTCCCACAAAACTTCTCTGAGGTCCAACGCCTCTCAGCTGTCCAGGACCCAAAGCCGAGAACCCAGGCAACAGGAAGAGAAACCCCTGAAGCTCC 2800   
       ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||        
   206 CGCAACTCCCACAAAACTTCTCTGAGGTCCAACGCCTCTCAGCTGTCCAGGACCCAAAGCCGAGAACCCAGGCAACAGGAAGAGAAACCCCTGAAGCTCC 107    
             *         *         *         *         *         *         *         *         *         *    
 
                *         *         *         *         *         *         *         *         *         * 
  2801 AGGTGTGGAGTGGGACAGAAGTCACGGCCCCCCAGGGAGCCACAGACAGGTAATAGCCCTAGCCATTGGTGCACAGGATGGGGGCAATGGGAGGGGATGC 2900   
       |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| ||||||||||||||||||| ||| |||||#|        
   106 AGGTGTGGAGTGGGACAGAAGTCACGGCCCCCCAGGGAGCCACAGACAGGTAATAGCCCTAGCCATTg-tgCACAGGAtgGgGGCAat-gGA-gGGatnc 10     
             *         *         *         *         *         *         *          *         *           * 
 
                *         *         *         *         *         *         *         *         *         * 
  2901 TACTGATGGGAATGATTAAGGGAGCTGCTGTTTAGGTGGTGCTGGTTTATGTTCTAGGAACTCTTCATGAGCACTTTGTAAACACCCTCTTGCTTAATCC 3000   
       ||| #|| |||                                                                                                 
     9 tAc-nat-gga~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 1 
 
 
 
Fig. 7.2 Annealing of the nucleotide sequence of the hH2R isoform 2 from NCBI database with 
the nucleotide sequence, obtained in sequencing using primer hH2R_R_Iso2_seq. The encoding 
region of the hH2R isoform 2 from NCBI database is shown in red (START and STOP codon are 
underlined) and part of the region before START and after STOP codon in black. The nucleotide 
sequence, obtained in sequencing, is shown in blue. 
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                *         *         *         *         *         *         *         *         *         * 
  1701 TAGTTGTCACATTGGGAGCAGAGAAGAAGCAACCAGGGGCCCTGATCAGGGGACTGAGCCGTAGAGTCCCAGGATGGCACCCAATGGCACAGCCTCTTCC 1800   
                                                                                                                   
     1 ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 1      
 
                *         *         *         *         *         *         *         *         *         * 
  1801 TTTTGCCTGGACTCTACCGCATGCAAGATCACCATCACCGTGGTCCTTGCGGTCCTCATCCTCATCACCGTTGCTGGCAATGTGGTCGTCTGTCTGGCCG 1900   
                                                                                                                   
     1 ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 1      
 
                *         *         *         *         *         *         *         *         *         * 
  1901 TGGGCTTGAACCGCCGGCTCCGCAACCTGACCAATTGTTTCATCGTGTCCTTGGCTATCACTGACCTGCTCCTCGGCCTCCTGGTGCTGCCCTTCTCTGC 2000   
                                                                                                                   
     1 ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 1      
 
                *         *         *         *         *         *         *         *         *         * 
  2001 CATCTACCAGCTGTCCTGCAAGTGGAGCTTTGGCAAGGTCTTCTGCAATATCTACACCAGCCTGGATGTGATGCTCTGCACAGCCTCCATTCTTAACCTC 2100   
                                                                                                                   
     1 ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 1      
 
                *         *         *         *         *         *         *         *         *         * 
  2101 TTCATGATCAGCCTCGACCGGTACTGCGCTGTCATGGACCCACTGCGGTACCCTGTGCTGGTCACCCCAGTTCGGGTCGCCATCTCTCTGGTCTTAATTT 2200   
                                                                                                                   
     1 ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 1      
 
                *         *         *         *         *         *         *         *         *         * 
  2201 GGGTCATCTCCATTACCCTGTCCTTTCTGTCTATCCACCTGGGGTGGAACAGCAGGAACGAGACCAGCAAGGGCAATCATACCACCTCTAAGTGCAAAGT 2300   
                                                                                                                   
     1 ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 1      
 
                *         *         *         *         *         *         *         *         *         * 
  2301 CCAGGTCAATGAAGTGTACGGGCTGGTGGATGGGCTGGTCACCTTCTACCTCCCGCTACTGATCATGTGCATCACCTACTACCGCATCTTCAAGGTCGCC 2400   
                                                               ||||||||||||||||||||||||||||||||||||||||||||        
     1 ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~tactGatcatGTGCATCACCTACTACCGCATCTTCAAGGTCGCC 44     
                                                                        *         *         *         *     
 
                *         *         *         *         *         *         *         *         *         * 
  2401 CGGGATCAGGCCAAGAGGATCAATCACATTAGCTCCTGGAAGGCAGCCACCATCAGGGAGCACAAAGCCACAGTGACACTGGCCGCCGTCATGGGGGCCT 2500   
       ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||        
    45 CGGGATCAGGCCAAGAGGATCAATCACATTAGCTCCTGGAAGGCAGCCACCATCAGGGAGCACAAAGCCACAGTGACACTGGCCGCCGTCATGGGGGCCT 144    
            *         *         *         *         *         *         *         *         *         *     
 
                *         *         *         *         *         *         *         *         *         * 
  2501 TCATCATCTGCTGGTTTCCCTACTTCACCGCGTTTGTGTACCGTGGGCTGAGAGGGGATGATGCCATCAATGAGGTGTTAGAAGCCATCGTTCTGTGGCT 2600   
       ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||        
   145 TCATCATCTGCTGGTTTCCCTACTTCACCGCGTTTGTGTACCGTGGGCTGAGAGGGGATGATGCCATCAATGAGGTGTTAGAAGCCATCGTTCTGTGGCT 244    
            *         *         *         *         *         *         *         *         *         *     
 
                *         *         *         *         *         *         *         *         *         * 
  2601 GGGCTATGCCAACTCAGCCCTGAACCCCATCCTGTATGCTGCGCTGAACAGAGACTTCCGCACCGGGTACCAACAGCTCTTCTGCTGCAGGCTGGCCAAC 2700   
       ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||        
   245 GGGCTATGCCAACTCAGCCCTGAACCCCATCCTGTATGCTGCGCTGAACAGAGACTTCCGCACCGGGTACCAACAGCTCTTCTGCTGCAGGCTGGCCAAC 344    
            *         *         *         *         *         *         *         *         *         *     
 
                *         *         *         *         *         *         *         *         *         * 
  2701 CGCAACTCCCACAAAACTTCTCTGAGGTCCAACGCCTCTCAGCTGTCCAGGACCCAAAGCCGAGAACCCAGGCAACAGGAAGAGAAACCCCTGAAGCTCC 2800   
       ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||        
   345 CGCAACTCCCACAAAACTTCTCTGAGGTCCAACGCCTCTCAGCTGTCCAGGACCCAAAGCCGAGAACCCAGGCAACAGGAAGAGAAACCCCTGAAGCTCC 444    
            *         *         *         *         *         *         *         *         *         *     
 
                *         *         *         *         *         *         *         *         *         * 
  2801 AGGTGTGGAGTGGGACAGAAGTCACGGCCCCCCAGGGAGCCACAGACAGGTAATAGCCCTAGCCATTGGTGCACAGGATGGGGGCAATGGGAGGGGATGC 2900   
       ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||        
   445 AGGTGTGGAGTGGGACAGAAGTCACGGCCCCCCAGGGAGCCACAGACAGGTAATAGCCCTAGCCATTGGTGCACAGGATGGGGGCAATGGGAGGGGATGC 544    
            *         *         *         *         *         *         *         *         *         *     
 
                *         *         *         *         *         *         *         *         *         * 
  2901 TACTGATGGGAATGATTAAGGGAGCTGCTGTTTAGGTGGTGCTGGTTTATGTTCTAGGAACTCTTCATGAGCACTTTGTAAACACCCTCTTGCTTAATCC 3000   
       |||||||||||||||||||||||||||||||||||||||||||||   |                                                           
   545 TACTGATGGGAATGATTAAGGGAGCTGCTGTTTAGGTGGTGCTGG---A~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 590 
            *         *         *         *         *       
 
 
Fig. 7.3 Annealing of the nucleotide sequence of the hH2R isoform 2 from NCBI database with 
the nucleotide sequence, obtained in sequencing using primer hH2R_F_middle. The encoding 
region of the hH2R isoform 2 from NCBI database is shown in red (START and STOP codon are 
underlined) and part of the region before START and after STOP codon in black. The nucleotide 
sequence, obtained in sequencing, is shown in blue.  
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                *         *         *         *         *         *         *         *         *         * 
  1701 TAGTTGTCACATTGGGAGCAGAGAAGAAGCAACCAGGGGCCCTGATCAGGGGACTGAGCCGTAGAGTCCCAGGATGGCACCCAATGGCACAGCCTCTTCC 1800   
       ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||        
   584 TAgtTGTCACATTGGGAGCAGAGAAGAAGCAACCAGGGGCCCTGATCAGGGGACTGAGCCGTAGAGTCCCAGGATGGCACCCAATGGCACAGCCTCTTCC 485    
           *         *         *         *         *         *         *         *         *         *      
 
                *         *         *         *         *         *         *         *         *         * 
  1801 TTTTGCCTGGACTCTACCGCATGCAAGATCACCATCACCGTGGTCCTTGCGGTCCTCATCCTCATCACCGTTGCTGGCAATGTGGTCGTCTGTCTGGCCG 1900   
       ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||        
   484 TTTTGCCTGGACTCTACCGCATGCAAGATCACCATCACCGTGGTCCTTGCGGTCCTCATCCTCATCACCGTTGCTGGCAATGTGGTCGTCTGTCTGGCCG 385    
           *         *         *         *         *         *         *         *         *         *      
 
                *         *         *         *         *         *         *         *         *         * 
  1901 TGGGCTTGAACCGCCGGCTCCGCAACCTGACCAATTGTTTCATCGTGTCCTTGGCTATCACTGACCTGCTCCTCGGCCTCCTGGTGCTGCCCTTCTCTGC 2000   
       ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||        
   384 TGGGCTTGAACCGCCGGCTCCGCAACCTGACCAATTGTTTCATCGTGTCCTTGGCTATCACTGACCTGCTCCTCGGCCTCCTGGTGCTGCCCTTCTCTGC 285    
           *         *         *         *         *         *         *         *         *         *      
 
                *         *         *         *         *         *         *         *         *         * 
  2001 CATCTACCAGCTGTCCTGCAAGTGGAGCTTTGGCAAGGTCTTCTGCAATATCTACACCAGCCTGGATGTGATGCTCTGCACAGCCTCCATTCTTAACCTC 2100   
       ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||        
   284 CATCTACCAGCTGTCCTGCAAGTGGAGCTTTGGCAAGGTCTTCTGCAATATCTACACCAGCCTGGATGTGATGCTCTGCACAGCCTCCATTCTTAACCTC 185    
           *         *         *         *         *         *         *         *         *         *      
 
                *         *         *         *         *         *         *         *         *         * 
  2101 TTCATGATCAGCCTCGACCGGTACTGCGCTGTCATGGACCCACTGCGGTACCCTGTGCTGGTCACCCCAGTTCGGGTCGCCATCTCTCTGGTCTTAATTT 2200   
       ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||        
   184 TTCATGATCAGCCTCGACCGGTACTGCGCTGTCATGGACCCACTGCGGTACCCTGTGCTGGTCACCCCAGTTCGGGTCGCCATCTCTCTGGTCTTAATTT 85     
           *         *         *         *         *         *         *         *         *         *      
 
                *         *         *         *         *         *         *         *         *         * 
  2201 GGGTCATCTCCATTACCCTGTCCTTTCTGTCTATCCACCTGGGGTGGAACAGCAGGAACGAGACCAGCAAGGGCAATCATACCACCTCTAAGTGCAAAGT 2300   
       ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||                        
    84 GGGTCATCTCCATTACCCTGTCCTTTCTGTCTATCCACCTGGGGTGGAACAGCAGGAACGAGACCAGCAAGGGCAATCAtaCca~~~~~~~~~~~~~~~~ 1      
           *         *         *         *         *         *         *         * 
 
                *         *         *         *         *         *         *         *         *         * 
  2301 CCAGGTCAATGAAGTGTACGGGCTGGTGGATGGGCTGGTCACCTTCTACCTCCCGCTACTGATCATGTGCATCACCTACTACCGCATCTTCAAGGTCGCC 2400   
                                                                                                                   
     1 ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 1      
 
                *         *         *         *         *         *         *         *         *         * 
  2401 CGGGATCAGGCCAAGAGGATCAATCACATTAGCTCCTGGAAGGCAGCCACCATCAGGGAGCACAAAGCCACAGTGACACTGGCCGCCGTCATGGGGGCCT 2500   
                                                                                                                   
     1 ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 1      
 
                *         *         *         *         *         *         *         *         *         * 
  2501 TCATCATCTGCTGGTTTCCCTACTTCACCGCGTTTGTGTACCGTGGGCTGAGAGGGGATGATGCCATCAATGAGGTGTTAGAAGCCATCGTTCTGTGGCT 2600   
                                                                                                                   
     1 ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 1      
 
                *         *         *         *         *         *         *         *         *         * 
  2601 GGGCTATGCCAACTCAGCCCTGAACCCCATCCTGTATGCTGCGCTGAACAGAGACTTCCGCACCGGGTACCAACAGCTCTTCTGCTGCAGGCTGGCCAAC 2700   
                                                                                                                   
     1 ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 1      
 
                *         *         *         *         *         *         *         *         *         * 
  2701 CGCAACTCCCACAAAACTTCTCTGAGGTCCAACGCCTCTCAGCTGTCCAGGACCCAAAGCCGAGAACCCAGGCAACAGGAAGAGAAACCCCTGAAGCTCC 2800   
                                                                                                                   
     1 ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 1      
 
                *         *         *         *         *         *         *         *         *         * 
  2801 AGGTGTGGAGTGGGACAGAAGTCACGGCCCCCCAGGGAGCCACAGACAGGTAATAGCCCTAGCCATTGGTGCACAGGATGGGGGCAATGGGAGGGGATGC 2900   
                                                                                                                   
     1 ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 1      
 
                *         *         *         *         *         *         *         *         *         * 
  2901 TACTGATGGGAATGATTAAGGGAGCTGCTGTTTAGGTGGTGCTGGTTTATGTTCTAGGAACTCTTCATGAGCACTTTGTAAACACCCTCTTGCTTAATCC 3000   
                                                                                                                   
     1 ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 1 
 
 
 
 
Fig. 7.4 Annealing of the nucleotide sequence of the hH2R isoform 2 from NCBI database with 
the nucleotide sequence, obtained in sequencing using primer hH2R_R_middle. The encoding 
region of the hH2R isoform 2 from NCBI database is shown in red (START and STOP codon are 
underlined and part of the region before START and after STOP codon in black. The nucleotide 
sequence, obtained in sequencing, is shown in blue.  
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